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This review is presented as a common foundation for scientists interested in nanoparticles, their origin,
activity, and biological toxicity. It is written with the goal of rationalizing and informing public health
concerns related to this sometimes-strange new science of “nano,” while raising awareness of
nanomaterials’ toxicity among scientists and manufacturers handling them. We show that humans have
always been exposed to tiny particles via dust storms, volcanic ash, and other natural processes, and
that our bodily systems are well adapted to protect us from these potentially harmful intruders. The
reticuloendothelial system, in particular, actively neutralizes and eliminates foreign matter in the body,
including viruses and nonbiological particles. Particles originating from human activities have existed
for millennia, e.g., smoke from combustion and lint from garments, but the recent development of
industry and combustion-based engine transportation has profoundly increased anthropogenic
particulate pollution. Signiﬁcantly, technological advancement has also changed the character of
particulate pollution, increasing the proportion of nanometer-sized particles—“nanoparticles”—and
expanding the variety of chemical compositions. Recent epidemiological studies have shown a strong
correlation between particulate air pollution levels, respiratory and cardiovascular diseases, various
cancers, and mortality. Adverse effects of nanoparticles on human health depend on individual factors
such as genetics and existing disease, as well as exposure, and nanoparticle chemistry, size, shape,
agglomeration state, and electromagnetic properties. Animal and human studies show that inhaled
nanoparticles are less efﬁciently removed than larger particles by the macrophage clearance
mechanisms in the lungs, causing lung damage, and that nanoparticles can translocate through the
circulatory, lymphatic, and nervous systems to many tissues and organs, including the brain. The key
to understanding the toxicity of nanoparticles is that their minute size, smaller than cells and cellular
organelles, allows them to penetrate these basic biological structures, disrupting their normal function.
Examples of toxic effects include tissue inﬂammation, and altered cellular redox balance toward
oxidation, causing abnormal function or cell death. The manipulation of matter at the scale of atoms,
“nanotechnology,” is creating many new materials with characteristics not always easily predicted
from current knowledge. Within the nearly limitless diversity of these materials, some happen to be
toxic to biological systems, others are relatively benign, while others confer health beneﬁts. Some of
these materials have desirable characteristics for industrial applications, as nanostructured materials
often exhibit beneﬁcial properties, from UV absorbance in sunscreen to oil-less lubrication of motors.
A rational science-based approach is needed to minimize harm caused by these materials, while
supporting continued study and appropriate industrial development. As current knowledge of the
toxicology of “bulk” materials may not sufﬁce in reliably predicting toxic forms of nanoparticles,
ongoing and expanded study of “nanotoxicity” will be necessary. For nanotechnologies with clearly
associated health risks, intelligent design of materials and devices is needed to derive the beneﬁts of
these new technologies while limiting adverse health impacts. Human exposure to toxic nanoparticles
can be reduced through identifying creation-exposure pathways of toxins, a study that may someday
soon unravel the mysteries of diseases such as Parkinson’s and Alzheimer’s. Reduction in fossil fuel
combustion would have a large impact on global human exposure to nanoparticles, as would limiting
deforestation and desertiﬁcation. While nanotoxicity is a relatively new concept to science, this review
reveals the result of life’s long history of evolution in the presence of nanoparticles, and how the
human body, in particular, has adapted to defend itself against nanoparticulate intruders. © 2007
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DEFINITIONS
aerosol—a material that, while not gaseous itself, remains
suspended in air for prolonged periods. Typical examples
include dust and ﬁne-droplet liquid paint or hairspray.
aggregate/aggregation—a material that is composed of a
large number of small components which have come to-
gether as clusters, usually with branching, porous shapes.
Aggregation is the process whereby the many small compo-
nents form clusters, and can be driven by gravity or other
forces.
Alzheimer’s disease—a progressive, irreversible, neurode-
generative disease characterized by loss of function and
death of nerve cells in several regions of the brain, leading to
loss of attention, memory, and language. Its cause is un-
known.
antibody—a protein produced by the immune system as a
response to a foreign substance, or antigen.
antigen—a foreign substance that triggers the production of
antibodies by the immune system.
apoptosis—also called “programmed cell death,” is the pro-
cess of cellular suicide that can be initiated for several rea-
sons: when extensive cellular damage occurs, when the cell
is no longer needed within the organism, and in embryonic
development, among others. Apoptosis is different from cell
necrosis a form of traumatic cell death due to physical or
biological injuries in its biochemical and morphological as-
pects. Aberrations in apoptosis contribute to various diseases,
such as cancer.
atomic force microscopy—a scanning-probe form of surface
microscopy that can image and manipulate matter at the na-
nometer scale.
autoimmune diseases—a group of disorders where overac-
tive functioning of the immune system results in the immune
system producing antibodies or autoreactive T cells a type
of white blood cells against its own tissue.
bacteriophage—a virus that infects bacteria.
cancer—disease characterized by rapid and uncontrolled cell
division.
chelator—a chemical agent that binds reversibly to a metal
ion, forming a metallic complex.
chronic disease—disease lasting a long time, which is ongo-
ing or recurring, usually not caused by an infection and not
contagious.
clearance—the removal of particles or substances out of an
organism, usually via urine or stool.
Crohn’s disease—a chronic inﬂammatory disease of un-
known cause that may affect any part of the gastrointestinal
tract, most commonly the small bowel, as well as other or-
gans. Symptoms of the disease include diarrhea, abdominal
pain, and excessive weight loss.
cytokine—a small protein released by cells that has a speciﬁc
effect on interactions between cells, on communications be-
tween cells, or on the behavior of cells.
cytoplasm—includes both the ﬂuid cytosol and the or-
ganelles contained within a cell.
degenerative disease—disease characterized by progressive
deterioration of function or structure of tissue.
DNA—a nucleic acid found within the nucleus of each cell,
carrying genetic information on cell growth, division, and
function. DNA consists of two long strands of nucleotides
twisted into a double helix and held together by hydrogen
bonds. The sequence of nucleotides determines hereditary
characteristics. Each cell contains an identical, complete
copy of the organism’s DNA, with differing cell characteris-
tics determined by differences in gene expression.
endemic disease—disease constantly present in and limited
to people living in a certain location.
endogenous—substances originating within, or synthesized
by an organism e.g., hormones and neurotransmitters.
endoplasmic reticulum—a membrane network that extends
throughout the cytoplasm and is involved in the synthesis,
processing, secretion, and transport of proteins throughout
the cell.
endothelium—the layer of cells that line the interior surface
of all parts of the circulatory system, including the heart, and
blood vessels. Specialized endothelial cells perform impor-
tant ﬁltering functions in the kidney and at the blood-brain
barrier.
enzyme—a protein that acts as a catalyst in a biochemical
reaction.
epidemiology—the branch of medical sciences that studies
various factors inﬂuencing the incidence, distribution, and
possible control of diseases in human population.
etiology—set of causes or origin of a disease.
exogenous—substances originating outside an organism.
ﬁbroblast—a connective-tissue cell that secretes collagen
and other components of the extracellular matrix. It migrates
and proliferates during wound healing and in tissue culture.
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gene—a sequence of nucleotides DNA that deﬁnes a pro-
tein. Genes are the fundamental unit of heritability, and their
collection in an individual organism its genome represents
a code or protocol for the growth and development of that
individual. Genes are arranged along the length of chromo-
somes, of which each species has a ﬁxed number.
genotype—the genetic constitution of an organism.
granuloma—tissue resulting from aggregation of
inﬂammation-ﬁghting cells unable to destroy foreign sub-
stances.
hydrophilic—having an afﬁnity for water, or causing water
to adhere.
hydrophobic—having no afﬁnity for water, or repelling wa-
ter.
inﬂammation—a localized protective response, produced by
tissue, injury that serves to destroy or arrest both the agent
and the affected tissue. Blood vessel permeability locally in-
creases, and the area becomes heavily populated with white
blood cells. Signs of inﬂammation are redness, swelling,
pain, and sometimes loss of function.
ischemia—decrease in the blood supply to an organ, tissue,
limb, or other part of a body caused by the narrowing or
blockage of the blood vessels. Ischemia may lead to a short-
age of oxygen hypoxia within the tissue and may result in
tissue damage or tissue death.
Kaposi’s sarcoma—type of cancer that may affect the blood
and lymph vessels among others.
lavage—washing out or clearance of a body cavity, organ, or
system.
lung burden—the product of exposure rate and residency
time of particulate matter inhaled into the lungs.
lymph—a ﬂuid containing white blood cells, proteins, and
fats; can also carry bacteria, viruses, and cancer cells around
the body. Lymph is collected from the tissues and returned to
the circulatory system.
lymphatic system—the network of vessels, nodes, and or-
gans spleen, thymus, and bone marrow that produce, store,
and carry lymph. The lymphatic system lacks a central
pump, such as the heart in the circulatory system, and must
rely on muscles pumping.
lymphedema—a condition in which lymph nodes become
enlarged and prevent lymph ﬂuid from passing through them.
macrophage—a phagocytic tissue cell of the reticuloendothe-
lial system that is derived from the blood monocyte. The
monocyte migrates from the blood into tissues, where it
transforms into a macrophage. Macrophages are present in
most tissues. Macrophages ingest and process degenerated
cells and foreign invaders, such as viruses, bacteria, and par-
ticles. The long-lived macrophages are reservoirs of HIV.
mesothelioma—a rare form of cancer occurring in the lining
of the lungs and chest cavity.
mitochondrion—an organelle responsible for most of the
oxidative metabolism in the cell. Mitochondria generate en-
ergy in the form of adenosine triphosphate ATP by break-
ing down glucose a type of sugar.
monocyte—the largest form of a white blood cell, with a
kidney-shaped nucleus; its function is the ingestion of for-
eign invaders, such as bacteria, tissue debris, and particles.
Monocytes belong to the group of phagocytes, and mature
into various macrophages in tissue.
murine—pertaining to the rodent family, i.e., rats and mice.
nanoparticulate matter—a collection of particles with at least
one dimension smaller than 1 m yet larger than atoms and
molecules.
neutrophil—an immune cell that ingests and degrades for-
eign organisms. Neutrophils are the most abundant type of
white blood cells, and are the ﬁrst to reach the site of an
infection to attack foreign antigens.
oxidative stress—an imbalance in favor of pro-oxidant ver-
sus antioxidant chemicals, potentially leading to damage to
biomolecules.
Parkinson’s disease—a progressive disorder of the nervous
system manifested by muscle tremors and rigidity, decreased
mobility, and slow voluntary movements.
particulate matter—airborne particles of solids and/or liquids
with sizes ranging from several nanometers to several hun-
dred microns.
phagocyte—cell that ingests and kills foreign intruders via
the process called phagocytosis. Three examples are mono-
cytes, macrophages, and neutrophils.
PM0.1—particulate matter having a diameter smaller than
0.1 m 100 nm.
PM10—particulate matter having a diameter smaller than
10 m.
PM2.5—particulate matter having a diameter smaller than
2.5 m.
pneumoconiosis—lung disease due to permanent deposition
of substantial amounts of particles in the lungs and by the
tissue reaction to its presence. Its severity varies from rela-
tively harmless forms of sclerosis to destructive ﬁbrosis and
scarring of the lungs.
podoconiosis—impaired lymphatic system drainage affecting
the limbs due to clogging with nano- and microparticles.
protein—molecule containing a long chain of amino acids in
the order speciﬁed by a gene’s DNA sequence. Proteins can
be, for example, enzymes, hormones, and antibodies.
quantum dot—semiconductor crystals with a diameter of a
few nanometers, having many properties resembling those of
atoms.
receptor—A protein or large molecule on the surface of a cell
that binds selectively to speciﬁc substances ligands.
reperfusion—restoration of blood ﬂow.
reticuloendothelial system—a part of the immune system
that consists of phagocytic cells, including macrophages and
macrophage precursors, specialized endothelial cells lining
the sinusoids of the liver, spleen, and bone marrow, and re-
ticular cells of lymphatic tissue macrophages and bone
marrow ﬁbroblasts.
rheumatoid arthritis—chronic, autoimmune, inﬂammatory
disorder affecting the connective tissue lining the joints.
Symptoms include pain, swelling, stiffness, and deformities.
It can extend to organs.
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scleroderma—a degenerative, autoimmune disease of the
connective tissue, characterized by the formation of ﬁbrous
tissue collagen which surround the joints, blood vessels,
and sometimes internal organs.
systemic lupus erythematosus—a chronic, autoimmune dis-
order. Symptoms include fatigue, butterﬂy-shaped facial
rash, inﬂammation of the joints, tendons, connective tissues,
and organs: heart, lungs, blood vessels, brain, kidneys, and
skin.
toxicology—the branch of medical and biological science
studying the nature, adverse effects, detection, and treatment
of poisons on living organisms. A fundamental principle of
toxicology is that any substance is poisonous if given in a
large amount. From the study of cancer-causing substances,
carcinogens, it appears that there are some materials for
which there is no safe dose, no level of exposure below
which they do not cause cancer.
transcription factor—a protein that binds to enhancer ele-
ments in DNA to regulate the level of transcription and ex-
pression of certain genes.
translocation—the process of transit of particles or sub-
stances within an organism.
ulcerative colitis—a chronic disease of unknown cause char-
acterized by inﬂammation of the colon producing ulcer-
ations. Symptoms are abdominal pain, cramps, loose dis-
charges of pus, blood, and mucus from the bowel, and
weight loss.
UFP—nanoparticles with size smaller than 100 nm.
I. INTRODUCTION
Every person has been exposed to nanometer-sized for-
eign particles; we inhale them with every breath, and con-
sume them with every drink. In truth, every organism on
Earth continuously encounters nanometer-sized entities. The
vast majority causes little ill effect, and go unnoticed, but
occasionally an intruder will cause appreciable harm to the
organism. The most advanced of the toxic intruders are vi-
ruses, composed as they are of nucleic-acid-based structures
that allow them to not only interfere with biological systems,
but also to parasitically exploit cellular processes to replicate
themselves. Among the more benign viruses are the ones
causing the familiar human symptoms of the common cold
or ﬂu, which are the evident manifestations of biochemical
battles occurring between these foreign intruders and our im-
mune systems, whose nanometer-sized constituents chemi-
cals and proteins usually destroy and remove the viral in-
vaders. A growing number of recent studies show, however,
that nano- and microorganisms may play a role in many
chronic diseases where infectious pathogens have not been
suspected, diseases that were previously attributed only to
genetic factors and lifestyle. Among these diseases are leu-
kemia caused by viruses from the retrovirus and herpesvirus
families,1 cervical cancer papillomavirus,2 liver cancer
hepatitis virus,3 gastric ulcer Helicobacter pylori,4 na-
sopharyngeal cancer Epstein-Barr virus,5 kidney stones
nanobacteria,6 severe acquired respiratory syndrome Co-
rona virus,7 heart disease Chlamydia pneumonia,8 juvenile
diabetes Coxsackie virus,9 Alzheimer’s disease Chlamydia
pneumoniae,10 pediatric obsessive-compulsive disorder
streptococcal bacteria,11 psychotic disorders Borna
virus,12 and prion diseases such as mad cow disease pro-
teins prions.13
One is tempted to think that nanoparticles such as dust or
ash particles, while similar in size to viruses, would be more
benign, as these materials lack the viruses’ ability to repli-
cate. Nevertheless, while nonreplicating bodily intruders do
not directly take control of cellular processes, some have
been shown to sufﬁciently interfere with cellular function to
inﬂuence basic process of cells, such as proliferation, me-
tabolism, and death. Many diseases can be associated with
dysfunction of these basic processes, the most notable being
cancer uncontrolled cells proliferation and neurodegenera-
tive diseases premature cell death. In addition, several dis-
eases with unknown cause, including autoimmune diseases,
Crohn’s, Alzheimer’s, and Parkinson’s diseases, appear to be
correlated with nanoparticle exposure. Conversely, the toxic
properties of some nanoparticles may be beneﬁcial, as they
are thereby able to ﬁght disease at a cellular level, and could
be used as a medical treatment by, for example, targeting and
destroying cancerous cells.
Very small particles, so-called nanoparticles, have the
ability to enter, translocate within, and damage living organ-
isms. This ability results primarily from their small size,
which allows them to penetrate physiological barriers and
travel within the circulatory systems of a host. While natural
processes have produced nanoparticles for eons, modern sci-
ence has recently learned how to synthesize a bewildering
array of artiﬁcial materials with structure that is engineered
at the atomic scale. The smallest particles contain tens or
hundreds of atoms, with dimensions at the scale of nanom-
eters, hence nanoparticles. They are comparable in size to
viruses, where the smallest have dimensions of tens of na-
nometers for example, a human immunodeﬁciency virus
HIV particle is 100 nm in diameter, and which in the
emerging science of nanotechnology might be called “na-
noorganisms.” Like viruses, some nanoparticles can pen-
etrate lung or dermal skin barriers and enter the circulatory
and lymphatic systems of humans and animals, reaching
most bodily tissues and organs, and potentially disrupting
cellular processes and causing disease. The toxicity of each
of these materials depends greatly, however, on the particular
arrangement of its many atoms. Considering all the possible
variations in shape and chemistry of even the smallest nano-
particles, with only tens of atoms, yields a huge number of
distinct materials with potentially very different physical and
toxicological properties. Asbestos is a good example of a
toxic nanomaterial causing lung cancer and other diseases.
Asbestos exists in several forms, with slight variations in
shape and chemistry, yet signiﬁcantly varying toxicity.
Nanometer-sized particles are created in countless physi-
cal processes from erosion to combustion, with health risks
ranging from lethal to benign. Industrial nanoparticle mate-
rials today constitute a tiny but signiﬁcant pollution source
that is, so far, literally buried beneath much larger natural
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sources and nanoparticle pollution incidental to other human
activities, particularly automobile exhaust soot.
The misapprehension of nanotoxicity may create a gen-
eral fear that all nanomaterials are toxic. The online14 and
printed media15 are inadvertently making no distinction be-
tween nanostructured ﬁxed structures, which are not likely to
cause harm such as computer processors, and detachable or
free nanoparticles, which are likely to cause adverse health
effects. While uncontained nanoparticles clearly represent a
serious health threat, ﬁxed nanostructured materials, such as
thin ﬁlm coatings, microchip electronics, and many other
existing nanoengineered materials, are known to be virtually
benign. Many synthetic nanoparticulate materials produce
positive health effects, for example, functionalized fullerene
chemicals that act as antioxidants. The use of nanoparticles
in medical diagnostics and treatment is driven by their safety
as well as utility.
In the following pages, we outline existing sources of
nanoparticles, both natural and man-made, and the known
effects of exposure to nanoparticles. In Sec. I, we introduce
basic concepts and terminology relevant to nanoscience and
nanotechnology, deﬁne concepts and terms, give examples of
nanoscale systems, and introduce the basics of nanoparticle
toxicity. In Sec. II, we brieﬂy discuss nanoparticle classiﬁca-
tions. Section III reviews natural and anthropogenic nanopar-
ticle sources together with their associated health effects and
treatment. In Sec. IV, we present current opinions and re-
search results related to the health implications and toxicol-
ogy of nanoparticles, and we deﬁne exposure pathways and
migration or translocation mechanisms within biological sys-
tems, adverse health effects, and treatment. The mechanics
and biochemistry of toxicity are discussed in Sec. V, as well
as toxicity-related risk factors, such as particle size, shape,
chemistry, and surface properties. In Sec. VI, we provide an
overview of current and developing applications of nanoma-
terials. Finally, Sec. VII contains conclusions and reﬂections.
A. Nano etymology
The preﬁx “nano,” derived from the Greek “nanos,” sig-
nifying “dwarf,” is becoming increasingly common in scien-
tiﬁc literature. Nano is now a popular label for much of
modern science, and many nano words have recently ap-
peared in dictionaries, including nanometer, nanoscale, nano-
science, nanotechnology, nanostructure, nanotube, nanowire,
and nanorobot. Many words that are not yet widely recog-
nized are used in respected publications, such as Science and
Nature. These include nanoelectronics, nanocrystal, nanov-
alve, nanoantenna, nanocavity, nanoscaffolds, nanoﬁbers, na-
nomagnet, nanoporous, nanoarrays, nanolithography, nano-
patterning, nanoencapsulation, etc. Although the idea of
nanotechnology, i.e., producing nanoscale objects and carry-
ing out nanoscale manipulations, has been around for quite
some time, the birth of the concept is usually linked to a
speech by Feynman at the December 1959 meeting of the
American Physical Society.16 where he asked, “What would
happen if we could arrange the atoms one by one the way we
want them?”
The nanometer is a metric unit of length, and denotes
one-billionth of a meter or 10−9 m. Popularly, nano is also
used as an adjective to describe objects, systems, or phenom-
ena with characteristics arising from nanometer-scale struc-
ture. While “micro” has come to mean anything small, nano
emphasizes the atomic granularity that produces the unique
phenomena observed in nanoscience. While there are some
exceptional examples, most of the exciting properties of
nano begin to be apparent in systems smaller than 1000 nm
or 1 m. For the purpose of this review, we will describe
particles with any dimension smaller than 1 m as “nano-
particles,” and those somewhat larger as “microparticles.”
Nanostructured materials did not ﬁrst come into existence
with the recent emergence of the ﬁeld of nanotechnology.
Many existing materials are structured on the micro- and
nanometer scales, and many industrial processes that have
been used for decades e.g., polymer and steel manufactur-
ing exploit nanoscale phenomena. The most advanced nano-
technological fabrication process is microelectronic fabrica-
tion, where thin ﬁlm coatings and lithography are used to
create micro- and nanosized features on computer chips. The
natural world is replete with examples of systems with
nanoscale structures, such as milk a nanoscale colloid, pro-
teins, cells, bacteria, viruses, etc. Moreover, many materials
that seem smooth to the naked eye have an intricate structure
on the scale of nanometers Fig. 1. Thus, in many ways,
nanomaterials are not new. Recent advances in synthesis and
characterization tools, however, have fueled a boom in the
study and industrial use of nanostructured materials. A new
vocabulary has emerged from this research, and its important
terms and concepts are deﬁned below.
Nanomaterials are materials that have structural compo-
nents smaller than 1 m in at least one dimension. While the
atomic and molecular building blocks 0.2 nm of matter
are considered nanomaterials, examples such as bulk crystals
with lattice spacing of nanometers but macroscopic dimen-
sions overall are commonly excluded.
Nanoparticles are particles with at least one dimension
smaller than 1 m, and potentially as small as atomic and
molecular length scales 0.2 nm. Nanoparticles can have
amorphous or crystalline form, and their surfaces can act as
carriers for liquid droplets or gases. To some degree, nano-
particulate matter should be considered a distinct state of
matter, in addition to the solid, liquid, gaseous, and plasma
states, due to its distinct properties large surface area and
quantum size effects. Examples of materials in crystalline
nanoparticle form are fullerenes and carbon nanotubes, while
traditional crystalline solid forms are graphite and diamond.
Many authors limit the size of nanomaterials to 50 nm Ref.
17 or 100 nm,18 the choice of this upper limit being justiﬁed
by the fact that some physical properties of nanoparticles
approach those of the bulk when their size reaches these
values. However, this size threshold varies with material type
and cannot be the basis for such a classiﬁcation. A legitimate
deﬁnition extends this upper size limit to 1 m, the submi-
cron range being classiﬁed as nano.
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Nanoparticulate matter refers to a collection of nanopar-
ticles, emphasizing their collective behavior.
Nanotechnology can be deﬁned as the design, synthesis,
and application of materials and devices whose size and
shape have been engineered at the nanoscale. It exploits
unique chemical, physical, electrical, and mechanical prop-
erties that emerge when matter is structured at the nanoscale.
Nanotoxicology was proposed as a new branch of toxicol-
ogy to address the adverse health effects caused by
nanoparticles.19 Despite suggestions that nanotoxicology
should only address the toxic effects of engineered nanopar-
ticles and structures,20 we recommend that nanotoxicology
should also encompass the toxic effects of atmospheric par-
ticles as well as the fundamentals of virology and bacteriol-
ogy. While signiﬁcant differences exist between the health
effects of nonbiological particles and viruses and bacteria,
there are signiﬁcant common aspects of intrusion and
translocation.
The new terminology of nano has united previously seem-
ingly disparate ﬁelds, and a lexicon is needed to ﬁnd and
appreciate the great wealth of existing nano research, not
conveniently labeled with the nano keyword.
Health sciences epidemiology terminology. In existing
medical and toxicological terminology, nanoparticles having
a diameter smaller than 100 nm are often called ultraﬁne
particles UFP or ultraﬁne particulate matter. Ultraﬁne par-
ticles are labeled as a function of their size. For example,
particulate matter with constituents having diameters smaller
than 10 m is abbreviated PM10. Particulate matter having a
size smaller than 100 nm is labeled as PM0.1.
Environmental sciences terminology. Ambient particulate
matter is categorized into three size distributions: ultraﬁne
particles less than 0.1 m in diameter mainly resulting from
combustion, accumulation mode particles between 0.1 and
2.5 m in diameter resulting from aggregation of ultraﬁne
particles and vapors, and coarse-mode particles larger than
2.5 m mostly mechanically generated.24
Proposed terminology. It is important, and timely, to unify
the terminology used for describing particle size in nanotech-
nology, health, and environmental sciences.
The materials under discussion can be classiﬁed as par-
ticles, regardless of their source. The size of these particles
varies between 1 nm and several microns, and they can,
therefore, be classiﬁed as either nanoparticles NP any di-
mension smaller than 1 m or microparticles MP all di-
mensions larger than 1 m. To further specify particle size,
we propose a modiﬁcation of the health sciences epidemiol-
ogy terminology, labeling particles by their largest dimen-
sion; for example, 10 nm in diameter are labeled “NP10,”
while 10 m microparticles are labeled “MP10.”
Given that microparticles and nanoparticles vary in their
conception by only their size, it can be difﬁcult to fully ap-
preciate the differences between them. To illuminate the ef-
fect of the size difference, the sizes of several natural micro-
and nanostructures are shown in Fig. 2, as measured from
scanning and transmission microscope images.25,26 Gener-
ally, the sizes of nanomaterials are comparable to those of
viruses, DNA, and proteins, while microparticles are compa-
rable to cells, organelles, and larger physiological structures
Fig. 2. A red blood cell is approximately 7 m wide, a hair
60 m, while lung alveoli are approximately 400 m.
B. Main differences between nanomaterials and bulk
materials
Two primary factors cause nanomaterials to behave sig-
niﬁcantly differently than bulk materials: surface effects
causing smooth properties scaling due to the fraction of at-
oms at the surface and quantum effects showing discon-
tinuous behavior due to quantum conﬁnement effects in ma-
FIG. 1. SEM images showing the complexity of the world at the micro- and
nanoscale: a the inner surface of a bird’s eggshell, credit: Janice Carr,
Sandra L. Westmoreland, courtesy Public Health Image Library Ref. 21;
b the rough surface of table grape, credit: Janice Carr, courtesy Public
Health Image Library Ref. 21; c the textured surface of a parsley leaf,
credit Janice Carr, courtesy Public Health Image Library Ref. 21; d
Kleenex paper, courtesy of Jim Ekstrom Ref. 22; e pollen from a vari-
ety of common plants, credit Louisa Howard, Charles Daghlian, courtesy
Public Health Image Library Ref. 21; f green algae, credit Elizabeth
Smith, Louisa Howard, Erin Dymek, Public Health Image Library Ref.
21; g Gecko nano-adhesive system, with increasing magniﬁcation from
left to right: gecko climbing vertical glass, adhesive surface microstructure,
individual setae, nanostructure of spatular endings, courtesy of PNAS Ref.
23.
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terials with delocalized electrons.27 These factors affect the
chemical reactivity of materials as well as their mechanical,
optical, electric, and magnetic properties.
The fraction of the atoms at the surface in nanoparticles is
increased compared to microparticles or bulk. Compared to
microparticles, nanoparticles have a very large surface area
and high particle number per unit mass. For illustration, one
carbon microparticle with a diameter of 60 m has a mass of
0.3 g and a surface area of 0.01 mm2. The same mass of
carbon in nanoparticulate form, with each particle having a
diameter of 60 nm, has a surface area of 11.3 mm2 and con-
sists of 1109 nanoparticles Fig. 3. The ratio of surface
area to volume or mass for a particle with a diameter of
60 nm is 1000 times larger than a particle with a diameter of
60 m Fig. 3b. As the material in nanoparticulate form
presents a much larger surface area for chemical reactions,
reactivity is enhanced roughly 1000-fold. While chemical re-
activity generally increases with decreasing particle size, sur-
face coatings and other modiﬁcations can have complicating
effects, even reducing reactivity with decreasing particle size
in some instances.
The atoms situated at the surface have less neighbors than
bulk atoms, resulting in lower binding energy per atom with
decreasing particle size.27 A consequence of reduced binding
energy per atom is a melting point reduction with particle
radius, following the Gibbs-Thomson equation.27. For ex-
ample, the melting temperature of 3 nm gold nanoparticles is
more than 300 degrees lower than the melting temperature of
bulk gold, as shown in Fig. 3c.27
An example of a class of materials that clearly exploits
quantum effects is quantum dots—synthesized nanostruc-
tures with sizes as small as a few nanometers Fig. 4. The
electronic behavior of quantum dots is similar to that of in-
FIG. 2. Logarithmical length scale showing size of nanomaterials compared
to biological components and deﬁnition of “nano” and “micro” sizes.
FIG. 3. a Schematics illustrating a
microparticle of 60 m diameter,
about the size of a human hair—
shown in the left at scale courtesy
Chelsea Elliott, and the number of
nanoparticles with diameter of 600
and 60 nm having the same mass as
one microparticle of 60 m diameter.
b Surface area normalized to mass
versus particle diameter. c Gold
melting temperature as a function of
particle diameter, according to Gibbs-
Thomson equation, shown inset; the
gold bulk melting temperature is
1336 K Ref. 27.
FIG. 4. a TEM image of CdSe semiconductor nanoparticles, and b pho-
tograph of CdSe nanoparticles in solution, photo-luminescent under UV
illumination. Images courtesy of Graham Rodway and Harry Ruda, Univer-
sity of Toronto.
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dividual atoms or small molecules, and quantum dots are
regarded as akin to artiﬁcial atoms.28 Notably, the conﬁne-
ment of the electrons in quantum dots in all three spatial
directions results in a quantized energy spectrum. Another
result of quantum conﬁnement effect is the appearance of
magnetic moments in nanoparticles of materials that are non-
magnetic in bulk, such as gold, platinum, or palladium.27
Magnetic moments result from several unpaired electron
spins in nanoparticles formed of several hundred atoms.
Quantum conﬁnement also results in quantiﬁed changes in
the ability to accept or donate electrical charge or electron
afﬁnity, also reﬂected in the catalytic ability.27 For example,
the reactivity of cationic platinum clusters in the decompo-
sition of N2O is dictated by the number of atoms in the
cluster, namely, 6–9, 11, 12, 15, and 20 atom-containing
clusters are very reactive, while clusters with 10, 13, 14, and
19 atoms have low reactivity.27
C. Nanomaterials and nanotoxicology publications
statistics
The number of publications on the topic of nanomaterials
has increased at an almost exponential rate since the early
1990s, reaching about 40 000 in the year 2005 Fig. 5, as
indicated by a search on the ISI Web of Knowledge
database.29 There is also a notable rise in the number of
publications discussing their toxicity, particularly in the past
two years. The total number of papers on toxicity, however,
remains low compared to the total number of publications on
nanomaterials, with only around 500 publications in the year
2005.
The large number of publications on nanomaterials can be
explained by the fact that nanoscience and nanotechnology
encompass a wide range of ﬁelds, including chemistry, phys-
ics, materials engineering, biology, medicine, and electron-
ics. There are several reviews addressing nanotoxicology as-
pects; however, they are intended for a narrow, specialized
audience. Several are comparatively general,18,20,30–32 while
others address selected aspects of nanoparticle toxicology,
such as health effects of air pollution;33 epidemiological re-
views of exposure to particles;34 epidemiological studies of
cardiovascular effects of airborne particles;35 occupational
aspects of nanoparticles;36 particle inhalation, retention, and
clearance;37 pulmonary effects of inhaled particles;38,39 inha-
lation and lung cancer;40,41 toxicity of combustion-derived
particles inhalation;42 environmental factors in neurodegen-
erative diseases;43 oxidative mechanisms;44–51 gastrointesti-
nal uptake of particles;52 targeted drug delivery;53 particle
characterization methods;54 screening strategies and future
directions of research;55 and regulation of nanomaterials.56
Existing reviews are either written in jargon comprehensive
only to specialists in a particular ﬁeld, or are, if more acces-
sible, very succinct.32,57 Most nanotechnology reviews writ-
ten to date focus on a speciﬁc subﬁeld, disregarding the vast
amount of existing knowledge on the general theme of nano.
In this review, we attempt to bring together a broader audi-
ence by unifying the language and experience of scientists
working within these diverse ﬁelds.
D. Introduction to nanoparticle toxicity
Human skin, lungs, and the gastrointestinal tract are in
constant contact with the environment. While the skin is gen-
erally an effective barrier to foreign substances, the lungs
and gastrointestinal tract are more vulnerable. These three
ways are the most likely points of entry for natural or anthro-
pogenic nanoparticles. Injections and implants are other pos-
sible routes of exposure, primarily limited to engineered
materials.
Due to their small size, nanoparticles can translocate from
these entry portals into the circulatory and lymphatic sys-
tems, and ultimately to body tissues and organs. Some nano-
particles, depending on their composition and size, can pro-
duce irreversible damage to cells by oxidative stress and/or
organelle injury. Figure 6 illustrates the size of an example
cell and its organelles compared to nanoparticles of various
sizes, making it easy to understand why nanoparticles are
able to enter cells and interact with various cell components
nucleus, mitochondria, etc..
In Fig. 7, we summarize the possible adverse health ef-
fects associated with inhalation, ingestion, and contact with
nanoparticles. We emphasize that not all nanoparticles pro-
duce these adverse health effects—the toxicity of nanopar-
ticles depends on various factors, including size, aggrega-
FIG. 5. Statistics on scientiﬁc articles published on a nanomaterials and b
their toxicity Ref. 29.
FIG. 6. Comparison of rat macrophage cells size to nanoparticles size at
scale. Human macrophages are up to two times larger than rat macroph-
ages. TEM image reproduced with permission from Environmental Health
Perspectives Ref. 238.
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tion, composition, crystallinity, surface functionalization, etc.
In addition, the toxicity of any nanoparticle to an organism is
determined by the individual’s genetic complement, which
provides the biochemical toolbox by which it can adapt to
and ﬁght toxic substances. While these effects will be dis-
cussed in detail in Secs. III and IV, we summarize below the
most extreme adverse health effects produced by nanopar-
ticles in order to immediately increase the awareness of po-
tential toxicity of some nanoparticles. Diseases associated
with inhaled nanoparticles are asthma, bronchitis, emphy-
sema, lung cancer, and neurodegenerative diseases, such as
Parkinson’s and Alzheimer’s diseases. Nanoparticles in the
gastrointestinal tract have been linked to Crohn’s disease and
colon cancer. Nanoparticles that enter the circulatory system
are related to occurrence of arteriosclerosis, blood clots, ar-
rhythmia, heart diseases, and ultimately cardiac death. Trans-
location to other organs, such as liver, spleen, etc., may lead
to diseases of these organs as well. Exposure to some nano-
particles is associated with the occurrence of autoimmune
diseases, such as systemic lupus erythematosus, scleroderma,
and rheumatoid arthritis.
II. NANOPARTICLE CLASSIFICATION
Nanoparticles are generally classiﬁed based on their di-
mensionality, morphology, composition, uniformity, and ag-
glomeration.
An important additional distinction should be made be-
tween nanostructured thin ﬁlms or other ﬁxed nanometer-
scale objects such as the circuits within computer micropro-
cessors and free nanoparticles. The motion of free
nanoparticles is not constrained, and they can easily be re-
leased into the environment, leading to human exposure that
may pose a serious health risk. In contrast are the many
objects containing nanostructured elements that are ﬁrmly
attached to a larger object, where the ﬁxed nanoparticles
should pose no health risk when properly handled. An ex-
ample of this important distinction is the material asbestos,
which is perfectly safe in its primary state basically a type
of solid rock, but is a signiﬁcant health hazard when mined
or worked in such a way as to produce the carcinogenic
nanometer-scale ﬁbrous particles that become airborne aero-
sol and are, therefore, readily absorbed in the lungs.
It is also very important to recognize that not all nanopar-
ticles are toxic; toxicity depends on at least chemical com-
position and shape in addition to simply size and particle
aging. In fact, many types of nanoparticles seem to be
nontoxic,58,59 others can be rendered nontoxic,60 while others
appear to have beneﬁcial health effects.61,62 An important
lesson we are in the process of learning from nanoscience is
that simple classiﬁcations of physical behavior and, there-
fore, toxicity are overly limiting and that we must study
FIG. 7. Schematics of human body with pathways of exposure to nanoparticles, affected organs, and associated diseases from epidemiological, in vivo and in
vitro studies.
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toxicology of each material and each morphology, in addi-
tion to particle aging, to obtain accurate information to in-
form policy and regulatory processes.
A. Dimensionality
As shape, or morphology, of nanoparticles plays an im-
portant role in their toxicity, it is useful to classify them
based on their number of dimensions Fig. 8. This is a gen-
eralization of the concept of aspect ratio.
One-dimensional (1D) nanomaterials. Materials with one
dimension in the nanometer scale are typically thin ﬁlms or
surface coatings, and include the circuitry of computer chips
and the antireﬂection and hard coatings on eyeglasses. Thin
ﬁlms have been developed and used for decades in various
ﬁelds, such as electronics, chemistry, and engineering. Thin
ﬁlms can be deposited by various methods,63 and can be
grown controllably to be only one atom thick, a so-called
monolayer.
Two-dimensional (2D) nanomaterials. Two-dimensional
nanomaterials have two dimensions in the nanometer scale.
These include 2D nanostructured ﬁlms, with nanostructures
ﬁrmly attached to a substrate, or nanopore ﬁlters used for
small particle separation and ﬁltration. Free particles with a
large aspect ratio, with dimensions in the nanoscale range,
are also considered 2D nanomaterials. Asbestos ﬁbers are an
example of 2D nanoparticles.
Three-dimensional (3D) nanomaterials. Materials that are
nanoscaled in all three dimensions are considered 3D nano-
materials. These include thin ﬁlms deposited under condi-
tions that generate atomic-scale porosity, colloids, and free
nanoparticles with various morphologies.64
B. Nanoparticle morphology
Morphological characteristics to be taken into account are
ﬂatness, sphericity, and aspect ratio. A general classiﬁcation
exists between high- and low-aspect-ratio particles Fig. 8.
High-aspect-ratio nanoparticles include nanotubes and nano-
wires, with various shapes, such as helices, zigzags, belts, or
perhaps nanowires with diameter that varies with length.
Low-aspect-ratio morphologies include spherical, oval, cu-
bic, prism, helical, or pillar. Collections of many particles
exist as powders, suspension, or colloids.
C. Nanoparticle composition
Nanoparticles can be composed of a single constituent
material Fig. 8 or be a composite of several materials. The
nanoparticles found in nature are often agglomerations of
materials with various compositions, while pure single-
composition materials can be easily synthesized today by a
variety of methods see Sec. III B 6.
D. Nanoparticle uniformity and agglomeration
Based on their chemistry and electromagnetic properties,
nanoparticles can exist as dispersed aerosols, as suspensions/
colloids, or in an agglomerate state Fig. 8. For example,
magnetic nanoparticles tend to cluster, forming an agglomer-
ate state, unless their surfaces are coated with a nonmagnetic
FIG. 8. Classiﬁcation of nanostructured materials from the point of view of nanostructure dimensions, morphology, composition, uniformity and agglomeration
state.
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material. In an agglomerate state, nanoparticles may behave
as larger particles, depending on the size of the agglomerate.
Hence, it is evident that nanoparticle agglomeration and size
and surface reactivity, along with shape and size, must be
taken into account when considering health and environmen-
tal regulations of new materials.
III. SOURCES OF NANOPARTICLES AND THEIR
HEALTH EFFECTS
A. Natural sources of nanoparticles
Nanoparticles are abundant in nature, as they are pro-
duced in many natural processes, including photochemical
reactions, volcanic eruptions, forest ﬁres, and simple erosion,
and by plants and animals, e.g., shedding of skin and hair.
Though we usually associate air pollution with human
activities—cars, industry, and charcoal burning—natural
events such as dust storms, volcanic eruptions, and forest
ﬁres can produce such vast quantities of nanoparticulate mat-
ter that they profoundly affect air quality worldwide. The
aerosols generated by human activities are estimated to be
only about 10% of the total, the remaining 90% having a
natural origin.65 These large-scale phenomena are visible
from satellites, and produce particulate matter and airborne
particles of dust and soot ranging from micro- to nanoscales.
Small particles suspended in the atmosphere, often known as
aerosols, affect the entire planet’s energy balance because
they both absorb radiation from the sun and scatter it back to
space.66 It has been estimated that the most signiﬁcant com-
ponents of total global atmospheric aerosols are, in decreas-
ing mass abundance, mineral aerosols primarily from soil
deﬂation wind erosion with a minor component 1% 
from volcanoes 16.8 Tg, sea salt 3.6 Tg, natural and an-
thropogenic sulfates 3.3 Tg, products of biomass burning
excluding soot 1.8 Tg, and of industrial sources including
soot 1.4 Tg, natural and anthropogenic nonmethane hydro-
carbons 1.3 Tg, natural and anthropogenic nitrates 0.6 Tg,
and biological debris67 0.5 Tg. Note: “Tg” here denotes
terragram, equal to 1012 g.
1. Dust storms and health effects
Terrestrial dust storms. Dust storms appear to be the larg-
est single source of environmental nanoparticles. Long-range
migration of both mineral dust and anthropogenic pollutants
from the major continents has recently been the subject of
intense investigation. Approximately 50% of troposphere at-
mospheric aerosol particles are minerals originating from the
deserts.68 The size of particles produced during a dust storm
varies from 100 nm to several microns Fig. 9d, with one-
third to a half of the dust mass being smaller than
2.5 m.65,68 Particles in the range 100–200 nm can reach
concentrations of 1500 particles /cm3.69
Meteorological observations and modeling have identiﬁed
ten main sources of global dust events, shown in Fig. 9e:
1 the Salton Sea, 2 Patagonia, 3 the Altipläno, 4 the
Sahel region, 5 the Sahara Desert, 6 the Namibian desert
lands, 7 the Indus Valley, 8 the Taklimakan Desert, 9 the
Gobi Desert, and 10 the Lake Eyre basin.65
Satellite imagery has revealed the dynamics of large-scale
dust migration across continents, and demonstrated that
nanoparticles generated by major environmental events in
one part of the world can affect regions thousands of kilo-
meters away, as shown in Fig. 9. For example, dust storms
occurring every spring in the Gobi Desert strongly affect the
air quality in Asia and North America.70,71 The dust route
across the Paciﬁc can be seen in satellite images by the yel-
low color of the dust itself Fig. 9a.72 The dust migration
pattern during the 1998 trans-Paciﬁc transport is shown in
Fig. 9c, the dates representing the approximate daily loca-
tion of the dust cloud.70 During this event, the dust cloud
reached the west coast of North America within ﬁve to six
days after emission, with the region affected experiencing an
intense haze and elevated particles concentrations, with an
average excess of 20–50 g /m3 with local peaks
100 g /m3.70,71
Extraterrestrial dust. Nanoparticles exist widely in extra-
terrestrial space. Examples of dust collected from space,
from the moon, and on Mars are shown in Fig. 10. The
extraterrestrial dust poses major environmental problems for
astronauts as well as for equipment.73 Lunar dust is very ﬁne
grained compared to typical terrestrial dust some of the
larger grains being shown in Fig. 10c, with more than 50%
of particles found to be in the micron range or smaller.74 The
lunar dust contains a considerable amount of magnetic
nanoparticles,75 clinging to electrostatically charged
surfaces74 such as the astronauts’ space suits Fig. 10b,
rendering it nearly impossible to remove. On Mars, dust ac-
cumulating on the solar panels of the exploration robots has
limited the power available to them for locomotion, sensing,
and communication.76 Aiming to mitigate the environmental
effects of extraterrestrial dust on humans and machines, vari-
ous research projects are directed towards the fabrication of
ﬁlters or thin ﬁlm coatings that repel dust.76
Health effects. Terrestrial airborne dust particles can lead
to a number of health problems, especially in subjects with
asthma and emphysema.65 The composition of dusts is im-
portant, as dust rich in iron or other metals can generate
reactive oxygen species on the lung surface that can scar
lung tissue.65 In addition, viruses, bacteria, fungi, or chemi-
cal contaminants hitchhiking dust particles may adversely
affect health and the environment Fig. 9f. In this regard, it
is important to note that 200 types of viable bacteria and
fungi have been found to survive ultraviolet light exposure
during intercontinental journeys from Africa to America.65
Extraterrestrial dust brought inside the lunar module be-
came airborne, and irritated the lungs and eyes of Apollo
astronauts.77 On longer missions to the moon or Mars, pro-
longed exposure could increase the risk of respiratory dis-
eases in the astronauts, and mechanical failures of spacesuits
and airlocks. Studies on rats have found that intratracheal
administration of small amounts of lunar material resulted in
pneumoconiosis with ﬁbrosis formation78 lung disease and
abnormal tissue growth.
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2. Forest ﬁres and health effects
Forest ﬁres and grass ﬁres have long been a part of
Earth’s natural history, and are primarily caused by lightning
strikes or by human activity. Major ﬁres can spread ash and
smoke Fig. 11a over thousands of square miles Figs.
11b and 11c and lead to an increase of particulate matter
including nanoparticles exceeding ambient air quality
standards.79 Satellite maps show a unique picture of global
ﬁre activity. Using daily global ﬁre detection provided by
moderate-resolution imaging spectroradiometer MODIS on
NASA’s Terra satellite, the ﬁre activity for the entire surface
of the Earth has been mapped every day since February 2000
Fig. 11d.80 As noticed in this ﬁgure, numerous ﬁres occur
throughout the world in the savannas of Africa, Australia,
and Brazil, and in North America, Europe, and Asia.
Health effects. Epidemiological studies showed that dur-
ing the weeks of forest ﬁres, medical visits increase more
than 50% in the affected regions.81 Patients with preexisting
cardiopulmonary conditions reported worsening symptoms
during smoke episodes. The usage of air cleaners was asso-
ciated with less adverse health effects on the lower respira-
tory tract.81 Around 75% of ﬁre-related deaths are due to
FIG. 9. Sand storms visualized at macro and microscale. a Satellite image showing dust blowing off mainland China over the Sea of Japan and Paciﬁc Ocean
in April 2002, credit Jacques Descloitres, MODIS Land Rapid Response Team, NASA/GSFC Ref. 72. b Beijing during a dust storm. c Approximate
location of the dust cloud from a Gobi desert dust storm during April 1998, based on satellite images, after Ref. 70. d Asia dust storm samples collected
during the 16 March 2002 dust storm Ref. 68, courtesy of American Geophysical Union. e Ten major sources of dust in the world; f bacteria collected
from African dust that reached North America. Both e and f were reproduced with permission from Environmental Health Perspectives Ref. 65.
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respiratory problems related to smoke inhalation and not
necessarily burns. The treatment for smoke inhalation in an
emergency room is usually oxygen. Due to the fact that the
symptoms may be delayed until 24–36 h after inhalation, the
patient must be kept under observation for several days.
3. Volcanoes and health effects
When a volcano erupts, ash and gases containing particu-
late matter ranging from the nanoscale to microns Figs.
12a–12c are propelled high into the atmosphere, some-
times reaching heights over 18 000 m. The quantity of par-
ticles released into the atmosphere is enormous; a single vol-
canic eruption can eject up to 30106 tons of ash.65
Volcanic ash that reaches the upper troposphere and the
stratosphere the two lowest layers of the atmosphere can
spread worldwide and affect all areas of the Earth for years.
A primary effect of upper atmospheric particulate debris is
the blocking and scattering of radiation from the sun. One
particularly harmful volcanic product is particles composed
of heavy metals, as these are known to be toxic to humans.
While some effects are seen worldwide, the highest levels of
particulate matter are found in areas within tens of kilome-
ters from the volcano.82
Health effects. Short-term effects of ash on health include
respiratory effects nose and throat irritation, and bronchitic
symptoms and eye and skin irritation. To assess the impact
of long-term exposure to volcanic particulate pollution, we
can look to the barefoot agricultural populations living in
parts of the world containing volcanic soils, such as Africa,
Mediterranean, and Central America. A large percentage of
this population is affected by diseases of lympho-endothelial
origin. The diseases include podoconiosis83–85 Fig. 12d
and Kaposi’s sarcoma81,86 Fig. 12f.
Podoconiosis is a noncommunicable disease producing
lymphedema localized ﬂuid retention of the lower limbs.
The cause of this disease is believed to be the absorption
through the skin of the feet podos of nano- and micropar-
ticles from the soil konia.87 Lymphedema occurs when the
lymphatic system fails to properly collect and drain the in-
terstitial ﬂuid of the body, resulting in the long-term swelling
of a limb or limbs Fig. 12d. The lymphatic system is a
FIG. 11. a TEM image of smoke aggregates from a ﬁre in Zambia Ref. 91 courtesy of American Geophysical Union. NASA satellite images showing
smoke pollution from ﬁres, indicated with red dots. b South California ﬁres credit: Jacques Descloitres, MODIS Rapid Response Team, NASA/GSFC Ref.
72. c Smoke from ﬁres of Central America spreads towards Golf of Mexico and US in May 2003, credit Jeff Schmaltz, MODIS Rapid Response Team,
NASA/GSFC. d Distribution of active ﬁres detected by Terra’s MODIS sensor across the planet on 10-19 July 2006 courtesy of NASA/MODIS Rapid
Response Team/Scientiﬁc Visualization Studio Ref. 72.
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FIG. 10. Extraterrestrial dust. a SEM of interplanetary dust composed of glass, carbon and silicate mineral nanoparticles courtesy of NASA Ref. 346. b
Lunar dust on the suit of an astronaut inside the lunar module on the lunar surface. The picture was taken after the second extravehicular activity on this
mission on December 12, 1972 Image ID: AS17-145-22224, courtesy of NASA Johnson Space Center NASA-JSC. c Larger lunar dust particles returned
from the moon by Apollo 17 in 1973. These orange glass spheres and fragments range in size from 20 to 45 m courtesy of NASA-JSC Ref. 89. d Global
Mars dust storm of 2001 courtesy NASA/JPL/Malin Space Science Systems Ref. 90. e Mars devil-streaked surface courtesy NASA/JPL/Malin Space
Science Systems Ref. 90. c Mars dust devil courtesy NASA Ref. 90.
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secondary circulatory system in the body that collects ﬂuid
from several sources, primarily that lost from the circulatory
system blood, for example, from damaged blood vessels in
an area of inﬂammation e.g., after a burn or other injury.88
The lymphatic system lacks a central pump, i.e., the equiva-
lent to the heart in the circulatory system, so it relies on a
network of vessels and nodes that pump during usual
muscle motion of the body. If the accumulation of the in-
terstitial ﬂuid is faster than the pumping, then the tissue
swells. In podoconiosis, the effect is irreversible, and affects
about 10% of the populations in volcanic tropics. Soil par-
ticles with size ranging from 400 nm up to 25 m were
found in the dermis of the foot of individuals with
podoconiosis.83,84 These particles were found in the mac-
rophages, in the cytoplasm of other cells, as well as in lymph
node biopsies, as indicated by scanning electron microscopy.
Energy-dispersive x-ray analysis techniques showed compo-
sitions consistent with the elements present in black lava soil
and red clay soil.85 It is hypothesized that large quantities of
small particles and chronic exposure overwhelm the normal
function of the lymphatic drainage system in the patients
with podoconiosis, blocking drainage of both particles and
lymph ﬂuid.83–85
Kaposi’s sarcoma is a form of cancer affecting the blood
and lymph vessels Fig. 12f, and is also related to human
herpesvirus infection.81 Endemic Kaposi’s sarcoma81,86 is
characteristic to parts of the world containing volcanic
soils.81 It was found that iron particles from the iron-rich
volcanic soils Fig. 12e may be one of the cofactors in-
volved in the etiology set of causes of Kaposi’s sarcoma.81
In chronic exposure to iron volcanic clays, ferromagnetic
nanoparticles penetrate the skin of barefoot agricultural
workers, leading to impaired lymphatic drainage and local
immunity, leaving the organism prone to infections such as
herpesvirus.
Treatment. The treatment of podoconiosis in early stages
involves elevation and elastic stockings, while in more ad-
vanced stages, the only treatment is surgical. Treatment of
Kaposi’s sarcoma involves iron withdrawal and iron
chelators.81 Both of these diseases, podoconiosis and Kapo-
si’s sarcoma, could be prevented by wearing shoes or boots
not sandals or shoes with open spaces starting from early
childhood.92
4. Ocean and water evaporation, and health effects
A large amount of sea salt aerosols are emitted from seas
and oceans around the world.67 These aerosols are formed by
water evaporation and when wave-produced water drops are
ejected into the atmosphere Fig. 13a. Their size ranges
from 100 nm to several microns. An example of sea salt
nanoparticles is shown in Fig. 13b. Nanoparticles can also
form in bodies of water through precipitation, as a result of
temperature changes and evaporation. An example of this
phenomenon is Lake Michigan that rests in a limestone ba-
sin, the water containing high levels of calcium carbonate.
During most of the year, the calcium carbonate remains dis-
solved in the cold water, but at the end of summer, the water
temperature increases, lowering the solubility of calcium car-
bonate. As a result, the calcium carbonate may precipitate
out of the water, forming clouds of nanometer-scale particles
that appear as bright swirls when viewed from above, as
shown in Fig. 13c.93
Health effects. No adverse health effects have been asso-
ciated with sea salt aerosols. On the contrary, beneﬁcial
health effects have been suggested from the use of salt aero-
sols in the restoration of the mucociliary clearance in patients
with respiratory diseases.94 The unique microclimate of salt
mines is a popular way to treat asthma, particularly in East-
ern Europe. However, sea salt aerosols may transport pollut-
FIG. 12. a The eruption plume of St. Helen volcano, in 1980 courtesy of
NASA. b Rabaul Eruption Plume, New Britain Island, 1994. The large
scale of eruption can be compared to the Earth’s curvature courtesy of
Image Science and Analysis Laboratory, NASA-JSC Ref. 95; c Scan-
ning electron microscope image of volcanic ash from the ﬁrst volcanic erup-
tion of Mount St. Helens, Washington state, USA in 1980, courtesy of
Chuck Daghlian Louisa Howard Ref. 96. d Podoconiosis Ref. 92; cour-
tesy of Elsevier. e Volcanic iron oxide rich soil in Rwanda Ref. 172;
courtesy Biomed Central. f Aggressive African-endemic Kaposi’s sar-
coma of the foot Ref. 172; courtesy Biomed Central.
FIG. 13. a Sea spray from ocean waves courtesy NASA. b TEM image
of mineral dust mixture with sea salt collected from the marine troposphere
Ref. 67. c the pale blue swirls in Lake Michigan are probably caused by
calcium carbonate chalk from the lake’s limestone ﬂoor credit: Jeff
Schmaltz, MODIS Rapid Response Team, NASA/GSFC Ref. 93.
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ants and microorganisms that themselves may cause adverse
health effects.
5. Organisms and health effects
Many organisms are smaller than a few microns Figs.
14c and 14d, including viruses 10–400 nm and some
bacteria 30 nm–700 m. However, we should make a
clear distinction between what we call “particles” micropar-
ticle or nanoparticle and nanoorganisms or their components
including bacteria, viruses, cells, and their organelles.
Cells, bacteria, and viruses are self-organizing, self-
replicating, dissipative structures with a shorter-lived struc-
ture than inorganic solids. Nanoorganisms generally dissipate
when their supply of energy is exhausted. In contrast, nano-
particles are typically inorganic solids that require no supply
of energy to remain in a stable form. They interact, dissipate,
or transform via chemical reactions with their environment.
Many organisms, both uni- and multicellular, produce
nanoparticulate inorganic materials through intracellular and
extracellular processes Fig. 14.97 For example, magnetite
nanoparticles are synthesized by magnetotactic bacteria, and
used for navigation relative to the Earth’s magnetic ﬁeld
Fig. 14a, siliceous materials are produced by diatoms
Fig. 14b, or calcium carbonate layers are produced by
S-layer bacteria.97 Magnetotactic bacteria Fig. 14a orient
and migrate along the geomagnetic ﬁeld towards favorable
habitats using nanometer-size magnetic particles inside the
cell. These bacteria are aquatic microorganisms inhabiting
freshwater and marine environments. In Fig. 14b are shown
various diatom species frustules siliceous shells. Diatoms
are unicellular algae with cell walls made of silica. They are
abundant in plankton communities and sediments in marine
and freshwater ecosystems, where they are an important food
source for other marine organisms. Some may even be found
in moist soils. Diatoms are used in forensic science to con-
ﬁrm drowning as a cause of death and localize the site of
drowning, based on the observation of diatoms in lungs,
blood, bone marrow, and organs.98 Nanobacterium is a na-
noorganism that synthesizes a shell of calcium phosphate to
cover itself, and resembles an inorganic particle Figs. 14e
and 14f. The shell ranges in size between 20 and 300 nm
and, due to its porous nature, it allows the ﬂow of a slimy
substance. This slime presumably together with electrical
charge promotes the adhesion to biological tissues and the
formation of colonies. Nanobacteria are very resilient, being
temperature and gamma radiation resistant.100
Health effects and treatment. Among these biological
nanoparticles, diatoms might pose a health risk to workers of
diatomaceous earth mining and processing;101 biogenic mag-
netite is associated with neurodegenerative diseases,20 and
nanobacteria shells were found in humans and animals.6,100
Nanobacteria are ubiquitous within living organisms, hu-
mans and animals, being identiﬁed in blood, serum, and
organs.100 These very small bacteria are suspected of being
the cause at least in part for many diseases involving cal-
ciﬁcations, such as artery plaque, aortic aneurysm, heart
valves, renal stone formation, chronic prostatitis, ovarian and
breast tumors.6,100,102 They may also be the cause of rapid
kidney stone formation in astronauts on space travels, ac-
cording to a NASA study, probably due to the fact that their
multiplication rate in a microgravity environment increases
fourfold compared to the rate under normal condition of
gravity of only about three days for doubling rate103. De-
ﬁnitive mechanisms relating nanobacteria to these above
mentioned diseases are unknown; however, there are specu-
lations that nanobacteria colonies may act as nucleation sites
for plaque or stone formation.104 Speciﬁc therapies, such as
laser irradiation,105 or antibiotics,104 have shown reduced
plaque formation and even the regression of plaques.
B. Anthropogenic nanomaterials
Humans have created nanomaterials for millennia, as they
are by-products of simple combustion with sizes down to
several nanometers and food cooking, and more recently,
chemical manufacturing, welding, ore reﬁning and smelting,
combustion in vehicle and airplane engines,106 combustion of
treated pulverized sewage sludge,107 and combustion of coal
and fuel oil for power generation.108 While engineered nano-
particles have been on the market for some time and are
FIG. 14. Organisms in the nanoscale range or producing solid-state nanos-
cale debris. a TEM of Aquaspirillum magnetotacticum bacterium showing
magnetosomes iron oxide granules. b SEM of diatom silica frustules or
skeletons. a and b © Dr. Dennis Kunkel/Visuals Unlimited. Reproduced
with permission from Visuals Unlimited Ref. 25. c SEM of bacterioph-
age courtesy of Ross Inman Ref. 99. d SEM of Bacillus anthracis
bacteria spores, that can live for many years, enabling the bacteria to survive
in a dormant state until they encounter a suitable host credit: Laura Rose,
courtesy of Public Health Image Library Ref. 21. e SEM of cultured
nanobacteria, f Dividing nanobacteria covered with a “hairy” apatite layer.
e and f courtesy of PNAS Ref. 6.
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commonly used in cosmetics, sporting goods, tires, stain-
resistant clothing, sunscreens, toothpaste, food additives,
etc., these nanomaterials, and new more deliberately fabri-
cated nanoparticles, such as carbon nanotubes, constitute a
small minority of environmental nanomaterials. The quantity
of man-made nanoparticles ranges from well-established
multiton per year production of carbon black for car tires to
microgram quantities of ﬂuorescent quantum dots markers
in biological imaging.
1. Diesel and engine exhaust nanoparticles and
health effects
Diesel and automobile exhaust are the primary source of
atmospheric nano- and microparticles in urban areas.109 Most
particles from vehicle exhaust are in the size range of
20–130 nm for diesel engines and 20–60 nm for gasoline
engines Fig. 15a,24,110 and are typically approximately
spherical in shape. Carbon nanotubes and ﬁbers, already a
focus of ongoing toxicological studies, were recently found
to be present in engine exhaust as a by-product of diesel
combustion111 and also in the environment near gas-
combustion sources.112 The aspect ratio of these ﬁbers is
comparable to those of lung-retained asbestos, suggesting
that strong carcinogens may exist in exhaust. Prior to the
release of this ﬁndings,111 they were thought not to exist in
the environment, and their existence was attributed exclu-
sively to engineering by materials scientists. Nanoparticles
constitute 20% of the particles’ mass but more than 90% of
the number of diesel-generated particles.17 Due to recent
health concerns, particle size distribution and number con-
centrations studies were conducted in various cities along
different continents.114
A high number concentration of nanoparticles can be lo-
cated near freeways on scales of hundreds of meters, show-
ing that vehicular pollution is a major source of local con-
taminant particulate matter that includes nanoparticles Fig.
15b. The daily proﬁle of nanoparticles matches that of
local vehicle usage.114 High pollution episodes or proximity
to high-trafﬁc roads can increase the mass concentration of
nanoparticles by several times from typically low back-
ground levels of approximately 0.5–2 g /m3.20
Health effects. Research has shown some heterogeneity in
the magnitude of adverse health effects of engine exhaust in
different cities, probably related to the complexity and com-
position of particle mixtures.50 Generally, diesel exhaust is
known to be toxic as it contains high levels of polynuclear
aromatic hydrocarbons including the known carcinogen
benzo-a-pyrene.115
Atmospheric particle pollution from automobile exhaust
seems to have a major inﬂuence on mortality, with a strong
association between increased cardiopulmonary mortality
and living near major roads.116,117 The ﬁndings of this epide-
miological study are in concordance with measurements of
nanoparticle concentration near highways, the concentration
decreasing exponentially over several hundred meters from
the trafﬁc.24 Childhood cancers were also found to be
strongly determined by prenatal or early postnatal exposure
to oil-based combustion gases, primarily engine exhaust.118
Professional drivers show elevated rates of myocardial in-
farction heart attack.119 Studies done in nonsmoking,
healthy, young patrol ofﬁcers have shown that nanoparticles
from vehicular trafﬁc may activate one or more signaling
pathways that cause proinﬂammatory, prothrombotic, and
hemolytic breakdown of red blood cells responses.120 It
was noted that heart rate variability was signiﬁcantly associ-
ated with measures of pollution. Epidemiological studies
conducted on diesel locomotive drivers showed a correlation
between occupational exposures to diesel engine exhaust and
incidence of lung cancer in the workers.121
These ﬁndings suggest that pollutants emitted by vehicles
harm the health of many people, and that professional driv-
ers, frequent drivers, passengers, and people living near ma-
jor roads are at elevated risk. Results seen in these studies
suggest that exposure to exhaust nanoparticles leads to in-
creased risk of cardiovascular events over the long term.
2. Indoor pollution and health effects
Indoor air can be ten times more polluted than outdoor air,
according to the Environmental Protection Agency EPA.122
Humans and their activities generate considerable amounts
of particulate matter indoors Fig. 16. Nanoparticles are
generated through common indoor activities, such as cook-
ing, smoking, cleaning, and combustion e.g., candles and
ﬁreplaces. Examples of indoor nanoparticles are textile ﬁ-
bers, skin particles, spores, dust mite droppings, chemicals,
and smoke from candles, cooking, and cigarettes. A quanti-
tative determination of nanoparticle emissions from selected
indoor sources is given in Table I.123 Particles have also been
shown to enter buildings from outdoors through ventilation
systems.24 As humans generally spend much of their time
indoors more than 80%, indoor pollution directly affects
our health.
Health effects. Long-term exposure to indoor cooking
emissions may pose adverse health effects due to particulate
matter inhalation.124 During cooking, the level of particulate
matter increases more than tenfold compared to noncooking
hours.124 In many regions of the world, death caused from
indoor smoke from solid fuels is considerable, especially in
Africa and Asia Fig. 16e. Poorly ventilated stoves using
biomass fuels wood, crop residue, dung, and coal are
FIG. 15. a TEM showing typical engine exhaust particles consisting of
carbon aggregates small arrow around a larger mineral particle large ar-
row Ref. 113. b particle concentration decreases exponentially with
downwind distance from the freeway particles’ diameter between 6 and
220 nm Ref. 24. c Trafﬁc in Los Angeles courtesy EPA.
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mainly responsible for the death of an estimated 1.6106
people annually, from which more than a half are children
under the age of 5.125 The World Health Organization esti-
mates that more than 50% of the world population uses solid
fuels for cooking and heating, including biomass fuels. Wood
burning is often disregarded as a source of nanoparticles and
assumed to be benign to the environment simply because
wood is a renewable source.
3. Cigarette smoke and health effects
As a combustion product, tobacco smoke is composed of
nanoparticles with size ranging from around 10 nm up to
700 nm, with a maximum located around 150 nm Fig.
17a.127 The environmental tobacco smoke has a very com-
plex composition, with more than 100 000 chemical compo-
nents and compounds.127
Health effects. Environmental tobacco smoke is known to
be toxic, both due to some of its gas phases and nanopar-
ticles. A plethora of studies have investigated the adverse
health effects of environmental cigarette smoke. Substantial
evidence shows that, in adults, ﬁrst or second hand cigarette
smoke is associated with an increased risk of chronic respi-
ratory illness Fig. 17b, including lung cancer, nasal can-
cer, and cardiovascular disease, as well as other malignant
tumors, such as pancreatic cancer128 and genetic
alterations.129 Children exposed to cigarette smoke show an
increased risk of sudden infant death syndrome, middle ear
disease, lower respiratory tract illnesses, and exacerbated
asthma.128 Cigarette smokers are more likely than nonsmok-
ers to develop many conditions including cancers and vascu-
lar diseases.130 It was noted that the risk of myocardial inf-
arction decreases substantially within two years after
smoking cessation, proving a reversibility of inhaled
nanoparticle-induced vulnerability.131
4. Building demolition and health effects
Concentrations of respirable particulate matter particles
with diameters smaller than 10 m can rise to very high
levels when large buildings are demolished.132 Older build-
ings are very likely to have been constructed with parts con-
taining known toxins. Consequently, respirable asbestos ﬁ-
bers, lead, glass, wood, paper, and other toxic particles are
often found at the site of demolition.132 In addition, the dust
cloud can travel tens of kilometers and affect the regions
neighboring the building site.132
Health effects of exposure to demolition particles and soot
Fig. 18 are not entirely known. Early clinical and epide-
miological assessments of ﬁreﬁghters present at the site of
the environmental disaster generated by the attack on the
World Trade Center on September 11, 2001, indicated
exposure-related health effects, with prevalence of respira-
tory symptoms, especially increased cough and bronchial
hyperactivity.133 Long-term effects, however, remain to be
seen.
5. Cosmetics and other consumer products, and
health effects
Cosmetics. The use of nanomaterials in cosmetics is not
new. Black soot and mineral powders have been used as
cosmetics thousands of years ago in ancient Egypt, and some
FIG. 16. Indoor air pollution from a heating, b cooking courtesy of E.K.
Schafhauser, and c candle smoke. d TEM of soot particle from indoors
pollution Ref. 126; reproduced with permission from Environmental Health
Perspectives. e Death from indoor smoke from solid fuels according to
World Health Organization Ref. 125.
TABLE I. Measured concentrations of nanoparticles resulting from various






Pure wax candle 241 500 3.65
Radiator 218 400 8.84
Cigarette 213 300 3.76
Frying meat 150 900 8.27
Heater 116 800 3.89
Gas stove 79 600 1.3
Scented candles 69 600 0.88
Vacuum cleaner 38 300 0.38
Air freshener spray 29 900 2.34
Ironing a cotton sheet 7 200 0.007
FIG. 17. a Measured environmental tobacco smoke particles concentration
versus nanoparticle diameter. Nanoparticles are generated upon smoking one
cigarette after Ref. 127. b Pathology of lung showing centrilobular em-
physema characteristic of smoking. The cut surface shows multiple cavities
heavily lined by black carbon deposits content providers Dr. Edwin P. Ew-
ing, Jr., courtesy of Public Health Image Library Ref. 21.
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of them continue to be used today. Due to the recent devel-
opment of nanotechnology, engineered nanomaterials have
been embraced by the cosmetics industry for several reasons.
a Because of their ability to penetrate deeper into the
protective layers of skin than any cosmetic before, they are
used as delivery agents for skin nutrients, such as synthetic
peptides that instruct cells to regenerate.136
b Some nanoparticles have antioxidant properties,137
features that help maintain a youthful appearance of the skin.
For example, functionalized fullerenes are now incorporated
into cosmetic products, such as creams, claiming radical
scavenging properties.14
c Due to their small size and speciﬁc optical properties,
they are thought to conceal wrinkles and small creases.14 For
example, alumina nanopowder is used for optical reduction
of ﬁne lines.14
Many cosmetic and personal care products incorporate
nanomaterials. For a compilation of websites and product
information, see Ref. 138. They include personal care prod-
ucts deodorants, soap, toothpaste, shampoo, and hair condi-
tioner, sunscreen, and cosmetics cream, foundation, face
powder, lipstick, blush, eye shadow, nail polish, perfume,
and after-shave lotion.
There are two trends regarding the use of engineered
nanoparticles in cosmetics. First, a swift application of nano-
technology advances in the cosmetic industry, in addition to
relabeling of the products that already contain nanoparticles,
so that they are more appealing to the consumers.139 Second,
targeting of cosmetic companies that use nanoparticles. For
the general public and uninformed journalists, there is not
much of a difference between the various types of nanopar-
ticles currently used in cosmetics, such as lipid based nano-
particles, fullerenes, silicon, etc. Everything labeled “nano-
particle” is considered dangerous to some. These trends
result, at least in part, from the lack of regulations for testing
of cosmetic products before they are sold to the public,56
unlike pharmaceutical products that are required to undergo
several years of research before being considered safe. De-
spite the fact that many of the cosmetic companies claim
safety related research, their results are not always disclosed
to the public.
Other consumer products. Many consumer products in-
corporate nano- or microparticles. A noncomprehensive list
of currently available consumer products that incorporate
nanotechnology can be found in Ref. 14. The authors of this
list make no distinction between nanostructured ﬁxed struc-
tures, which are not likely to cause harm an example is their
listing of computer processors, and detachable or free nano-
particles, which can cause adverse health effects.
Titanium dioxide TiO2 particles with diameter larger
than 100 nm are considered biologically inert in both hu-
mans and animals.140 Based on this understanding, titanium
dioxide nanoparticles have been widely used in many prod-
ucts, such as white pigment, food colorant, sunscreens, and
cosmetic creams.19 However, adverse effects of titanium di-
oxide nanoparticles have recently been uncovered.141–145
New research is exploring the potential use of nanostructured
titanium dioxide photocatalyst materials for sterilizing equip-
ment of environmental microorganisms in the health care
facility.146
Silver nanoparticles are used as antibacterial/antifungal
agents in a diverse range of applications: air sanitizer sprays,
socks, pillows, slippers, face masks, wet wipes, detergent,
soap, shampoo, toothpaste, air ﬁlters, coatings of refrigera-
tors, vacuum cleaners, washing machines, food storage con-
tainers, cellular phones, and even in liquid condoms.14
Coatings of nanoparticles are widely used for modifying
fabrics to create stain- and wrinkle-free properties. In addi-
tion, one can ﬁnd clothes with built-in sunscreen and mois-
ture management technology.14 Fabric containing bamboo-
charcoal nanoparticles claims antibacterial and antifungal
properties.14 They are intended for use as face mask cloth
and shoe insoles. Nanocoatings are applied to wetsuits for
higher performance of athletes, or self-cleaning surfaces.
Textiles with 30 nm embedded nanoparticles help prevent
pollen from entering gaps in the fabric.14 Nanoparticles or
nanoﬁbers are starting to be used in water-repellent, stain-
resistant plush toys and stain-repellent mattresses.14 Nano-
sealant sprays for fabrics or leather, and hydrophobic nano-
particle solutions adhering to concrete, wood, glass, cloth,
FIG. 18. a Dust cloud from the World Trade Center collapse spreads to
neighboring streets courtesy EPA. b Heavy dust accumulation in store
closed to World Trade Center Ref. 134. Particle collected from the site of
collapse and neighboring streets: c soot Ref. 134, d glass ﬁber Ref.
134, e and f dust containing Ca, S, and O Ref. 135, g lead Ref. 134,
h titanium particle Ref. 135. Images b–h courtesy Environmental
Health Perspectives.
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etc., allow the surfaces to deﬂect water.14 The most peculiar
applications of nanoﬁbers and nanoparticles discovered in
our literature review are nanoﬁbers that hide hair loss, and
liquid condoms.14
Health effects. All the health effects of the gamut of nano-
particles used in consumer products are not yet known,
though nanotoxicology has revealed adverse health effects of
materials previously considered safe. For example, silver,
widely used as an antibacterial agent, proves to be toxic to
humans or animal cells when in nanoparticle form, its cyto-
toxicity being higher than that of asbestos.112 Inhalation of
silver nanoparticles leads to their migration to the olfactory
bulb, where they locate in mitochondria,20 as well as trans-
location to circulatory system, liver, kidneys, and heart.147
Silver nanoparticles have been found in the blood of patients
with blood diseases148 and in the colon of patients with colon
cancer.
149
A controversial subject is the association between the up-
take of aluminum and Alzheimer’s disease. Epidemiological
studies researching the connection between aluminum in an-
tiperspirants, antacids, or drinking water, and Alzheimer’s
disease are conﬂicting, some ﬁnding positive associations
and others none.150 Due to their latent evolving nature and
multipart etiology, these neurological diseases are difﬁcult to
associate with speciﬁc factors. For example, the exposure
takes place much earlier than the disease occurrence, hence
the subjects may not recall possible exposure, their memory
being already affected by the disease. Moreover, subjects that
suffer from advanced neurodegenerative diseases are not
likely to participate in epidemiological studies due to their
reduced ability to communicate and remember.150 In addi-
tion, multiple factors are known to contribute to Alzheimer’s
disease, such as genetics, increasing age, endocrine condi-
tions, oxidative stress, inﬂammation, smoking, infections,
pesticides, and electromagnetic ﬁelds.150
In general, several questions arise related to the safety of
nanoparticles as consumer products. Are they biocompatible?
Do the nanoparticles enter the lymphatic and circulatory sys-
tems? If not, do they accumulate in the skin, and what are the
long-term effects of accumulation? Do they produce inﬂam-
mation? If they enter the lymphatic and circulatory system, is
the amount signiﬁcant? What are the long-term effects of this
uptake? Related to the beneﬁcial antioxidant properties of
some nanomaterials, long-term effect need to be studied, in
addition to the short-term antioxidant effect. What is the
long-term fate of these nanoparticles? Are they stored in the
skin? Do they enter circulation? What happens when the
nanoparticles undergo chemical reactions and lose their anti-
oxidant properties? The answers to some of these questions
are known, and will be presented in the section dedicated to
nanoparticle toxicity; however, most of the remaining ques-
tions still remain unanswered.
6. Engineered nanomaterials and health effects
The fabrication of nanomaterials is a broad and evolving
ﬁeld. Nanomaterials can be synthesized by many methods
including gas phase processes ﬂame pyrolysis, high tem-
perature evaporation, and plasma synthesis; vapor deposi-
tion synthesis electron, thermal, and laser beam evapora-
tion; colloidal or liquid phase methods in which chemical
reactions in solvents lead to the formation of colloids; and
mechanical processes including grinding, milling, and alloy-
ing. A review of nanomaterial fabrication processes is given
in Ref. 151. A critical fact to consider with engineered nano-
materials is that they can be synthesized in almost any shape
and size by materials scientists. Several examples are given
in Figs. 19–21. Nanostructured materials shown in Fig. 19
are ﬁrmly attached to a substrate and do not pose a health
risk as long as they do not detach from the substrate. Figure
20 shows nanostructured materials where nanostructures are
free and can become airborne, consequently posing a poten-
tial health risk. In Fig. 21, man-made nanoparticles engi-
neered by glancing angle deposition152,153 are shown together
with microorganisms, such as bacteria and viruses.
Health effects. As a main focus of this paper, the adverse
health effects of engineered nanoparticles will be discussed
in Sec. IV. An important initiative by the National Institute
for Occupational Safety and Health was the creation of an
online nanoparticles information library that is updated with
various compositions of nanoparticles as well as with the
known health effects of some nanoparticles.154 As the ﬁelds
of nanotechnology and nanotoxicology are developing so
quickly, this is a great way to update the current knowledge
on nanoparticles fabrication and toxicology.
C. Environmental and occupational exposure to toxic
substances
1. Metals and other dusts
Small quantities of many metals, including copper, mag-
nesium, sodium, potassium, calcium, and iron are essential
for proper functioning of biological systems. At higher
doses, however, metals can have toxic effects, and exposure
to high levels of environmental metals causes disease in
humans.160 The metals listed below are known to be toxic
upon inhalation, ingestion, or dermal exposure. Nanopar-
ticles manufactured from these metals will have health ef-
fects not necessarily easily predicted from previous studies
of non-nanoparticulate quantities of the same metals. As it
FIG. 21. Engineered nanoparticles Ref. 64 together with selected microor-
ganisms, shown at equal magniﬁcation.
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could easily expose workers to these toxic materials, manu-
facturing of metal nanoparticles should be considered a seri-
ous occupational hazard.
The inhalation of metallic or other dusts is known to have
negative health effects. The type of lung disease caused by
dust inhalation depends on the nature of the material, expo-
sure duration, and dose. The inhalation of some metal fumes
e.g., zinc and copper may lead to metal fume fever, an
inﬂuenzalike reaction.162 Several metal dusts e.g., platinum,
nickel, chromium, and cobalt can lead to asthma,162 while
inhalation of other metallic dusts can cause pulmonary ﬁbro-
sis and ultimately lung cancer. The percentage of lung can-
cers attributable to occupational hazards is about 15%, with
exposure to metals being a major cause.162
Beryllium. Beryllium alloys are used for making electrical
and electronic parts, and molds for plastic. Inhalation can
cause lung damage, leading to a pneumonialike syndrome
called acute beryllium disease.163 Beryllium exposure can
also lead to hypersensitivity and allergic reaction character-
ized by an inﬂammatory immune response to even tiny
amounts of beryllium. Hypersensitivity can lead to chronic
beryllium disease, where white blood cells accumulate
around absorbed beryllium particles and form granulomas,
leading to anorexia, weight loss, cyanosis of the extremities,
and heart enlargement.163 Long-term exposure to beryllium
causes cancer in animals and increased risk of lung cancer in
humans.164
Lead. Exposure to lead occurs through the air, household
dust, food, and drinking water. Airborne lead may be present
in industrial emissions, such as those from smelters and re-
ﬁneries. Exposure to high levels of lead and its compounds
can cause serious disability. At highest risk are workers in-
volved in the manufacture of batteries, metals, and paints;
the printing industry; or those chronically exposed to lead
dust e.g., through sanding of surfaces coated with lead or
insecticides. Inhaled or ingested lead circulates in the blood
and is deposited in bone and other tissue.160 Following inha-
lation, about 50%–70% of lead is absorbed into the blood,
allowing it to circulate to most organs. Manifestations of lead
intoxication include impairment of mental functions, visual-
motor performance, memory, and attention span, as well as
anemia, fatigue, lack of appetite, abdominal pain, and kidney
disease, among others.160
Cobalt. Diseases associated with exposure to cobalt are—
asthma, acute illness fever, anorexia, malaise, and difﬁculty
breathing, resembling a viral illness, and interstitial
pneumonitis.162,163
Cadmium. Cadmium is used in batteries, pigments, metal
coatings, and plastics, and is a by-product of the burning of
fossil fuels and cigarettes. As a result of industrial and con-
sumer waste, cadmium accumulates in soil at a rate increase
of 1% per year.160 Plants and feed crops growing in contami-
nated soil take up cadmium, leading to contamination of veg-
etables and animals. High-dose inhalation exposure leads to
severe lung irritation, nausea, and vomiting. Long-term low-
dosage exposure in humans causes lung emphysema, impair-
ment of the immune system and central nervous system, and
FIG. 19. Examples of nanostructured materials in thin ﬁlm form, which are
not toxic unless the nanoparticles get detached: a Si rugate ﬁlter Ref.
155, b Si 12-layered structure Ref. 156, c MgF2 capping layered heli-
cal ﬁlms Reff. 157, d Ti pillars Ref. 158, e Cu pyramids unpub-
lished, f Cu oblique columns Ref. 158, g ZnO nanowires credit: Y.
Lu, courtesy of National Science Foundation, h porous Ag Ref. 64, and
i porous Si Ref. 159. The scale bars represent 100 nm.
FIG. 20. Examples of free nanoparticles. a MWCNTs and b ground
MWCNTs Ref. 224 reproduced with permission from Elsevier. c Sili-
con rods Ref. 347. d Carbon black. e Silver f titanium dioxide Ref.
112; reproduced with permission from Springer Science and Business Me-
dia. g Gold nanorods Ref. 161; courtesy of National Academy of Sci-
ences of US. h Silicon zigzags Ref. 347. i Magnesium ﬂuoride helices
Ref. 347. The scale bar represents 100 nm.
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liver damage.160 Occupational exposure to cadmium has
been linked to lung cancer in humans, some studies associ-
ating cadmium exposure with cancer of the liver, bladder,
and stomach, and possibly of pancreas.165
Aluminum. Exposure to aluminum occurs through con-
sumption of food and water, as well as usage of many prod-
ucts containing aluminum, including antacids and antiperspi-
rants. The use of antiperspirants combined with underarm
shaving has been associated with an earlier age of breast
cancer diagnosis.166 Aluminum excess can lead to anemia,
bone disease, and dementia.167 Exposure to high levels of
aluminum and other metals, such as iron is implicated in
neurological disorders, such as dialysis encephalopathy, Par-
kinson dementia, and especially Alzheimer’s disease.168
Studies of brain plaques associated with Alzheimer’s disease
show abnormally high aluminum,160 but have not shown if
this is a cause or effect of the disease. However, it is hypoth-
esized that a critical mass of metabolical errors is important
in producing Alzheimer’s disease.169 If aluminum can reach
the brain via the olfactory bulb by passing the blood-brain
barrier, or via the circulatory system, then brain metabolical
errors resulting from accumulations of this metal in parts of
the brain could contribute to the onset of Alzheimer’s
disease.169 Rats that received subcutaneous injection of alu-
minum glutamate show pathological signs similar to those
observed in human Alzheimer’s disease.170 They show a sig-
niﬁcant increase of aluminum content in the brain hippoc-
ampus, occipitoparietal cortex, cerebellum, and striatum and
symptoms that include trembling, equilibrium instabilities,
and convulsions, followed by death 1 h after the injection.
Nickel and chromium. Nickel is used for the production of
stainless steel and other nickel alloys with numerous appli-
cations. Occupational exposure to nickel via inhalation of
dust and fumes is associated with cancers of the lung and
sinus.160 Chromium derived from smelting has also been
found to cause cancer.
Manganese. Manganese is an essential nutrient, but is also
known to have neurotoxic effects.150,171 At high levels, man-
ganese exposure through contaminated water or inhalation
results in neurological impairment. Occupational exposure
generally occurs only to those involved in mining and weld-
ing. An example of welding-generated nanoparticles is given
in Fig. 22a. There is a clear association between manganese
and neurological disease in miners exposed to MnO2 dust.171
The neurological disorder linked most closely to manganese
is Parkinson’s disease.150,171 Some welders develop Parkin-
son’s disease much earlier in their life, usually in their mid
40s, compared to the 60s in the general population.150 Of
concern for public health is the risk of neurological diseases
emerging after long latencies in regions with only mildly
elevated environmental manganese levels.
Iron. Iron is incorporated into numerous enzymes in-
volved in cell division, DNA replication, and cellular me-
tabolism, and it is essential for oxygen transport and gas
exchange. As with manganese, low doses of iron are vital for
survival. Several observations have been made linking cellu-
lar iron content to the development of cancers.172 In studies
of animals administered excessive amounts of iron, orally
and by injection, an increased risk of adenocarcinomas, col-
orectal tumors, hepatomas, mammary tumors, mesothelioma,
renal tubular cell carcinomas, and sarcomas was observed. In
humans, injection of iron compounds has been shown to
cause sarcomas at the sites of deposition. Patients with
hemochromatosis genetic disease characterized by increased
iron absorption have an enhanced susceptibility to liver can-
cer. The accumulation of iron in brain regions with decreased
function, and cell loss has been observed in many neurologi-
cal diseases, such as Parkinson’s disease, Alzheimer’s dis-
ease, etc.173 Inhalation of iron dust causes a respiratory dis-
ease called pneumoconiosis.162
Organic dust. Organic dusts originate from animals and/or
plants, and contain fragments and ﬁbers from wood, bone,
fur, skin, leather, brooms, ﬂour, grains, tobacco, carpets, pa-
per, etc. Organic dust from these various sources irritates the
upper respiratory system, eyes, and skin, causing bronchitis,
allergic reactions, asthma, conjunctivitis, and dermatitis.160
Silica. Exposure to silica, or silicon dioxide SiO2, the
main constituent of sand and granite, produces silicosis, a
disabling pulmonary ﬁbrosis. A controversial subject in oc-
cupational medicine is the association of silicosis with lung
cancer.
160 In addition, exposure to silica is associated with
autoimmune diseases including scleroderma, rheumatoid ar-
thritis, and systemic lupus erythematosus.174
Coal and coal ash. Coal dust produces pneumoconiosis in
coal miners, their lungs retaining a considerable amount of
dust, of up to 30 g roughly two tablespoons of dust.175
Epidemiological study on more than 500 chimney sweeps
showed an increased number of deaths due to heart and res-
piratory diseases, lung, esophageal, and liver cancer.176
Asbestos. Asbestos is a naturally occurring ﬁbrous mate-
rial consisting of very long chains of silicon and oxygen
polysilicate or long chain silicate. A scanning electron mi-
croscope SEM image of asbestos can be seen in Fig. 22b.
Asbestos ﬁbers have high tensile strength, ﬂexibility, and
ﬂame retardant and insulating properties. In ancient times,
asbestos was woven and used “in fabrics such as Egyptian
burial cloths and Charlemagne’s tablecloth, which according
to legend he threw in a ﬁre to clean.”177 Due to its desirable
properties, it was once used extensively in construction ma-
terials cement, ﬂoors, rooﬁng, pipe insulation, and ﬁre
FIG. 22. a TEM of welding nanoparticles courtesy of Pam Drake, Na-
tional Institute for Occupational Safety and Health NIOSH. b Asbestos
ﬁbers courtesy of the US Geological Survey.
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prooﬁng and in materials industry brake pads.178 Asbestos
exposure occurs when its handling produces small ﬁbers,
nanoparticles, that are easily carried as a suspension in both
air and water where they are absorbed by inhalation and
ingestion. Studies of occupational health show that exposure
can cause lung cancer and mesothelioma a rare cancer of the
membranes lining the abdominal cavity and surrounding in-
ternal organs.160 Recent studies in a community with occu-
pational and environmental exposures to asbestos showed
increased risk of autoimmune diseases, such as systemic lu-
pus erythematosus, scleroderma, and rheumatoid
arthritis.174,179 These diseases affect connective tissues, skin,
and organs.
Polymer fumes. Humans exposed to polytetraﬂuoroethyl-
ene or Teﬂon and other polymer fumes develop an inﬂuen-
zalike syndrome polymer fume fever. The symptoms occur
several hours after exposure, and include chest pain, fever,
chills, sweating, nausea, and headache.180 Severe toxic ef-
fects, such as pulmonary edema, pneumonitis, and death, are
also possible.181
2. Carcinogens and poorly soluble „durable… particles
It is clear that some types of particles cause cancer, but it
is not known which characteristics of the particles are re-
sponsible for their carcinogenicity. Some particles are inher-
ently toxic, such as metal dust, welding fume, and quartz
dust, while other particles have a much lower toxicity, but
still cause toxic effects under some circumstances. The latter
category includes poorly soluble particles, biodurable par-
ticles without known speciﬁc toxicity that include diesel ex-
haust particles, carbon black, coal-mine dust, titanium diox-
ide, and several others listed in Table II.40 Poorly soluble
particles have been shown to cause cancer in rodents; how-
ever, epidemiologic studies do not clearly indicate increased
cancer rates in humans exposed to these particles. The latest
research on nanoparticles shows that they can exhibit more
pronounced toxicity than larger microparticles, suggesting
that environmental and health regulating agencies must take
more consideration of particle size distribution, shape,
and agglomeration when establishing regulatory exposure
guidelines.
D. Aerosol pollution, monitoring, and health effects
1. Aerosol size and composition
Aerosol pollution is a combination of particulate matter
and gaseous and liquid phases from natural and anthropo-
genic sources. Ambient particulate matter is generally classi-
ﬁed according to three size distributions: nanoparticles
smaller than 100 nm in diameter mainly resulting from
combustion, accumulation mode particles between 100 nm
and 2.5 m in diameter from aggregation of smaller par-
ticles and vapors, and coarse-mode particles larger than
2.5 m mostly mechanically generated.24 These three par-
ticle categories have distinct chemical compositions Fig.
23, sources, and lifetime in the atmosphere. The larger par-
ticles, which settle faster due to gravity, are removed from
the atmosphere fastest. Smaller particles are transported over
greater distances and have longer lifetimes in the
atmosphere.24 Nanoparticles usually form atmospheric
TABLE II. Particles with proven lung carcinogenic effects in animals and/or humans adapted from Ref. 40.
Some poorly soluble particles are shown to be carcinogenic only in rodents, while epidemiological studies do
not clearly indicate human carcinogenicity. Classiﬁcation in animal studies was done as follows: “” means
positive in more than one animal during inhalation studies, “” means negative or no inhalation studies, “/”








NiO Exhaust  Carcinogenic
Quartz crystalline silica Constructions  Carcinogenic
Asbestos Insulation, mining  Carcinogenic
Carbon black Pigments, toner, tires  Possibly carcinogenic
Refractory ceramic ﬁbers insulation  Possibly carcinogenic
Wood dust Furniture making, saw mills / Carcinogenic some types
TiO2 Pigments, sunscreens 
Diesel exhaust Engines, cars 
Talc Cosmetics, mining 
Volcanic ﬂy ash Ambient 
Coal mine dust Mining  Not classiﬁable
Rockwool Insulation  Not classiﬁable




Cement Constructions, buildings  Not classiﬁable
Amorphous silica Cleaning, paints, drugs  Not classiﬁable
MR40 Buzea, Pacheco, and Robbie: Nanomaterials and nanoparticles: Sources and toxicity MR40
Biointerphases, Vol. 2, No. 4, December 2007
fractal-like dendritic aggregates similar to the soot in Fig.
16d. The polydispersity variation in particle sizes varies
with the source, for example, primary particles in diesel ag-
gregates range from 10 to 40 nm. Atmospheric measure-
ments show that nanoparticles make up a small portion of the
particulate matter mass concentration compared to
microparticles.122 However, the number concentration of
nanoparticles is signiﬁcantly larger than that of micropar-
ticles.
Combustion-derived carbon particles, with traces of tran-
sition metals, make up about 50% of the mass of typical
urban particulate matter, while the remaining 50% includes
salts, geological dust, and organic matter.50 As shown in this
study of particulate matter in Los Angeles Fig. 23,122 when
sorted by size, we see that the particles vary considerably in
composition, with the smallest nanoparticles being mostly
carbon organic and elemental, while the larger micropar-
ticles are mostly metal. In general, environmental pollution
particles differ in their quantities of nitrates, sulfates, crustal
materials, and carbon, with blown soil a major source in
rural areas. Due to the high chemical reactivity of atmo-
spheric nanoparticles resulting from their high surface area,
they are very likely to interact with water or other chemicals
in the atmosphere to form new species. This dynamic nature
of aerosol nanoparticles means that their environmental im-
pact will be long and complex, as reactions create a cascade
of products with varying effects—while some particles will
be long lived, or persistent, others may experience transfor-
mations to more or less damaging states.
2. Aerosol concentration: Air quality index
Nanoparticles with sizes smaller than 100 nm are present
in large numbers in typical ambient air with a level ranging
between 5000 and 10 000 particles /ml, increasing during
pollution episodes to 3 000 000 particles /ml.50 Their concen-
tration varies from region to region, as well as from season to
season. Nanoparticles smaller than 100 nm make up about
70% of the total number of ambient aerosols in urban areas,
while their mass contribution is only about 1%.182 In certain
parts of the world, the peak number concentration of air-
borne nanoparticles was found to increase over time. For
example, in California, the peak concentration of nanopar-
ticles in January 1999 1.451011 particles /m3 was found
to be three times higher than previously measured peaks.183
At the other extreme are modern cleanroom facilities where
air particles are almost eliminated through careful design of
airﬂow and ﬁltering, and meticulous elimination of potential
particle sources. A typical cleanroom, with Class 10 or ISO 3
particle levels, has only several hundred 100 nm particles per
cubic meter.
Increased awareness of the inﬂuence of particle size and
shape on health impact has led the Environment Protection
Agency to propose new ambient standards on ﬁne particles
smaller than 2.5 m. The air quality index AQI is a stan-
dard measure used by the Environmental Protection Agency
for monitoring daily air quality.122 It quantiﬁes air pollution
and predicts health effects of concern that may be experi-
enced within a few hours or days of exposure to polluted air.
The calculation of the AQI includes ﬁve major pollutants:
particulate matter, ozone, carbon monoxide, sulfur dioxide,
and nitrogen dioxide, all of which are regulated under the
Clean Air Act. The AQI has not been standardized interna-
tionally, and other countries use different systems for de-
scribing air quality.122,184 The AQI values for particulate mat-
ter are shown in Table III.
3. Satellite monitoring of aerosol concentration and
size
Aerosols play an important role in the global atmosphere,
directly inﬂuencing global climate and human health. Dust,
smoke, and haze locally impair visibility and health in both
urban and rural regions. Anthropogenic aerosol nanoparticles
are especially abundant in the atmosphere, and they consti-
tute a signiﬁcant uncertainty factor in estimating the climatic
change resulting from human pollution.67 Satellite images
clearly show particulate matter from both anthropogenic and
natural sources in industrialized and heavily populated parts
of the world Figs. 24a–24d.185 Atmospheric aerosols are
monitored worldwide via satellites, and several years worth
of measured global aerosol maps are available from NASA’s
FIG. 23. a Los Angeles smog. b Size distribution and composition of
particulate matter over Los Angeles during 2002-2003. NP, nanoparticles;
MP, microparticles after Ref. 122.
TABLE III. AQI values for concentrations of particulate matter with diam-





g /m3 Air quality descriptor
0–50 0.0–15.4 0.54 Good
51–100 15.5–40.4 55–154 Moderate
101–150 40.5–65.4 155–254 Unhealthy for sensitive groups
151–200 65.5–150.4 255–354 Unhealthy
201–300 150.5–250.4 355–452 Very unhealthy
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FIG. 24. Images of pollution over the world. While clouds appear solid-white, pollution appears as a misty semitransparent gray that masks the image’s
geographic and aquatic features. a Smog layer over upstate New York and North-Eastern Ontario courtesy Earth Science and Image Analysis Laboratory,
Johnson Space Center. b Dust from the Sahara Desert, air pollution, and smoke lingers over the Atlantic Ocean and Great Britain in April 2003 Ref. 72
credit Jacques Descloitres, MODIS Rapid Response Team, NASA/GSFC. c Pollution in China blowing east towards the Yellow Sea, Korea and Japan.
Beijing, China’s capital, lies under the densest portion of the aerosol pollution credit NASA-GSFC Ref. 185. d Pollution over India. Haze follows the
course of the Ganges River in northern India, ﬂowing eastward along the Himalaya Mountains, before turning south and spreading out in the Indian Ocean
credit Jacques Descloitres, MODIS Rapid Response Team, NASA/GSFC Ref. 185. e Optical depth showing worldwide concentration of aerosols on June
2005, derived from data taken by MISR, NASA’s ﬁrst Earth Observing System EOS spacecraft, launched on December 18, 1999. The MISR instrument
orbits the Earth about 15 times each day, observes the Earth continuously from pole to pole, and every nine days views the entire globe between 82 degrees
north and 82 degrees south latitude Ref. 186.
MR42 Buzea, Pacheco, and Robbie: Nanomaterials and nanoparticles: Sources and toxicity MR42
Biointerphases, Vol. 2, No. 4, December 2007
multiangle imaging spectroradiometer MISR Figs.
24e.186 Global aerosol data are measured by imaging se-
quential columns through the atmosphere below the satellite
as it orbits the Earth, in each of four wavelengths blue,
green, red, and near infrared. These measures also give
some indication of particle size and shape, from the variation
in scene brightness over several different view angles and
wavelengths. The MISR results distinguish desert dust from
pollution and forest ﬁre particles: desert dust particles and
sea salt are usually larger than aerosols originating from the
processes of combustion, e.g., forest ﬁres and burning of
fossil fuels. MISR can help to determine ground-level pollu-
tion concentrations necessary in understanding and assessing
links between pollution exposure and human health. A full
assessment of the impact of pollution aerosol exposure will
require records of aerosol mapping for several decades—the
typical time scale of pollution-linked disease appearance.
4. Health effects associated with air pollution
Human exposure to inhaled ambient particles can have
adverse health effects.19,116,160,187,188 Pulmonary and cardio-
vascular diseases result when inhaled particles interfere with
the normal function of bodily systems.49,189,190 The health
consequences of particle inhalation vary greatly with particle
composition, concentration, etc., from benign candle wax to
carcinogenic asbestos or tobacco smoke.
As our understanding of nanoparticles has grown, so has
our knowledge of disease resulting from their exposure. Un-
til recently, it was believed that particles 10 m or smaller
were responsible for diseases resulting from particle pollu-
tion. But further study has shown that most of these diseases
are caused by particles smaller than 100 nm, similar in size
to viruses. Nanoparticles seem to be generally more toxic
than microparticles, primarily due to their ability to penetrate
living cells, translocate within the body, and affect the func-
tion of major organs.
Cardiovascular diseases. The correlation between ambi-
ent particle exposure and heart disease was accepted in the
mid 1990’s, when it was observed that hospital admission for
cardiovascular illness increased on days with high concentra-
tions of particles.191 Atmospheric particle pollution from au-
tomobile exhaust seems to have a major inﬂuence on mortal-
ity, with a strong association between increased
cardiopulmonary mortality and living near major roads.116
The risk of myocardial infarction onset increases with el-
evated concentrations of particulate matter smaller than
2.5 m on the day before onset and with volume of vehicu-
lar trafﬁc. Cardiovascular diseases and effects associated
with particulate pollution include ischemic heart disease, hy-
pertensive heart disease,192 arrhythmia, heart failure, arterio-
sclerosis, brachial artery vasoconstriction, and increased
blood pressure in subjects with lung disease.116
Respiratory illnesses. Pneumonia, bronchial asthma,
chronic bronchitis, emphysema, lung cancer, acute deteriora-
tion of lung function, and hospital admissions for respiratory
illnesses were all found to increase with higher levels of
pollution.193,194
Malignant tumors. An epidemiological study researching
the effects of chronic exposure to particulate matter smaller
than 10 m in nonsmoking subjects revealed a high inci-
dence of lung cancer.195 This study also showed an 8% in-
crease in risk of lung cancer for each 10 g /m3 increase in
particulate matter smaller than 2.5 m.192 To some surprise,
levels of particulate matter smaller than 2.5 m pollution
were also found to correlate signiﬁcantly with cancers of the
breast, endometrium, and ovary,194 an effect that might be
explained by recent studies of nanoparticle translocation to
organs. Childhood cancers were also found to be strongly
determined by prenatal or early postnatal exposure to oil-
based combustion gases, primarily engine exhaust.118
Mortality and morbidity. There is compelling evidence of
correlation between particle pollution levels on a given day,
and overall mortality the following day.116,160 Epidemiologi-
cal studies have shown that the increased morbidity and mor-
tality, correlated with increased particle pollution, are fre-
quently the result of respiratory problems,172 but primarily
due to cardiovascular diseases.160,196 In 1998, it was esti-
mated that around 4000 deaths were related to atmospheric
pollution in Canada. These deaths occur mainly in heavily
industrialized urban centers.160
Analysis of mortality statistics for approximately 500 000
adults residing in the United States of America covering a
16 year period of chronic exposure to air pollutants shows
that cardiovascular deaths increased by 0.69% for each
10 g /m3 increase in particulate matter.116,192 The study
found a strong correlation between a cause of death of either
cardiopulmonary disease or lung cancer, and levels of par-
ticulate matter smaller than 2.5 m.192
Figure 25 shows the correlation of mortality rates with
extreme levels of pollution during London smog episodes of
the 1950s through the 1970s.20 The exposure-response obser-
vations of daily mortality exhibit two distinct regions, with a
steeper slope at lower mass concentrations and a shallower
slope at higher mass concentrations. It has been suggested
that a high concentration of aerosol nanoparticles would pro-
FIG. 25. Correlation between daily mortality rate and urban particle concen-
trations during the London smog episodes in the winters of 1958-1972 data
from Ref. 200. Also shown are the regression lines for the steep and shal-
low slopes together with the inﬂection point at 125 g /m3 after Ref. 20.
MR43 Buzea, Pacheco, and Robbie: Nanomaterials and nanoparticles: Sources and toxicity MR43
Biointerphases, Vol. 2, No. 4, December 2007
mote particle aggregation.147 Aggregation of nanoparticles at
high particle concentrations reduces toxicity by decreasing
the reactive surface area and possibly limiting the transloca-
tion of the particles.
Postneonatal infant mortality and birth defects. Positive
associations between exposure to particles and selected birth
defects such as atrial septal defects were reported in studies
in various countries.197,198 It was found that outdoor air pol-
lution above a reference level of 12.0 g /m3 of particulate
matter smaller than 10 m contributes substantially to post-
neonatal infant mortality in infants born with a normal birth
weight.199
Exacerbation of preexisting diseases and other risks. Cer-
tain segments of the population appear to be at greater risk to
the toxic effects of particulate pollution. Patients suffering
from various diseases, such as diabetes, chronic pulmonary
diseases, heart diseases, or with previous myocardial infarc-
tion, are likely to suffer an increase in the severity of symp-
toms on days with high levels of pollutants.49,116 In addition,
the presence of inﬂammation may enhance the translocation
of nanoparticles into circulation,30,201–204 or via blood-brain
barrier.18,205
Cumulative exposure. In addition to immediate effects,
time-series studies have shown cumulative effects over
weeks, associated with elevated particle concentrations.49
Further studies are needed to assess the health effects of
chronic exposure to nanoparticles.
Treatment. Ambient particles induce oxidative stress in
biological systems, either directly by introducing oxidant
substances, or more indirectly by supplying soluble metals,
including transition metals, that shift the redox balance of
cells toward oxidation. Oxidative stress is believed to be the
primary mechanism by which nanoparticles generate disease.
Consequently, dietary nutrients that play a protective role in
the oxidative process are suggested as potential mitigators of
the toxic effects of nanoparticle pollution. Antioxidant vita-
mins such as vitamin C have a protective effect against
lung diseases, and a high intake of fresh fruit and some veg-
etables appears to have a beneﬁcial effect on overall lung
health206 perhaps due to the reduction of the toxic effects of
environmental nanoparticles. Treatment of underlying health
conditions also reduces the impact of air pollution.206
IV. NANOTOXICOLOGY: TOXICOLOGY OF
NANOPARTICLES
A. Respiratory tract uptake and clearance
1. Particle size dependent inhalation
After inhalation, nanoparticles deposit throughout the en-
tire respiratory tract, starting from nose and pharynx, down
to the lungs.38,207 Lungs consist of airways, which transport
air in and out, and alveoli, which are gas exchange surfaces,
as shown in Figs. 26c and 26d Human lungs have an
internal surface area between 75 and 140 m2, and about
300106 alveoli.30 Due to their large surface area, the lung
is the primary entry portal for inhaled particles.
Spherically shaped solid material with particle diameters
smaller than 10 m can reach the gas exchange surfaces
Fig. 26d.30,38 Larger diameter particles tend to be depos-
ited further up in the respiratory tract as a result of gravita-
tional settling, impaction, and interception.208 Many larger-
diameter ﬁbers are deposited at “saddle points” in the
branching respiratory tree. Smaller-diameter particles are
more affected by diffusion, and these can collect in the
smaller airways and alveoli. Fibers having a small diameter
may penetrate deep into the lung, though very long-aspect-
ratio ﬁbers will remain in the upper airways.30 As shown in
Fig. 26e, the nasopharyngeal region captures mainly micro-
particles and nanoparticles smaller than 10 nm, while the
lungs will receive mainly nanoparticles with diameters be-
tween 10 and 20 nm.38
2. Upper airway clearance: Mucociliary escalator
Pulmonary retention and clearance of particles has been
under study for many years. The 1950s were marked by a
FIG. 26. a SEM image of lung trachea epithelium, showing cilia muco-
ciliary escalator, courtesy Louisa Howard. b Human alveolar macrophage
center, yellow phagocytosis of E. coli multiple ovoids, green, together
with a red blood cell red. © Dr. Dennis Kunkel/Visuals Unlimited, repro-
duced with permission from Visuals Unlimited Ref. 25. c and d
Alveoli in the lung. © Dr. David M. Phillips/Visuals Unlimited, reproduced
with permission from Visuals Unlimited Ref. 25. e Deposition of in-
haled particles in the human respiratory tract versus the particle diameter
after Ref. 38.
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great interest in pneumoconiosis and studies of the effects of
inhalation of radioactive particles, while in the 1990s, studies
of occupational and environmental particles generated a con-
siderable amount of knowledge regarding the adverse health
effects of nano- and microparticles in the respiratory tract.37
The clearance of deposited particles in the respiratory
tract is by physical translocation to other sites, and chemical
clearance. Chemical dissolution in the upper or lower respi-
ratory tract occurs for biosoluble particles in the intracellular
or extracellular ﬂuids, and will not make the subject of fur-
ther discussions in this review. Nonsoluble particles will un-
dergo a different, much slower clearance mechanism that we
will discuss further in detail later. For relatively insoluble
particles, the elimination process is very slow in comparison
to soluble nanoparticles.147
In the upper airways, particle clearance is performed
mainly by the mucociliary escalator.37 The ﬁrst contact of
inhaled nanoparticles in the respiratory tract is with the lin-
ing ﬂuid, composed of phospholipids and proteins.209 This
contact leads to particle wetting and displacement towards
the epithelium by surface forces from the liquid-air
interface.205 When in contact with esophageal epithelial
cells, nanoparticles uptake by these cells is possible in the
presence of preexistent inﬂammation.210 The cilia of the
bronchial epithelial cells Fig. 26a move the covering mu-
cous layer, including particles, away from the lungs and into
the pharynx, a process generally requiring up to several
hours.211 The nanoparticles that are cleared from the lung via
the mucociliary escalator enter the gastro-intestinal
tract.147,212 The clearance from the gastrointestinal tract will
be discussed in Sec. IV G. The mucus layer contains protec-
tive antioxidants, which can become depleted when large
numbers of oxidative compounds are inhaled.209
3. Lower airways clearance: Phagocytosis and
passive uptake
Phagocytosis. Particles smaller than 10 m can reach the
lower airways.213 Particle clearance from the lung alveoli
occurs primarily through macrophage phagocytosis. Mac-
rophages are cells that act as vehicles for the physical re-
moval of particles from alveoli to the mucociliary escalator
or across the alveolar epithelium to the lymph nodes in the
lung or to those closely associated with the lungs.205 When
the lung is subjected to prolonged exposure, white blood
cells from the circulatory system neutrophils are recruited
to help.
Phagocytes engulf and break down pathogenic microor-
ganisms, damaged or apoptotic cells, and inert particles.214 In
addition to the “professional cleaners,” phagocytes neutro-
phils and monocyte/macrophages, see Fig. 26b, most cells
also have some phagocytic ability.214 The main difference
between the phagocytic ability of professional and nonpro-
fessional phagocytes is related to the presence of dedicated
receptors able to recognize molecules pertaining to patho-
gens, molecules very different from those found in the hu-
man body.214 Phagocytosis is a very complex mechanism due
to the diversity of receptors, its understanding requiring thor-
ough knowledge of chemical processes at molecular level.
Many phagocytic receptors serve a dual function: adhesion
and particle internalization.214 The phagocytosis of particles
is more effective if the particles are labeled with special mol-
ecules such as antibodies or complement molecules able to
speed up phagocytosis, a labeling process called opsoniza-
tion. Opsonins are present in the lung-lining ﬂuid.213 Hydro-
phobic particles will be readily coated by opsonins and will
subsequently be available for phagocytosis.215 Coating of
particles with hydrophilic polymers, such as polyethylene
glycol, diminishes the opsonization of particles, conse-
quently decreasing the probability of being phagocytized.215
However, unopsonized particles are, nevertheless, eventually
phagocytized by macrophages.216
Phagocytosis takes up to several hours and involves sev-
eral steps:
1. First, speciﬁc receptors on the phagocyte membrane bind
with speciﬁc molecules ligands localized on the surface
of the particle.214,216 Older studies suggest that the op-
sonization with complement protein 5a may be respon-
sible for the chemotactic pertaining to the movement of a
cell in a direction corresponding to a concentration gradi-
ent of a chemical substance signal of nanoparticles,20
while newer studies propose that the electric charge may
play a role in activating the scavenger-type receptors for a
certain type of nanoparticles such as titanium dioxide,
iron oxide, quartz.217 For uncharged nanoparticles, such
as carbon based nanoparticles diesel exhaust, some au-
thors suggest that toll-like receptors are responsible for
the recognition of these nanoparticles as well as bacteria,
virus, and fungi.218
2. After the binding of the phagocyte receptor with a ligand,
the cytoskeleton a network of protein ﬁlaments of the
phagocyte rearranges, resulting in pseudopod formation,
and ultimately leading to internalization of the particle
with the formation of a phagocytic vesicle
phagosome.219
3. The phagosome fuses with a lysosome an organelle con-
taining digesting enzymes, forming a phagolysosome.
The fusion process can take from 30 min up to several
hours, depending on the chemical interaction between the
surface of the particle and the phagosome membrane.214
Lysosomes release protease which break down proteins
and nicotinamide adenine dinucleotide phosphate
NADPH oxidase oxygen radicals.219 This process as-
sists in the chemical dissolution of the particle.219 De-
pending on the type of receptor used in the detection of
the particle, macrophages may also release intercellular
chemical messengers alerting the immune system that an
infection is present.
4. If the particle is digested by lysosome enzymes, the resi-
dues are removed by exocytosis release of chemical sub-
stances into the environment. If not, phagocytosis is fol-
lowed by gradual movement of macrophages with
internalized particles towards the mucociliary escalator, a
process that can last up to 700 days in humans.20 If the
macrophage is unable to digest the particle and the par-
ticle produces damage to the phagosomal membrane due
to peroxidation, the oxidative compounds will likely in-
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teract with the macrophage’s cytoskeleton and lead to re-
duced cell motility, impaired phagocytosis, macrophage
death,220 and ultimately reduced clearance of particles
from the lungs.221 Macrophage death can lead to the re-
lease of oxidative lysosome compounds outside the cells.
If particles cannot be cleared, they can kill successive
macrophages in an attempt to clear them and create a
source of oxidative compounds and cause inﬂammation
with macrophage debris accumulation pus. Oxidative
stress is associated with various diseases, such as cancer
and neurodegenerative and cardiovascular diseases.
This mechanism of alveolar clearance is not perfect, as it
allows smaller nanoparticles to penetrate the alveolar epithe-
lium and reach the interstitial space.20 From the interstitial
space, nanoparticles may enter the circulatory and lymphatic
systems, and reach other sites throughout the body.24,147
Phagocytosis occurs in different areas of the body; phago-
cytes present in lungs, spleen, liver, etc., have different
names according to their location, such as alveolar macroph-
ages, splenic macrophages, and Kupfer cells, respectively.88
4. Nanoparticle size dependent phagocytosis
Human alveolar macrophages measure between 14 and
21 m, while rat alveolar macrophages measure between 10
and 13 m.39 Macrophages can engulf particles of a size
comparable to their own dimensions, but are signiﬁcantly
less effective with particles that are much larger or smaller.
Experimental data show that, compared with larger particles,
nanoparticles smaller than 100–200 nm are more capable of
evading alveolar macrophage phagocytosis,205 entering pul-
monary interstitial sites, and interacting with epithelial cells
to get access to the circulatory and lymphatic systems.20,147
There are contradictory reports related to the phagocytosis
of nanoparticles smaller than 100 nm. In vitro studies show
that nanoparticles activate and are phagocytized by alveolar
macrophages.20 However, macrophage lavage recovery stud-
ies show that nanoparticles smaller than 100 nm are not ef-
ﬁciently phagocytized in comparison with particles between
1 and 3 m.20,147 A 12-week inhalation study in rats showed
that 20 nm nanoparticles of titanium dioxide are character-
ized by longer retention time in the lungs and increased
translocation to interstitial sites than larger nanoparticles
250 nm of the same material.222 Small nanoparticles that
evade the alveolar macrophages penetrate the alveolar epi-
thelium, resulting in a slower clearance rate from the lung
and possibly later translocation to the circulatory and lym-
phatic systems.
5. Concentration-dependent phagocytosis
At high concentrations, nanoparticles tend to cluster,
forming aggregates often larger than 100 nm. Larger nano-
particles 100 nm can be readily phagocytized by alveolar
macrophages.147,223 Results of studies involving inhalation or
intratracheal instillation of high concentrations of nanopar-
ticle silver, iron, India ink, or titanium dioxide smaller than
100 nm, which aggregate in larger particles, suggest that
most nanoparticles are indeed stopped by alveolar
macrophages.147 Rat studies based on inhalation of low con-
centrations of 15 nm diameter silver nanoparticles showed
that soon after inhalation 30 min, nanoparticles are distrib-
uted in the blood and brain, and subsequently, to organs,
such as heart and kidney, while the lungs are rapidly cleared
off of the nanoparticles.147 Hence, minute concentrations of
nanoparticles with size smaller than 100 nm can have a
higher probability of translocating to the circulatory system
and organs and produce damage than high concentrations
of the same particles, which are likely to form aggregates
and which will be stopped from translocation by macrophage
phagocytosis.
6. Lung burden
Insoluble particle burden in the lungs can induce a range
of toxicological responses differing from those due to soluble
particles.40 Particles that are soluble or partly soluble for
example, cement will dissolve in the aqueous ﬂuid lining
the epithelium and pass into the circulatory and lymphatic
systems, while the insoluble ones such as carbon black
must be removed through other mechanisms such as the mu-
cociliary escalator. Particles that are not soluble or degrad-
able in the lungs will rapidly accumulate upon continued
exposure, as shown in Fig. 27 for carbon black, asbestos,
multiwall carbon nanotubes, and grounded carbon
nanotubes.224 If the macrophage clearance capacity is ex-
ceeded, then the lungs defense mechanisms are over-
whelmed, resulting in injury to the lung tissue.
The adverse effect of inhaled nanoparticles on the lungs
depends on the lung burden determined by the rate of par-
ticle deposition and clearance and on the residence time of
the nanoparticles in the lungs.40,205 For example, carbon
nanotubes are not eliminated or very slowly eliminated 81%
found in rat lungs after 60 days from the lungs.224 The per-
sistent presence within the alveoli of inhaled particles Fig.
27, especially those with mutagenic potential, increases the
risk of lung cancer.40
7. Translocation and clearance of inhaled
nanoparticles
Inhaled nanoparticles are shown to reach the nervous sys-
tem via the olfactory nerves,18,20,225 and/or blood-brain
barrier.18,205 Nanoparticles that reach the lungs are predomi-
nantly cleared via the mucociliary escalator into the gas-
trointestinal tract and then eliminated in the feces,212 lym-
phatic system,226 and circulatory systems.20 From the
lymphatic and circulatory systems, nanoparticles may be dis-
tributed to organs, including kidneys from where partial or
total clearance may occur.
8. Adverse health effects in the respiratory tract
Adverse health effects. Recent research has led to changes
in terminology and brought about the realization that no par-
ticles are completely inert, and that even low concentrations
of particles can have negative health effects.37 The adverse
health effects of nanoparticles depend on the residence time
in the respiratory tract.205 Smaller particles have a higher
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toxicity than larger particles of the same composition and
crystalline structure, and they generate a consistently higher
inﬂammatory reaction in the lungs.222 Smaller nanoparticles
are correlated with adverse reactions such as impaired mac-
rophage clearance, inﬂammation, accumulation of particles,
and epithelial cell proliferation, followed by ﬁbrosis, emphy-
sema, and the appearance of tumors.37,40,222,227–229 Particle
uptake and potential health effects may be dependent on ge-
netic susceptibility and health status.212
Recent research has demonstrated that nanoparticle inha-
lation can affect the immune system defense ability to com-
bat infections.230 Nanoparticles of various compositions are
able to modulate the intrinsic defensive function of macroph-
ages, affecting their reactivity to infections. It was found that
several types of nanoparticles such as ZrO2 enhance the
expression of some viral receptors, making macrophages ex-
posed to nanoparticles hyper-reactive to viral infections and
leading to excessive inﬂammation.230 On the other hand, ex-
posure to other nanoparticles SiO2 and TiO2 leads to a
decrease in the expression of some other viral and bacterial
receptors, leading to lower resistance to some viruses or
bacteria.
Adaptability. Organisms are capable of adapting to spe-
ciﬁc environmental stresses. Recent studies suggest that pre-
exposure to low concentrations of nanoparticles stimulates
the phagocytic activity of cells, while high concentrations of
nanoparticles impair this activity.231,232 At the same time,
genotype is an important factor in adaptability.233
Treatment. Treatments for inhalation of nanoparticles in-
clude those that act to enhance mucociliary clearance and
those that reduce the effects of oxidation and inﬂammation.
Mucociliary clearance can be enhanced twofold by inhala-
tion of increasing concentrations of saline solutions.234 The
saline solution acts as an osmotic agent, increasing the vol-
ume of airway surface liquid. Anti-inﬂammatory medicine
sodium cromoglycate was found to strongly reduce airway
inﬂammation caused by diesel exhaust nanoparticles.116 So-
dium cromoglycate works by reducing allergic responses in-
hibits the release of mediators from mast cells—cells respon-
sible for the symptoms of allergy. Antioxidant vitamins
particularly vitamin C,206 rosmarinic acid,47 and a high in-
take of fresh fruit and some vegetables have a protective
effect against lung diseases.206
In order to better understand the adverse health effects
and possible treatment of inhaled nanoparticles, the next sec-
tion explores the biological interaction of nanoparticles at a
cellular level.
B. Cellular interaction with nanoparticles
1. Cellular uptake
Like nanoorganisms viruses, nanoparticles are able to
enter cells and interact with subcellular structures. Cellular
uptake, subcellular localization, and ability to catalyze oxi-
dative products depend on nanoparticle chemistry, size, and
shape.235 The mechanism by which nanoparticles penetrate
cells without speciﬁc receptors on their outer surface is as-
sumed to be a passive uptake or adhesive interaction. This
uptake may be initiated by van der Waals forces, electrostatic
charges, steric interactions, or interfacial tension effects, and
does not result in the formation of vesicles.205,236 Steric in-
teractions occur when nanoparticles have molecules with
size, geometries, bondings, and charges optimized for the
interaction with the receptors. After this type of uptake, the
nanoparticles are not necessarily located within a phagosome
which offers some protection to the rest of the cellular or-
ganelles from the chemical interaction with the nanopar-
ticle. For example, C60 molecules enter cells and can be
found along the nuclear membrane and within the nucleus.220
This type of uptake and free movement within the cell makes
them very dangerous by having direct access to cytoplasm
proteins and organelles. Upon nonphagocytic uptake, nano-
FIG. 27. Rat lung lesions induced by nanoparticles of B,G,L carbon black, C,H,M asbestos, D,I,N multiwall carbon nanotubes, and F,J,O grounded
nanotubes compared to saline solution A,F,K Ref. 224; Reproduced with permission from Elsevier.
MR47 Buzea, Pacheco, and Robbie: Nanomaterials and nanoparticles: Sources and toxicity MR47
Biointerphases, Vol. 2, No. 4, December 2007
particles can be found in various locations inside the cell,
such as the outer-cell membrane,132,237 cytoplasm,132,237
mitochondria,235,238 lipid vesicles,115,237 along the nuclear
membrane,132 or within the nucleus.235,237 Depending on
their localization inside the cell, the nanoparticles can dam-
age organelles or DNA, or ultimately cause cell death.
Nanoparticles are internalized not only by professional
phagocytes such as alveolar macrophages,30,147,235 but by
various types of cells, including endothelial cells,237 pulmo-
nary epithelium,140,239–244 gastrointestinal epithelium,210 red
blood cells,205,245 platelets,246 and nerve cells.247
Particle internalization location depends on nanoparticle
size. For example, environmental particles with size between
2.5 and 10 m were found to collect in large cytoplasmic
vacuoles Figs. 28c and 28d, while smaller nanoparticles
100 nm localize in organelles, such as mitochondria
Figs. 28e and 28f, leading to disruption of mitochon-
drial architecture.238 Very small nanoparticles, such as C60
molecules with a diameter of 0.7 nm, are able to penetrate
cells via a different mechanism than phagocytosis, probably
through ion channels or via pores in the cell membrane.220
Uptake location is likely to depend on material type; how-
ever, current research does not provide sufﬁcient information
to drawing conclusions on this subject.
2. Oxidative stress, inﬂammation, and genotoxicity
While the exact mechanism whereby nanoparticles induce
proinﬂammatory effects is not known, it has been suggested
that they create reactive oxygen species, and thereby modu-
late intracellular calcium concentrations, activate transcrip-
tion factors, and induce cytokine production.248 Below we
outline in a very simpliﬁed and schematic depiction the cur-
rent understanding of these very complex cellular
mechanisms.
Oxidative stress generation. Both in vivo and in vitro
studies have shown that nanoparticles of various composi-
tions fullerenes, carbon nanotubes, quantum dots, and auto-
mobile exhaust create reactive oxygen species.20 Reactive
oxygen species have been shown to damage cells by peroxi-
dizing lipids, altering proteins, disrupting DNA, interfering
with signaling functions, and modulating gene
transcription.248
Oxidative stress is a response to cell injury, and can also
occur as an effect of cell respiration, metabolism, ischemia/
reperfusion, inﬂammation, and metabolism of foreign
compounds.47
The oxidative stress induced by nanoparticles may have
several sources:47
i Reactive oxygen species can be generated directly
from the surface of particles when both oxidants and
free radicals are present on the surface of the par-
ticles. Many compounds hitchhiking on the surface of
nanoparticles usually present in ambient air are ca-
pable of inducing oxidative damage, including ozone
O3 and NO2.
ii Transition metal iron, copper, chromium, vanadium,
etc. nanoparticles can generate reactive oxygen spe-
cies acting as catalysts in Fenton-type reactions.47 For
example, the reduction of hydrogen peroxide H2O2




·OH + OH− + O2
results in the formation of a hydroxyl radical ·OH
that is extremely reactive, attacking biological mol-
ecules situated within the diffusion range.47
iii Altered functions of mitochondrion. As shown in sev-
eral studies, small nanoparticles are able to enter
mitochondria235,238 and produce physical damage,
contributing to oxidative stress.24
iv Activation of inﬂammatory cells, such as alveolar
macrophages and neutrophils, which can be induced
by phagocytosis of nanoparticles, can lead to genera-
tion of reactive oxygen species and reactive nitrogen
species.47,249 Alveolar macrophages participate in the
initiation of inﬂammation in the lungs see Sec.
IV A 3.
FIG. 28. TEM images showing effects of environmental particles size P on
murine macrophage cells RAW 264.7 treated with various size particles: a
and b untreated, c and d 2.5–10 m size particles, and e and f
particles smaller than 100 nm. M denotes mitochondria Ref. 238; repro-
duced with permission from Environmental Health Perspectives.
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Nanoparticles have been shown to generate more free
radicals and reactive oxygen species than larger particles,
likely due to their higher surface area.24,239,250
Inﬂammation. Inﬂammation is the normal response of the
body to injury. When generated in moderation, inﬂammation
stimulates the regeneration of healthy tissue; however, when
in excess, it can lead to disease.50 In vitro and in vivo experi-
ments demonstrate that exposure to small nanoparticles is
associated with inﬂammation, with particle size and compo-
sition being the most important factors.47 Inﬂammation is
controlled by a complex series of intracellular and extracel-
lular events. The oxidative stress results in the release of
proinﬂammatory mediators or cytokines—intercellular
chemical messengers alerting the immune system when an
infection is present.221,249 Some nanoparticles can produce
cell death via mitochondrial damage without
inﬂammation.235
Antioxidants. The oxidative stress also results in the re-
lease of antioxidants—proteins that act to remove the oxida-
tive stress.47,50 In addition to the antioxidants released as a
response to the oxidative process, nanoparticles may interact
with metal-sequestering proteins and antioxidants from
body ﬂuids and intracellularly that will likely modify the
surface properties of the nanoparticle to some extent, render-
ing them less toxic.47
DNA damage. Generation of reactive oxygen species to
the point that they overwhelm the antioxidant defense system
shifting the redox balance of the cell can result in oxida-
tion, and therefore destruction, of cellular biomolecules, such
as DNA, leading to heritable mutations.47,205. For example,
the chemical modiﬁcation of histones or binding proteins
that support the supercoiled structure of DNA opens the
coiled DNA and allows its alteration.50 Epidemiological, in
vitro and in vivo studies show that nanoparticles of various
materials diesel, carbon black, welding fumes, and transi-
tion metals are genotoxic in humans or rats.42 Oxidative
DNA damage markers showed higher levels on workdays for
bus drivers from central areas compared to bus drivers from
suburban/rural areas of Copenhagen.47 Nasal biopsies from
children living in Mexico City showed greater DNA damage
compared to children living on less polluted areas.47
A general schematic of the molecular events by which
nanoparticles exert their toxic effects at the cellular level is
given in Fig. 29. In summary, nanoparticles can directly gen-
erate reactive oxygen species on their surfaces or by activa-
tion of macrophages.20,47,249 Overall, the generation of oxi-
dative species leads to increased inﬂammation,221,249 and
increased antioxidant production.50 The activation of mac-
rophages leads to modulation in intracellular calcium con-
centration that, in turn, activates further the reactive oxygen
species production, which, in turn, enhances further calcium
signaling by oxidation of calcium pumps in the endoplasmic
reticulum, leading to calcium depletion.47,248,251 Intracellular
calcium modulation results in impaired motility and reduced
macrophage phagocytosis.47 Nonphagocytized nanoparticles
are likely to access and interact with epithelial cells,47 thus
enhancing inﬂammation. Ultimately, the interaction of nano-
particles with cells may lead to DNA modiﬁcations, cell in-
jury, and disease.50
3. Adverse health effects and treatment
Nanoparticles, due to their small size, can inﬂuence basic
cellular processes, such as proliferation, metabolism, and
death. Many diseases can be associated with dysfunction of
FIG. 29. Schematics of the molecular
events by which nanoparticles exert
their toxic effects at the cellular level.
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these basic processes. For example, cancer results from un-
controlled cell proliferation, while neurodegenerative dis-
eases are caused in part by premature cell death.150 Oxidative
stress has been implicated in many diseases, including car-
diovascular and neurological diseases, pancreatitis, and
cancer.
47 Severe inﬂammation is assumed to be the initiating
step51 in the appearance of autoimmune diseases systemic
lupus erythematosus, scleroderma, and rheumatoid arthritis
that can sometimes be associated with exposure to some
nanoparticles, such as silica and asbestos.174,179
Regarding the treatment of adverse health effects caused
by nanoparticle cytotoxicity, antioxidants,24,50,61,62,206 anti-
inﬂammatory drugs,116,252 and metal chelators248,253 show
promising effects. It has been reported that rats that under-
went instillation of nanoparticles into the lungs together with
an antioxidant nacystelin showed inﬂammation reduced by
up to 60% in comparison to those exposed to nanoparticles
alone.50 Antioxidant therapy has been found to protect
against the development of hypertension, arteriosclerosis,
cardiomyopathies, and coronary heart disease,24 providing
further evidence of the link between the oxidative stress re-
sponse and cardiovascular effects. The adverse health effects
of transition metals can be diminished by metal chelators.248
4. “Noninvasive” terminology to be questioned
The process of nanoparticle uptake by cells is clinically
used today in targeted drug delivery and cell imaging Fig.
30. The safety of these techniques, however, depends on
cellular uptake of nanoparticles without affecting normal cel-
lular function. Cellular imaging techniques are currently
named “noninvasive” techniques,254,255 which means non-
penetrating; however, they should perhaps be relabeled as
“minimally invasive,” given that the nanoparticles enter the
cells and are likely to affect cellular functions. Iron oxide
and other magnetic nanoparticles have been used for many
years as magnetic resonance imaging MRI contrast agents.
Depending on their size and coating, MRI nanoparticles can
localize in liver, spleen, lymph nodes, etc.254 Some nanopar-
ticles were found to be teratogenic causing birth defects in
rats and rabbits.254 Minor side effects of contrasting agents
are nausea, vomiting, hives, and headache.256 More serious
adverse reactions involving life-threatening cardiovascular
and respiratory reactions are possible in patients with respi-
ratory disorders.256
C. Nervous system uptake of nanoparticles
The nervous system is composed of the brain, spinal cord,
and nerves that connect the brain and spinal cord to the rest
of the body. In addition to nanoparticle uptake due to inha-
lation discussed below, nervous system uptake may occur
via other pathways such as dermal. Olfactory nerves and
the blood-brain barrier are the most studied pathways.
1. Neuronal uptake via olfactory nerves
Neuronal uptake Fig. 31a of inhaled nanoparticles may
take place via the olfactory nerves18,20,225 or/and blood-brain
barrier.18,205
The nasal and tracheobronchial regions have many sen-
sory nerve endings.20 As demonstrated several decades ago
with polio viruses 30 nm and silver coated gold nanopar-
ticles 50 nm in monkeys, intranasally instilled viruses and
particles migrate to the olfactory nerves and bulb with an
axonal transport velocity of about 2.5 mm /h.20 The silver
coated gold nanoparticles that reached the olfactory bulb
were preferentially located in mitochondria,20 raising a major
concern of their toxicity. More recent studies conﬁrm the
uptake of inhaled nanoparticles from olfactory mucosa via
the olfactory nerves in the olfactory bulb.18,20,225,247 For ex-
FIG. 30. a Head MRI image courtesy of United States National Library of
Medicine, National Institute of Health. b MRI courtesy of National In-
stitute of Neurological Disorders and Stroke.
FIG. 31. a Schematics of the nanoparticles neuronal uptake via olfactory
bulb and blood-brain barrier. b Cortical neurons nerve cells growing in
culture. Neurons have a large cell body with several long processes extend-
ing from it, usually one thick axon and several thinner dendrites. The axon
carries nerve impulses away from the neuron. Its branching ends make con-
tacts with other neurons and with muscles or glands. © Dr. Dennis Kunkel/
Visuals Unlimited. Reproduced with permission from Visuals Unlimited
Ref. 25. c TEM images of iron accumulation in the brain of neurologi-
cally affected patients. Iron is stored in ferittin, Ft, a protein involved in
excess iron storage Ref. 173; reproduced with permission from Elsevier.
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ample, rat inhalation studies with 30 nm magnesium oxide207
and 20–30 nm carbon247 nanoparticles indicate that nanopar-
ticles translocate to the olfactory bulb.207 If inhalation oc-
curred via one nostril only, the accumulation was observed
only in the side of the open nostril.20 Experiments show that
microparticles with diameter larger than a micron do not
cross the olfactory nerve, as expected from the geometrical
restrictions imposed by the diameter of the olfactory axons
of only 100–200 nm Fig. 31a.20 Translocation of nano-
particles into deeper brain structures may be possible,147 as
suggested by the movement of viruses through neurons.20
2. Neuronal uptake via blood-brain barrier
The passage of nanoparticle to the nervous system is also
possible via the blood-brain barrier Fig. 31a. The blood-
brain barrier is a physical barrier with negative electrostatic
charge between the blood vessels and brain,257 selectively
restricting the access of certain substances.18 This anionic
barrier is believed to stop most anionic molecules, while the
cationic molecules increase the permeability of the blood-
brain barrier by charge neutralization.18 This route has been
extensively studied for the purpose of drug delivery to the
brain.18,257 Regarding the passage of nanoparticles, the
blood-brain-barrier permeability is dependent on the charge
of nanoparticles.257 It allows a larger number of cationic
nanoparticles to pass compared to neutral or anionic par-
ticles, due to the disruption of its integrity.257 As shown by
MRI with magnetic nanoparticles, the blood-brain barrier in
healthy subjects stops some proteins and viruses present in
the brain vascular system from translocating to the brain.18
However, subjects with speciﬁc circulatory diseases like
hypertension,18 brain inﬂammation,18 and respiratory tract
inﬂammation increased levels of cytokines that cross the
blood-brain barrier and induce inﬂammation205 may have
increased blood-brain-barrier permeability, which will allow
nanoparticles access to the nervous system.
3. Adverse health effects of neuronal nanoparticle
uptake and treatment
Experimental evidence suggests that the initiation and
promotion of neurodegenerative diseases, such as Alzhe-
imer’s disease, Parkinson’s disease, and Pick’s disease, are
associated with oxidative stress and accumulation of high
concentrations of metals such as copper, aluminum, zinc,
and especially iron in brain regions associated with function
loss and cell damage.169,253,258 Iron is necessary in many cel-
lular functions, especially in the brain, where it participates
in many neuronal processes. In excess, however, iron is toxic
to cells. The brain continuously accumulates iron, resulting
in increased stored iron amounts with age. In order to pre-
vent its toxicity, organisms developed a way to store excess
iron in proteins called ferittin Ft. Dysfunction of ferittin
resulting from excessive accumulation of iron Fig. 31b
may lead to oxidative stress and myelin the electrically in-
sulating coatings of axons breakdown.173 Metal homeostasis
imbalance and neuronal loss are both present in neurodegen-
erative diseases. Homeostasis is a dynamic equilibrium bal-
ancing act necessary for a proper function of a living sys-
tem. It is not known if the presence of metals in the brain of
subjects with neurodegenerative diseases is due to nanopar-
ticles themselves translocating to the brain or their soluble
compounds.42
Despite the fact that the etiology of neurodegenerative
diseases is unknown, environmental factors are believed to
play a crucial factor in their progress, being able to trigger
proinﬂammatory responses in the brain tissue.43,258 Recent
studies on DNA damage in nasal and brain tissues of canines
exposed to air pollutants show evidence of chronic brain
inﬂammation, neuronal dysfunction, and similar pathological
ﬁndings with those of early stages of Alzheimer’s
disease.205,259 Autopsy reports on humans suggest similar
results.205 Signiﬁcant oxidative damage was found in the
brain of largemouth bass after exposure to C60.260 Rat inha-
lation studies with stainless steel welding fumes showed that
manganese accumulates in the blood, liver, and brain.42 Epi-
demiological studies show a clear association between inha-
lation of dust containing manganese and neurological dis-
eases in miners171 and welders.150 Some welders develop
Parkinson’s disease much earlier in their life, usually in their
mid 40s, compared to the 60s in the general population.150
Brain inﬂammation appears to be a cumulative process, and
the long-term health effects may not be observed for
decades.205 Currently there are 1.5106 people suffering
from Alzheimer’s disease in the United States of America,205
and an estimated 18106 worldwide.261
Treatment. Antioxidants and metal chelators are treatment
options for the adverse health effects caused by the neuronal
uptake of nanoparticles. In the therapy of neurodegenerative
diseases, metal chelators transported across the blood-brain
barrier seem to be a very promising approach.253 Functional-
ized fullerenes61 and nanoparticles made of compounds hold-
ing oxygen vacancies show great antioxidant properties.62
Fullerols, or polyhydroxylated fullerenes, are excellent anti-
oxidants with high solubility and ability to cross the blood-
brain barrier, showing promising results as neuroprotective
agents.61 CeO2 and Y2O3 nanoparticles have strong antioxi-
dant properties on rodent nervous system cells.62 Cerium ox-
ide tends to be nonstoichiometric; Ce atoms having a dual
oxidation state, +3 or +4, lead to oxygen vacancies. Dual
oxidation state confers CeO2 and probably Y2O3 nanopar-
ticle antioxidant properties that promote cell survival under
conditions of oxidative stress. It appears that the antioxidant
properties depend on the structure of the particle, but they
are independent of its size within 6–1000 nm.
D. Nanoparticle translocation to the lymphatic
systems
Translocation of nanoparticles to lymph nodes is a topic
of intense investigation today for drug delivery and tumor
imaging.226 Progression of many cancers lung, esophageal,
mesothelioma, etc. is seen in the spread of tumor cells to
local lymph nodes.226 The detection and targeted drug deliv-
ery to these sites are the steps involved in the therapeutic
treatment of cancer. Several studies show that interstitially
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injected particles pass preferentially through the lymphatic
system and not through the circulatory system, probably due
to permeability differences.226 After entering the lymphatic
system, they locate in the lymph nodes.226 The free nanopar-
ticles reaching the lymph nodes are ingested by resident
macrophages.262 Nanoparticles that are able to enter the cir-
culatory system can also gain access to the interstitium and
from there are drained through the lymphatic system to the
lymph nodes as free nanoparticles and/or inside
macrophages.226,262
The adverse health effects of nanoparticle uptake by the
lymphatic system are not sufﬁciently explored. However, one
can hypothesize that oxidative stress created by certain types
of nanoparticles could lead to damage of lymphocytes type
of white blood cell, lymph nodes, and/or spleen.
E. Nanoparticle translocation to the circulatory system
Inhalation or instillation studies in healthy animals show
that metallic nanoparticles with size smaller than 30 nm pass
rapidly into the circulatory system,20,42,147,226,236 while non-
metallic nanoparticles with size between 4 and 200 nm pass
very little or not at all.201–203,263,264 In contrast, subjects suf-
fering from respiratory and circulatory diseases have higher
capillary permeability, allowing fast translocation of metallic
or nonmetallic nanoparticles into circulation.201–203
1. Long-term translocation
Nanoparticles, unlike larger particles, are able to translo-
cate across the respiratory epithelium after being deposited
in the lungs.20,236 Once they have crossed the respiratory
epithelium, they may persist in the interstitium for years or
they may enter the lymphatic system226 and circulatory
system.147 From the circulatory system, long-term transloca-
tion to organs such as the liver, heart, spleen, bladder, kid-
ney, and bone marrow is possible, depending on the dura-
tion of exposure.20 Smaller particles 20 nm are cleared
faster from the lungs than larger particles 100 nm, probably
because small nanoparticles are not efﬁciently phagocytized
by macrophages and are able to enter more rapid the circu-
latory and/or lymphatic systems.147
2. Short-term translocation of metals
Evidence of rapid translocation of metal nanoparticles
from lungs into the circulation and to organs has been pro-
vided by animal studies. These results show the location of
nanoparticles with diameters of 30 nm Au20 and 22 nm
TiO2 Ref. 236 in pulmonary capillaries, and 15 nm
Ag,147 and particles of various compositions from welding
fumes42 in the blood, liver, kidney, spleen, brain, and heart.
Animal studies on rats with inhalation of titanium dioxide
nanoparticles 22 nm diameter show that they can translo-
cate to the heart and can be found in the heart connective
tissue ﬁbroblasts.236 Within 30 min postexposure, large
quantities of intratracheally instilled gold nanoparticles
30 nm have been found in platelets inside of pulmonary
capillaries of rats,20 motivating the hypothesis that nanopar-
ticles may induce aggregation of platelets, leading to the for-
mation of blood clots. Figure 32a shows an electron micro-
scope image of a capillary with red blood cells.
3. Short-term translocation of nonmetals
There is no conclusive evidence showing fast transloca-
tion of carbon-based nanomaterials into systemic circulation.
Short-term translocation of radiolabeled nanoparticles from
lungs to the organs is currently the subject of debate as a
signiﬁcant fraction of radioactive labels detach from their
labeled nanoparticles, so radioactivity observed throughout
the body may not indicate the actual translocation of nano-
particles, but of radiolabels. Technetium’s short-lived isotope
99mTc, with an atomic diameter of about 0.37 nm, is used in
labeling nanoparticles that are subsequently injected or in-
haled by subjects. In many cases, the radiolabel can separate
from the nanoparticles and follow a different translocation
route. In the presence of oxygen, the radioactive label can
transform into pertechnetate 99mTcO4− having a slightly
larger diameter of roughly 0.5 nm. Most studies show very
little or no translocation of radiolabeled polystyrene nanopar-
ticles with diameters of 56 and 200 nm,201 or carbon nano-
particles with diameters of 5 nm,202 4–20 nm,263 35 nm,203
and 100 nm,264 while others show a rapid and substantial
translocation into circulation for particles sized 5–10 nm
Ref. 196 and 20–30 nm.247
While the short-term extrapulmonary translocation into
circulation in healthy subjects is still under debate, there
seems to be agreement on the fact that nanoparticle fast
translocation into circulation may be enhanced by pulmonary
inﬂammation201–203 and increased microvascular
permeability.201 Subjects suffering from respiratory or blood
diseases may have an increased susceptibility of nanoparticle
translocation from lungs to circulation and organs.
FIG. 32. a Red blood cells in a capillary. b Platelets, red, and white blood
cells. © Dr. Dennis Kunkel/Visuals Unlimited. Reproduced with permission
from Visuals Unlimited Ref. 25. c Particulate debris entrapped inside the
tissue formed around a vena cava ﬁlter removed after 156 days in a patient
with blood disease Ref. 148. d EDS spectrum showing the composition
of the debris shown in c, identiﬁed as stainless steel Ref. 148. c and d
reproduced from Ref. 148 with kind permission of Springer Science and
Business Media.
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4. Nanoparticle interaction with and uptake by blood
cells
There are three main types of cells in the blood Fig.
32b: red cells in charge of oxygen transport, white cells
responsible for ﬁghting infections, and platelets that help
prevent bleeding by forming blood clots. The uptake of
nanoparticles by each type of blood cells is essentially
different.
Nanoparticle uptake by red blood cells that do not have
phagocytic abilities, due to the lack of phagocytic receptors
is entirely dictated by size,205 while the nanoparticle charge
or material type plays little importance.245
In contrast, nanoparticle charge plays an essential role in
their uptake by platelets and their inﬂuence on blood clot
formation.246 Uncharged polystyrene particles do not have an
effect on blood clot formation. Negatively charged nanopar-
ticles signiﬁcantly inhibit thrombi formation, while posi-
tively charged nanoparticles enhance platelet aggregation
and thrombosis.246 The interaction between platelets and
positively charged particles seems to be due to the net nega-
tive charge that platelets carry on their surface.246 The posi-
tively charged nanoparticles interact with negatively charged
platelets and reduce their surface charge, making them more
prone to aggregation. Until now, it was thought that blood
clots can be formed due to three main causes: when the
blood ﬂow is obstructed or slowed down, when the vascular
endothelial cells are damaged, or due to the blood chemistry.
However, it seems possible, in the view of recent ﬁndings,
that nanoparticles may act as nucleating centers for blood
clots.148,265 It is important to note that pulmonary instillation
of large nanoparticles 400 nm caused pulmonary inﬂam-
mation of similar intensity to that caused by 60 nm particles,
but did not lead to peripheral thrombosis.30 The fact that the
larger particles failed to produce a thrombotic effect suggests
that pulmonary inﬂammation itself is insufﬁcient to cause
peripheral thrombosis,30 and that thrombi formation occurs
via direct activation of platelets.116,246
Microscopic and energy-dispersive spectrometry EDS
analyses of blood clots from patients with blood disorders
revealed the presence of foreign nanoparticles, as shown in
Figs. 32c and 32d. The blood clots were collected after
half a year of wear of vena cava ﬁlters implanted in order to
prevent pulmonary embolism in patients affected by blood
disorders.148 Most notably, patients with the same type of
blood disorder show ﬁbrous tissue clots containing nanopar-
ticles with various compositions: gold, silver, cobalt, tita-
nium, antimony, tungsten, nickel, zinc, mercury, barium,
iron, chromium, nickel, silicon, glass, talc, and stainless
steel. The common denominator of the particles is their size,
ranging from tens of nanometers to a few microns.148
The uptake of nanoparticles by macrophages a type of
white cell has already been discussed.
5. Adverse health effects of circulatory system
uptake
Thrombosis. Translocation of nanoparticles into the circu-
latory system was correlated with the appearance of thrombi
or blood clots.116,246 The time frame of this process is very
short, thrombosis occurring during the ﬁrst hour after expo-
sure. Hamster studies of tracheally or intravenously instilled
nanoparticles of charged polystyrene116 60 nm and diesel
exhaust particles116,266 20–50 nm revealed signiﬁcantly in-
creased arterial or venous thrombus formation during the
ﬁrst hour after administration. There is a clear dose-
dependent response correlating the quantity of pollutant ad-
ministered and the observed thrombus sizes.30,116 Prothrom-
botic effects persisted 24 h after instillation.30
If inhaled nanoparticles were to be found in red blood
cells located in pulmonary capillaries,205 one would expect
adverse health effects such as blood-related diseases, like
anemia, due to reduced oxygen transport capacity of the red
blood cells.
Cardiovascular malfunction. It is clear from clinical and
experimental evidence that inhalation of nano- and micropar-
ticles can cause cardiovascular effects.267 Despite the fact
that there is an intuitive relationship between inhaled nano-
particles and adverse respiratory effects, the causal link be-
tween particles in the lungs and cardiovascular effects is not
entirely understood.50 It was thought that the pulmonary in-
ﬂammation caused by the particles triggers a systemic re-
lease of cytokines, resulting in adverse cardiovascular ef-
fects. However, recent studies on animals,147,268 and
humans196 have shown that nanoparticles diffuse from the
lungs into the systemic circulation, and then are transported
to the organs, demonstrating that cardiovascular effects of
instilled or inhaled nanoparticles can arise directly from the
presence of nanoparticles within the organism.190 Proposed
mechanisms of cardiovascular effects are summarized in Fig.
33.50,116
F. Liver, spleen, and kidneys: Uptake of nanoparticles
1. Organs’ nanoparticle uptake
Endothelial cells cells that line the vascular system form
a physical barrier for particles, having very tight junctions,
typically smaller than 2 nm.269 Nevertheless, larger values
from 50 nm Ref. 52 up to 100 nm Ref. 269 have been
FIG. 33. Diagram of hypothetical mechanisms and pathways that link nano-
particles in the lung with adverse cardiovascular effects modiﬁed after
Refs. 50 and 116.
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reported, depending on the organ or tissue. A very tight en-
dothelial junction is present in the brain, often called the
blood-brain barrier. However, experiments performed on rats
injected with ferritin macromolecules with size around
10 nm into the cerebrospinal ﬂuid demonstrated passage of
ferritin into deep brain tissue. In certain organs, such as the
liver, the endothelium is fenestrated with pores of up to
100 nm, allowing easier passage of larger particles Fig.
34a. In the presence of inﬂammation, the permeability of
the endothelium is increased, allowing a larger passage of
particles.
Micro- and nanoparticle debris were detected by scanning
electron microscopy in organs and blood of patients with
orthopedic implants,270 drug addiction,270 worn dental
prostheses,204 blood diseases,148 colon cancer, Crohn’s dis-
ease, ulcerative colitis,149 and diseases of unknown
etiology.270 Coal workers’ autopsies reveal an increased
amount of particles in the liver and spleen compared to non-
coal workers.42 The workers with pronounced lung diseases
have more nanoparticles in their organs than healthier ones.42
The pathway of exposure most likely involves the transloca-
tion from lungs to circulation of the inhaled nanoparticles,
followed by uptake by the organs.
Rat inhalation studies with stainless steel welding fumes
showed that manganese accumulates in the blood and liver.42
Rat inhalation studies with 4–10 nm silver nanoparticles
show that within 30 min the nanoparticles enter the circula-
tory system, and after a day can be found in the liver, kidney,
and heart, until subsequently cleared from these organs after
a week.147 Clearance from the liver can occur via biliary
secretion into the small intestine.271
A case study shows that the wear of dental bridges leads
to the accumulation of wear nanoparticles in the liver and
kidneys.204 The most probable absorption pathway was as-
sumed to be via intestinal absorption.204 Scanning electron
microscopy and energy-dispersive microanalytical tech-
niques identiﬁed the chemical compositions of particles in
the liver and kidney biopsies, as well as in the stool, to be the
same as the porcelain from dental prostheses. The maximum
size of particles found in the liver 20 m was larger than
in the kidneys below 6 m, suggesting that particles are
absorbed by intestinal mucosa, and translocate to the liver
before reaching the circulatory system and kidneys. After the
removal of dental bridges, particles in the stool are no longer
observed.
2. Adverse health effects of liver and kidney uptake
Up to now there is little knowledge or discussion on the
effect of nanoparticles on organs such as the liver, kidneys,
spleen, etc. However, one can speculate that as long as there
is translocation to and accumulation of nanoparticles in these
organs, potentially adverse reactions and cytotoxicity may
lead to disease.
Diseases with unknown origins have been correlated with
the presence of micro- and nanoparticles in kidneys and liver
Figs. 34b and 34c.270 For comparison, the liver and kid-
neys of healthy subjects did not show any debris. Particle
debris has been found also in the liver of patients with worn
orthopedic prosthesis.270
Dental prosthesis debris internalized by intestinal absorp-
tion can lead to severe health conditions, including fever,
enlarged spleen and liver, suppression of bile ﬂow, and acute
renal failure.204 These symptoms appeared about a year after
the application of dental porcelain bridges. After the removal
of dental bridges, and subsequent treatment with steroids, the
clinical symptoms declined.204
G. Gastrointestinal tract uptake and clearance of
nanoparticles
1. Exposure sources
Endogenous sources of nanoparticles in the gastrointesti-
nal tract are derived from intestinal calcium and phosphate
secretion.272 Exogenous sources are particles from food
such as colorants, e.g., titanium oxide, pharmaceuticals,
water, cosmetics toothpaste and lipstick,272 dental prosthe-
sis debris,204 and inhaled particles.147 The dietary consump-
tion of nanoparticles in developed countries is estimated
around 1012 particles/person per day.260 They consist mainly
of TiO2 and mixed silicates. The use of speciﬁc products,
such as salad dressing containing nanoparticulate TiO2 whit-
ening agent, can lead to an increase by more than 40-fold of
FIG. 34. a Mouse liver with fenestrated hepatic endothelial cells Ref. 269. SEM and EDS spectrum of particles found in patients with diseased b liver and
c kidneys Ref. 270; reproduced from with permission from Elsevier.
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the daily average intake.260 These nanoparticles do not de-
grade in time and accumulate in macrophages. A database of
food and pharmaceuticals containing nanoparticles can be
found in Ref. 272. A portion of the particles cleared by the
mucociliary escalator can be subsequently ingested into the
gastrointestinal tract. Also, a small fraction of inhaled nano-
particles was found to pass into the gastrointestinal tract.147
2. Size and charge dependent uptake
The gastrointestinal tract is a complex barrier-exchange
system, and is the most important route for macromolecules
to enter the body. The epithelium of the small and large
intestines is in close contact with ingested material, which is
absorbed by the villi Fig. 35.
The uptake of nano- and microparticles has been the focus
of many investigations, the earliest dating from the mid-17th
century, while more recently entire issues of scientiﬁc jour-
nals have been devoted to the subject.52 The extent of par-
ticle absorption in the gastrointestinal tract is affected by
size, surface chemistry and charge, length of administration,
and dose.30
The absorption of particles in the gastrointestinal tract de-
pends on their size, the uptake diminishing for larger
particles.273 A study of polystyrene particles with size be-
tween 50 nm and 3 m indicated that the uptake decreases
with increasing particle size from 6.6% for 50 nm, 5.8% for
100 nm nanoparticles, 0.8% for 1 m, to 0% for 3 m par-
ticles.
The time required for nanoparticles to cross the colonic
mucus layer depends on the particle size, with smaller par-
ticles crossing faster than larger ones: 14 nm diameter latex
nanoparticles cross within 2 min, 415 nm within 30 min, and
1000 nm particles do not pass this barrier.30 Particles that
penetrate the mucus reach the enterocytes and are able to
translocate further.30 Enterocytes are a type of epithelial cell
of the superﬁcial layer of the small and large intestine tissue,
which aid in the absorption of nutrients. When in contact
with the submucosal tissue, nanoparticles can enter the lym-
phatic system and capillaries, and then are able to reach vari-
ous organs.30
Diseases, such as diabetes, may lead to higher absorption
of particles in the gastrointestinal tract.30 For example, rats
with experimentally induced diabetes had a 100-fold increase
in the absorption of 2 m polystyrene particles30 relative to
nondiabetic rats. Also inﬂammation may lead to the uptake
and translocation of larger particles of up to 20 m.204
The kinetics of particles in the gastrointestinal tract de-
pends strongly on the charge of the particles, positively
charged latex particles are trapped in the negatively charged
mucus, while negatively charged latex nanoparticles diffused
across the mucus layer and became available for interaction
with epithelial cells.30
3. Translocation
Varying the characteristics of nanoparticles, such as size,
surface charge, attachment of ligands, or surfactant coatings,
offers the possibility for site-speciﬁc targeting of different
regions of the gastrointestinal tract. The fast transit of mate-
rial through the intestinal tract on the order of hours, to-
gether with the continuous renewal of epithelium, led to the
hypothesis that nanomaterials will not remain there for in-
deﬁnite periods.30 Most of the studies of ingested nanopar-
ticles have shown that they are eliminated rapidly: 98% in
the feces within 48 h and most of the remainder via urine.20
However, other studies indicate that certain nanoparticles can
translocate to the blood, spleen, liver, bone marrow,273 lymph
nodes, kidneys, lungs, and brain, and can also be found in the
stomach and small intestine.274 Oral uptake of polystyrene
spheres of various sizes 50 nm–3 m by rats resulted in a
systemic distribution to the liver, spleen, blood, and bone
marrow.
273 Particles larger than 100 nm did not reach the
bone marrow, while those larger than 300 nm were absent
from the blood.273 In the study, no particles were detected in
the heart or lung tissue. Studies using iridium did not show
signiﬁcant uptake, while titanium oxide nanoparticles were
found in the blood and liver.20 For several days following
oral inoculation of mice with a relatively biologically inert
nanometer-sized plant virus cowpea mosaic virus, the virus
was found in a wide variety of tissues throughout the body,
including the spleen, kidney, liver, lungs, stomach, small in-
testine, lymph nodes, brain, and bone marrow.274
The exact order of translocation from the gastrointestinal
tract to organs and the blood is not known; however, a case
study of dental prosthesis porcelain debris internalized by
intestinal absorption suggests that intestinal absorption of
particles is followed by liver clearance before they reach the
general circulation and the kidneys.204
4. Adverse health effects of gastrointestinal tract
uptake
Reaction reduced toxicity. In the intestinal tract there is a
complex mix of compounds, enzymes, food, bacteria, etc.,
that can interact with ingested particles and sometimes re-
duce their toxicity.30 It was reported that particles in vitro are
less cytotoxic in a medium with high protein content.
Crohn’s disease, ulcerative colitis and cancer. Nanopar-
ticles have been found consistently in colon tissue of subjects
FIG. 35. TEM image of a thin section cut through a segment of human small
intestine epithelial cell. One notices densely packed microvilli, each mi-
crovillus being approximately 1 m long and 100 nm in diameter courtesy
of Chuck Daghlian, Louisa Howard, Katherine Connollly Ref. 96.
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affected by cancer, Crohn’s disease, and ulcerative colitis
Fig. 36, while in healthy subjects, nanoparticles were
absent.149 The nanoparticles present in diseased subjects had
various chemical compositions and are not considered toxic
in bulk form. Microscopic and energy-dispersive spectros-
copy analysis of colon mucosa indicated the presence of car-
bon, ceramic ﬁlosilicates, gypsum, sulphur, calcium, silicon,
stainless steel, silver, and zirconium.149 The size of debris
varied from 50 nm to 100 m, the smaller the particle, the
further it is able to penetrate. The particles were found at the
interface between healthy and cancerous tissue. Based on
these ﬁndings, it was suggested that the gastrointestinal bar-
rier is not efﬁcient for particles smaller than 20 m.204
Crohn’s disease affects primarily people in developed
countries, and occurs in both the native population and in
immigrants from underdeveloped countries. It affects 1 in
1000 people.252 Crohn’s disease is believed to be caused by
genetic predisposition together with environmental
factors.252 Recently, it was suggested that there is an associa-
tion between high levels of dietary nanoparticles
100 nm–1 m and Crohn’s disease.252 Exogenous nano-
particles were found in macrophages accumulated in lym-
phoid tissue of the human gut, the lymphoid aggregates be-
ing the earliest sign of lesions in Crohn’s disease.252
Microscopy studies showed that macrophages located in
lymphoid tissue uptake nanoparticles of spherical anatase
TiO2, with size ranging between 100 and 200 nm from
food additives; ﬂakylike aluminosilicates 100–400 nm typi-
cal of natural clay; and environmental silicates 100–700 nm,
with various morphologies.275 A diet low in exogenous par-
ticles seems to alleviate the symptoms of Crohn’s disease.252
This analysis is still controversial, with some proposing
that an abnormal response to dietary nanoparticles may be
the cause of this disease, and not an excess intake.272 More
precisely, some members of the population may have a ge-
netic predisposition where they are more affected by the in-
take of nanoparticles, and therefore develop Crohn’s
disease.260 Some evidence suggest that dietary nanoparticles
may exacerbate inﬂammation in Crohn’s disease.272 These
studies measured the intake of dietary particle, but did not
analyze the levels of outdoor and indoor nanoparticle pollu-
tion at the subjects’ residences. As was described previously,
signiﬁcant quantities of nanoparticles are cleared by the mu-
cociliary escalator and subsequently swallowed, ultimately
reaching the gastrointestinal tract.
Treatment. The diseases associated with gastrointestinal
uptake of nanoparticles such as Crohn’s disease and ulcer-
ative colitis have no cure and often require surgical inter-
vention. Treatments aim to keep the disease in remission and
consist of anti-inﬂammatory drugs and specially formulated
liquid meals.252 If dietary nanoparticles are conclusively
shown to cause these chronic diseases, their use in foods
should be avoided or strictly regulated.
H. Dermal uptake of nanoparticles
1. Penetration sites
The skin is composed of three layers—epidermis, dermis,
and subcutaneous Fig. 37a. The outer portion of the epi-
dermis, called stratum corneum, is a 10 m thick keratinized
layer of dead cells and is difﬁcult to pass for ionic com-
pounds and water soluble molecules.30 The surface of the
epidermis is highly microstructured, as seen in Fig. 37, hav-
ing a scaly appearance as well as pores for sweat, sebaceous
glands, and hair follicle sites.
As with many subjects involving nanoparticles, dermal
penetration is still controversial.18 Several studies show that
nanoparticles are able to penetrate the stratum
corneum.
18,20,83–85,276,277 Nanoparticle penetration through
the skin typically occurs at hair follicles,276 and ﬂexed277 and
FIG. 36. EDS spectrum and SEMs of
particles of different size and morphol-
ogy in patients with colon cancer Ref.
149. Particles are composed mainly
of a calcium and silicon, b stainless
steel, and c silver reproduced from
Ref. 149 with permission from
Elsevier.
FIG. 37. a Schematics of cross section in the skin. b The surface of
human skin epidermis © Dr. David M. Phillips/Visuals Unlimited, repro-
duced with permission from Visuals Unlimited Ref. 25.
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broken skin.20 Intracellular nanoparticle penetration is also
possible, as demonstrated by cell culture experiments.278
Multiple-wall carbon nanotubes MWCNTs are internalized
by human epidermal keratinocytes the major cell type of the
epidermis in cytoplasmic vacuoles and induce the release of
proinﬂammatory mediators.278 Spherical particles with diam-
eter between 750 nm and 6 m selectively penetrate the skin
at hair follicles, with a maximum penetration depth of more
than 2400 m 2.4 mm.276 Broken skin facilitates the entry
of a wide range of larger particles 500 nm–7 m.20 While
stationary unbroken skin has been shown to be impervious to
penetration, nanoparticles have been observed to penetrate
when the skin is ﬂexed. Thus, mechanical deformation is
capable of transporting particles through the stratum cor-
neum and into the epidermis and dermis.
A current area under discussion is whether or not nano-
particles of TiO2 found in commercially available sunscreens
penetrate the skin.279 For example, the application of a sun-
screen containing 8% nanoparticles 10–15 nm onto the
skin of humans showed no penetration, while oil-in-water
emulsions showed penetration, higher penetration being
present in hairy skin at the hair follicle site or pores.279 The
quantity of nanoparticles that penetrate is very small, with
less than 1% of the total amount in the applied sunscreen
being found in a given hair follicle.142
2. Translocation
The dermis has a rich supply of blood and macrophages,
lymph vessels, dendritic cells, and nerve endings.20 There-
fore, the particles that cross through the stratum corneum and
into the epidermis and dermis are potentially available for
recognition by the immune system.
Translocation of nanoparticles through the skin into the
lymphatic system is demonstrated by soil particles found in
lymph nodes of patients with podoconiosis.83–85
Neuronal transport of small nanoparticles along sensory
skin nerves may be possible, in a similar way to the proven
path for herpesvirus.20
3. Adverse health effects of dermal uptake
Many manufacturing processes pose an occupational
health hazard by exposing workers to nanoparticles and
small ﬁbers, as suggested from the intracellular uptake of
MWCNTs by human epidermal keratinocytes.278 This can
explain beryllium sensitization in workers wearing inhalation
protective equipment exposed to nanoparticulate
beryllium.277 Also, this may be relevant for latex sensitivity
and other materials that provoke dermatologic responses.
Soil particles. Lymphatic system uptake of nanoparticles
via the dermis is shown to cause podoconiosis83–85 Fig.
12d and Kaposi’s sarcoma81,86 Fig. 12f, diseases dis-
cussed in Sec. III A 3.
Titanium dioxide. Currently, a controversial subject is the
toxicity of titanium dioxide from cosmetics.280 There are
concerns about the toxicity of titanium dioxide—commonly
used as a physical sunscreen since it reﬂects and scatters
UVB 290–320 nm and UVA 320–400 nm light rays—
the skin-damaging portion of the solar spectrum. TiO2 also
absorbs a substantial amount of UV radiation, however,
which in aqueous media leads to the production of reactive
oxygen species, including superoxide anion radicals, hydro-
gen peroxide, free hydroxyl radicals, and singlet oxygens.
These reactive oxygen species can cause substantial damage
to DNA.140 Titanium dioxide particles under UV light irra-
diation have been shown to suppress tumor growth in cul-
tured human bladder cancer cells via reactive oxygen
species.143 Sun-illuminated titanium dioxide particles in sun-
screen were observed to catalyze DNA damage both in vitro
and in vivo.141,144 Reports regarding the toxicity of titanium
dioxide nanoparticles in the absence of UV radiation are con-
tradictory. Nanoparticles were seen to have no inﬂammatory
effect or genotoxicity in rats when introduced by
instillation.145 However, several other studies reported that
titanium dioxide caused chronic pulmonary inﬂammation in
rats again by instillation,281 and in vitro had a proinﬂam-
matory effect in cultured human endothelial cells.282
Silver. It is known that silver has a beneﬁcial antibacterial
effect when used as a wound dressing, reducing inﬂamma-
tion and facilitating healing in the early phases.283,284 How-
ever, there are contradictory studies on silver nanoparticles
and ion cytotoxicity from laboratories around the world. Sil-
ver is known to have a lethal effect on bacteria, but the same
property that makes it antibacterial may render it toxic to
human cells. Concentrations of silver that are lethal for bac-
teria are also lethal for both keratinocytes and ﬁbroblasts.283
I. Nanoparticle uptake via injection
Injection is the administration of a ﬂuid into the subcuta-
neous tissue, muscle, blood vessels, or body cavities. Injec-
tion of nanoparticles has been studied in drug delivery.
The translocation of nanoparticles following injection de-
pends on the site of injection: intravenously injected nano-
particles quickly spread throughout the circulatory system,
with subsequent translocation to organs; intradermal injec-
tion leads to lymph nodes uptake, while intramuscular injec-
tion is followed by neuronal and lymphatic system uptake.20
For example, the injection of magnetic nanoparticles smaller
than 100 nm into the tongues and facial muscles of mice
resulted in synaptic uptake.20
Nanoparticles injected intravenously are retained longer
in the body than ingested ones. For example, 90% of injected
functionalized fullerenes are retained after one week of
exposure.20
Intravenously injected nanoparticles quantum dots,
fullerenes, polystyrene, and plant virus with size ranging
from 10 to 240 nm show localization in different organs,
such as the liver, spleen, bone marrow, lymph nodes,20 small
intestine, brain, and lungs.274 Talc particles introduced by
injection are found in the liver of intravenous drug users.270
The distribution of particles in the body is a function of their
surface characteristics and their size. Coating nanoparticles
with various types and concentrations of surfactants before
injection signiﬁcantly affects their distribution in the body.285
For example, coating with polyethylene glycol or other sub-
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stances almost completely prevents hepatic and splenic
localization.20,285 Another example is the modiﬁcation of the
nanoparticle’s surface with cationic compounds that facilitate
arterial uptake by up to tenfold.286
The adverse health effects of injected nanoparticles are a
function of particle chemistry and charge. A common side
effect of injecting nanoparticles intravenously is hypersensi-
tivity, a reaction that occurs in a large number of recipients
and is probably due to the complement activation.287
J. Nanoparticle generation by implants
Nanoparticle debris produced by wear and corrosion of
implants is transported to the region beyond the implant.270
Implants release metal ions and wear particles and, after sev-
eral years of wear, in some cases, the concentration of metals
in the blood exceeds the biological exposure indices recom-
mended for occupational exposure.288
Materials considered chemically inert in bulk form like
ceramic porcelain and alumina, or in other terms biocom-
patible, are used for implants and prostheses.270 However,
nanoparticles with the same composition have been observed
in the liver and kidneys of diseased patients with implants
and prostheses. It was suggested that the concept of biocom-
patibility should be revised in view of these ﬁndings.270
Patients with orthopedic implants have a statistically sig-
niﬁcant rise in the incidence of autoimmune diseases, per-
haps due to the particulate wear debris generated by the im-
plant, which is associated with electrochemical processes
that may activate the immune system.289 Immunological re-
sponses and aseptic inﬂammation in patients with total hip
replacement are a response to wear particles.290 Exposure to
orthopedic wear debris leads to inﬂammatory initiated bone
resorption, implant failure, dermatitis, urticaria, and
vasculitis.289,291
K. Positive effects of nanoparticles
1. Nanoparticles as antioxidants
Fullerene derivatives61 and nanoparticles made of com-
pounds holding oxygen vacancies CeO2 and Y2O3 Ref.
62 have demonstrated neuroprotective properties and anti-
apoptotic activity. Fullerene derivatives have been shown to
prevent apoptosis in hepatic, kidney, and neuronal cells, a
fact attributed to their antioxidant properties.61 The decrease
of apoptotic cell death is related to the neutralization of re-
active oxygen species both in vitro and in vivo. Neurodegen-
erative disorders, such as Parkinson’s and Alzheimer’s dis-
eases present hyperproduction of oxygen and nitric oxide
radical species.61 As described previously, oxidative stress by
oxygen radicals induces cellular instability by a cascade of
events, leading to cell death. The use of fullerenes as radical
sponges or scavengers has been shown to decrease neu-
ronal death.61 Functionalized fullerenes can react with oxy-
gen species that attack lipids, proteins, and DNA, conferring
neuroprotective properties. In particular, polyhydroxylated
fullerenes fullerols C60OHn are excellent antioxidants
and offer exceptional neuroprotective properties, having high
solubility and ability to cross the blood-brain barrier.61
2. Antimicrobial activity
Several types of nanoparticle are known to have an anti-
microbial effect, such as silver,14 titanium dioxide,292
fullerenes,61 zinc oxide,293 and magnesium oxide.287
Antimicrobial activity of fullerenes was observed on vari-
ous bacteria, such as E. coli Fig. 38b, Salmonella, and
Streptococcus spp.61 The bactericide action is probably due
to inhibition of energy metabolism once the bacteria have
internalized the nanoparticles. Zinc oxide nanoparticles are
bactericidal, disrupting membrane permeability and being in-
ternalized by Escherichia coli bacteria.293 Silver nanopar-
ticles and ions are broad spectrum antimicrobial agents.294
Their antibacterial action results from destabilization of the
outer membrane of bacteria, and depletion of the levels of
adenosine triphosphate, a molecule that is the principal form
of energy immediately usable by the cell.
Fullerenes have also been shown to have an anti-HIV ac-
tivity, probably due to a good geometrical ﬁt of a C60 sphere
into the active site diameter of about 1 nm on the funda-
mental enzyme HIV protease necessary for HIV Fig.
38a survival, leading to strong van der Waals interactions
between the enzyme and fullerene.61 It has been demon-
strated that silver nanoparticles undergo a size-dependent in-
teraction with HIV-1 virus, with nanoparticles exclusively in
the range of 1–10 nm attached to the virus.295 Due to this
interaction, silver nanoparticles inhibit the virus from bind-
ing to host cells, as demonstrated in vitro.
V. PHYSICOCHEMICAL CHARACTERISTICS
DEPENDENT TOXICITY
From previous knowledge of toxicological properties of
ﬁbrous particles such as asbestos, it is believed that the
most important parameters in determining the adverse health
effects of nanoparticles are dose, dimension, and durability
the three D’s.39 However, recent studies show different cor-
relations between various physicochemical properties of
nanoparticles and the associated health effects, raising some
uncertainties as to which are the most important parameters
in deciding their toxicity: mass, number, size, bulk or surface
chemistry, aggregation, or all together. In the following, we
FIG. 38. a E. Coli bacteria, just after division, showing ﬁmbriae on the cell
surface © Dr. Dennis Kunkel/Visuals Unlimited. Reproduced with permis-
sion Ref. 25. b HIV © Dr. Hans Gelderblom/Visuals Unlimited. Repro-
duced with permission Ref. 25.
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will emphasize what we believe are the most important nano-
particle characteristics associated with their toxicity.
A. Dose-dependent toxicity
Dose is deﬁned as the amount or quantity of substance
that will reach a biological system. The dose is directly re-
lated to exposure or the concentration of substance in the
relevant medium air, food, and water multiplied by the du-
ration of contact.
Generally, the negative health effects of nanoparticles do
not correlate with nanoparticle mass dose see Fig. 39.20,50
Comparing the health effects of inhaled TiO2 nanoparticles
with different sizes, it is remarkable that the low dose
10 mg /m3 exposure to 20 nm diameter particles resulted in
a greater lung tumor incidence than the high dose
250 mg /m3 exposure of 300 nm diameter particles.30 The
measure that correlates with the effects is the surface area
and not the mass dose Fig. 39a.20,222,296
B. Size-dependent toxicity
In the past decade, toxicological studies have demon-
strated that small nanoparticles 100 nm cause adverse
respiratory health effects, typically causing more inﬂamma-
tion than larger particles made from the same
material.20,50,140,222,250,297 Rat inhalation222 and instillation20
of titanium oxide particles with two sizes, 20 and 250 nm
diameter, having the same crystalline structure show that
smaller particles led to a persistently high inﬂammatory re-
action in the lungs compared to larger size particles. In the
postexposure period up to one year, it was observed that
the smaller particles had 1 a signiﬁcantly prolonged reten-
tion, 2 increased translocation to the pulmonary intersti-
tium and pulmonary persistence of nanoparticles, 3 greater
epithelial effects such as type II cell proliferation, and 4
impairment of alveolar macrophage function.222
C. Surface-area-dependent toxicity
For the same mass of particles with the same chemical
composition and crystalline structure, a greater toxicity was
found from nanoparticles than from their larger counterparts.
This led to the conclusion that the inﬂammatory effect may
be dependent on the surface area of nanoparticles, suggesting
a need for changes in deﬁnitions and regulations related to
dose and exposure limits. Indeed, smaller nanoparticles have
higher surface area and particle number per unit mass com-
pared to larger particles. The body will react differently to
the same mass dose consisting of billions of nanoparticles
compared to several microparticles. Larger surface area leads
to increased reactivity27 and is an increased source of reac-
tive oxygen species, as demonstrated by in vitro
experiments.50
Intratracheal instillation studies on mice with titanium di-
oxide anatase show that small nanoparticles 20 nm induce
a much greater inﬂammatory response than larger nanopar-
ticles 250 nm for the same mass dose.20 If instilled at the
same surface area dose, they generated similar toxicity, ﬁt-
ting the same curve.20
The higher surface area of nanoparticles causes a dose-
dependent increase in oxidation50 and DNA damage,47 much
higher than larger particles with the same mass dose.50 Giv-
ing an example for the dose, high levels of oxidative DNA
damage have been observed in cell culture experiments at
25 g per well, with surface area of wells of 9.6 cm2.47 In a
simpliﬁed calculation, for a total surface area of the human
lung alveolar region of 75 m2, from which 3% are type II
epithelial cells target for cancer development, this dose is
equivalent to about four years of exposure at the highest
ambient particle concentration.47 However, mathematical
modeling of particle deposition in the airways indicates that
some cells may receive 100-fold more particles depending
on their orientation geometry.298 Other studies suggested a
threshold of 20 cm2 surface area of instilled nanoparticles,
below which there is no signiﬁcant inﬂammatory response in
mice.296 Extrapolating these ﬁndings to humans and environ-
mental pollution, the critical surface area of nanoparticles
becomes 30 000 cm2.296 In a busy urban area with nanopar-
ticle concentrations of up to 10 g /m3, with speciﬁc surface
area of 110 m2 /g, and deposition efﬁciency of 70%, the lung
burden results in 150 cm2 /day. If deposited particles accu-
mulate in the lungs, the surface threshold for signiﬁcant in-
ﬂammatory effects is reached in about half a year.296 How-
ever, subjects with respiratory or cardiovascular diseases
may have a lower threshold. In addition, cardiovascular con-
sequences may appear at a lower pollution threshold. We
must emphasize that epidemiological studies do not indicate
the existence of a threshold below which there are no adverse
health effects.296
Attempts have been made to contradict surface-area-
dependent toxicity.299 One study claims that they tested the
toxicity of smaller nanoparticles against larger nanoparticles
of similar composition, and their ﬁndings show that they
generate similar cytotoxicity or inﬂammatory reaction within
the lungs.299 However, they used two different forms of tita-
nium dioxide: rutile and anatase, which seem to have differ-
ent toxicity levels regarding generation of oxidative
compounds.140 Similar composition does not necessarily im-
ply similar chemistry and chemical bonds. The best example
FIG. 39. a Inﬂammation generated by instillation of low-toxicity particles
carbon black, titanium dioxide and polystyrene with the dose expressed as
surface area after Ref. 50. b Indication of oxidation induced ﬂuorescence
for nanoparticles and microparticles versus mass dose after Ref. 50.
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is carbon, whose allotropes are graphite, diamond, carbon
nanotubes, and fullerenes, each with distinct physical and
biological characteristics.
D. Concentration-dependent toxicity
There are many contradictory results related to the toxic
effects of nanoparticles at different concentrations. Some
studies show that certain materials are not as toxic as was
observed by other studies. When comparing the results of
different studies, one must take into account that there are
differences in the aggregation properties of nanoparticles in
air and water, resulting in inherent discrepancies between
inhalation studies and instillation or in vitro experiments.
The aggregation may depend on surface charge, material
type, and size, among others.
One must stress the fact that aggregation of nanoparticles
is essential in determining their toxicity, due to a more effec-
tive macrophage clearance for larger particles compared to
smaller ones that seem to easily evade this defense mecha-
nism, leading to reduced toxicity of nanoparticle aggregates
larger than 100–200 nm.20,147 It has been demonstrated that
a high concentration of nanoparticles would promote particle
aggregation,140,300 and therefore reduce toxic effects com-
pared to lower concentrations.147 Most aggregates are ob-
served to be larger than 100 nm, a size that seems to be a
threshold for many of the adverse health effects of small
particles. Therefore, experiments performed with high con-
centrations of nanoparticles will lead to the formation of
nanoparticle aggregates that may not be as toxic as lower
concentrations of the same nanoparticles.
E. Particle chemistry and crystalline structure
dependent toxicity
Although there have been suggestions that size may be
more important than chemical composition in deciding nano-
particle toxicity,47 one cannot generally extrapolate the re-
sults of studies showing similar extent of inﬂammation for
different nanoparticle chemistries. Particle chemistry is criti-
cal in determining nanoparticle toxicity. Particle chemistry is
especially relevant from the point of view of cell molecular
chemistry and oxidative stress. Namely, depending on their
chemistry, nanoparticles can show different cellular uptake,
subcellular localization, and ability to catalyze the produc-
tion of reactive oxygen species.235
One must make the distinction between composition and
chemistry. Though particles may have the same composition,
they may have different chemical or crystalline structures.
The toxicity of a material depends on its type of crystalline
form.140 Let us take, for example, rutile and anatase, shown
in Figs. 40a and 40b, both allotropes of titanium dioxide,
i.e., polymorphs with the same chemical composition, but
different crystalline structures, and hence, different chemical
and physical properties. Rutile nanoparticles 200 nm were
found to induce oxidative DNA damage in the absence of
light, but anatase nanoparticles of the same size did not.140
Nanoparticles can change crystal structure after interac-
tion with water or liquids. For example, it is reported that
zinc sulphide ZnS nanoparticles 3 nm across, containing
around 700 atoms rearrange their crystal structure in the
presence of water and become more ordered, closer to the
structure of a bulk piece of solid ZnS.301 Nanoparticles often
exhibit unexpected crystal structures due to surface effects
Fig. 40c. The collection of gold nano- and microparticles
shown in Fig. 40c was made by evaporting gold by heating
it with an electron beam, and then allowing the vaporized
atoms sufﬁcient time and density to condens into clusters
before collection on a substrate. Condensation dynamics dic-
tate that gold under these conditions will form these crystal-
line particles, which form equilibrium-seeking quasispheres
as the condensing atoms jostle each other in random walks
on the surface towards ﬁnal resting places within the crystal.
The effects of crystallinity on condensation are clearly ob-
served in the faceting and ﬁne nano structure of the crystal
faces. Incidentally interesting is the dendritic patterns on the
111 faces, where the condensation forms a classic
FIG. 40. a Unit cells of rutile and b anatase, both crystalline forms of titanium dioxide; c gold micro- and nanoparticles formed by vacuum evaporation
and vapor-phase condensation Ref. 347.
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diffusion-limited aggregation structure. These nanoparticles
are similar to the engineered nanoparticles produced in many
industrial processes—they are engineered or designed by de-
veloping unique recipes that yield materials with beneﬁcial
characteristics. Finally, note the size of the largest gold par-
ticle in Fig. 40c, and that of the two progressively smaller
particles stacked one upon the other. The largest is 2.5 m in
diameter with approximately 1011 atoms, the middle is
450 nm with 109 atoms, and the smallest on top is 80 nm
with 107 atoms. The smallest nanoparticle in the image, just
below the “x” arrow, is only 25 nm in diameter, and contains
roughly half a million atoms. A unique behavior emerges
from these and other nanomaterials when small clusters of
atoms form and manifest quantum effects.
F. Aspect-ratio-dependent toxicity
It was found that the higher the aspect ratio, the more
toxic the particle is.208 More exactly, lung cancer was asso-
ciated with the presence of asbestos ﬁbers longer than 10 m
in the lungs, mesothelioma with ﬁbers longer than 5 m, and
asbestosis with ﬁbers longer than 2 m.208 All of these ﬁbers
had a minimum thickness of about 150 nm.208 Long ﬁbers
longer than 20 m for humans will not be effectively
cleared from the respiratory tract due to the inability of mac-
rophages to phagocytize them.30 Alveolar macrophages were
measured to have average diameters of 14–21 m.39 The
biopersistence of these long-aspect-ratio ﬁbers leads to long-
term carcinogenic effects, as shown in Fig. 41.39
The toxicity of long-aspect-ratio ﬁbers is closely related
to their biodurability. The biodurability of a ﬁber depends on
its dissolution and mechanical properties breaking. Longer
ﬁbers that break perpendicular to their long axis become
shorter and can be removed by macrophages. Asbestos ﬁbers
break longitudinally, resulting in more ﬁbers with smaller
diameter, being harder to clear.30 If the lung clearance is
slow, the longer the time these ﬁbers will stay in the lungs
and the higher the probability of an adverse response. Fibers
that are sufﬁciently soluble in lung ﬂuid can disappear in a
matter of months, while the insoluble ﬁbers are likely to
remain in the lungs indeﬁnitely. Even short insoluble ﬁbers
that are efﬁciently phagocytized by alveolar macrophages
may induce biochemical reactions release of cytokines, re-
active oxygen species, and other mediators.
Long-aspect-ratio engineered nanoparticles, such as car-
bon nanotubes CNTs, are new materials of emerging tech-
nological relevance and have recently attracted a lot of atten-
tion due to their possible negative health effects,224,278,302–309
as suggested by their morphological similarities with asbes-
tos. However, there is no consensus in the characterization of
CNT toxicity.
The contradictory reports on CNT toxicity could be asso-
ciated with the multitude of morphologies, sizes, and chemi-
cal functionalizations of their surface or ends. Carbon nano-
tubes can be single walled SWCNTs or multiple walled
MWCNTs, with varying diameter and length, with closed
capped sections or open ends.310 In addition to the many
forms of nanotubes, they can also be chemically modiﬁed.
The diameter of CNTs varies between 0.4 and 100 nm. Their
lengths can range between several nanometers to
centimeters.310 Due to their hydrophobicity and tendency to
aggregate, they are harmful to living cells in culture.278,308
For many applications, CNTs are oxidized to create hydroxyl
and carboxyl groups, especially in their ends, which makes
them more readily dispersed in aqueous solutions.311
The conclusions of research on carbon nanotube cytotox-
icity are that, in general, CNTs are very toxic, inducing cell
death at sufﬁciently high doses of 400 g /ml on human T
cells311 and 3.06 g /cm2 on alveolar macrophages.309 Cell
cultures with added SWCNTs at much lower doses of
3.8 g /ml did not show cytotoxicity.307 However, dose re-
lated inﬂammation or cell death is not in agreement between
various studies. It was found that cells actively respond to
SWCNTs by secreting proteins to aggregate and wrap
them.307 At the same time, SWCNTs induce up-regulation of
apoptosis-associated genes.307
Long-aspect-ratio particles SWCNTs were reported to
produce signiﬁcant pulmonary toxicity compared to spheri-
cal particles amorphous carbon black.302,304,311 Pharyngeal
introduction of SWCNTs resulted in acute inﬂammation with
onset of progressive ﬁbrosis and granulomas in rats.302,304
For comparison, equal doses of carbon black or silica nano-
particles did not induce granulomas, alveolar wall thicken-
ing, causing only a weak inﬂammation and limited
damage.302 The enhanced toxicity was attributed to physico-
chemical properties and ﬁbrous nature. Carbon nanotubes are
not eliminated from the lungs or very slowly eliminated,
81% are found in rat lungs 60 days after exposure.224
G. Surface coating and functionalization
Due to the possibility of chemical interactions, the com-
bined effects of inhalation, ingestion, or dermal application
of nanoparticles with other nanoparticles, chemicals, and
gases are largely unknown. The estimated risk of two or
more pollutants is not a simple additive process. Particle sur-
face plays a critical role in toxicity as it makes contact with
cells and biological material. Surfactants can drastically
change the physicochemical properties of nanoparticles, such
as magnetic, electric, and optical properties and chemical
reactivity,20,312,313 affecting their cytotoxicity. Surface coat-
ings can render noxious particles nontoxic, while less harm-
FIG. 41. Fiber health indices describing diseases associated to ﬁbers of dif-
ferent size after Ref. 208.
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ful particles can be made highly toxic. The presence of oxy-
gen, ozone,47 oxygen radicals,314 and transition metals50 on
nanoparticle surfaces leads to the creation of reactive oxygen
species and the induction of inﬂammation. For example, the
speciﬁc cytotoxicity of silica is strongly associated with the
occurrence of surface radicals and reactive oxygen species.30
Experiments performed on hamsters showed that the forma-
tion of blood clots is more prominent when the surface of
polystyrene nanoparticles is aminated.246 Diesel exhaust par-
ticles interacting with ozone cause increased inﬂammation in
the lungs of rats compared to diesel particles alone.47 Nickel
ferrite particles, with and without surface oleic acid, show
different cytotoxicity.312 The cytotoxicity of C60 molecules
systematically correlates with their chemical functionality in
human skin and liver carcinoma cells, with cell death oc-
curring due to lipid oxidation caused by the generation of
oxygen radicals.314 Spherical gold nanoparticles with various
surface coatings are not toxic to human cells, despite the fact
that they are internalized.58,59 Quantum dots of CdSe can be
rendered nontoxic when appropriately coated.60
H. Adaptability to nanomaterials inhalation
Recent studies suggest that preexposure to lower concen-
trations of nanoparticles or shorter exposure times stimulates
the phagocytic activity of cells, while a high concentration of
nanoparticles impairs this activity.180,231,232 As a result, pul-
monary inﬂammation is drastically reduced by several previ-
ous shorter exposure times to the same nanomaterials.180 The
severe pulmonary inﬂammatory response observed in rats
after only 15 min exposure to 50 g /m3 Teﬂon fume par-
ticles with diameter of about 16 nm can be prevented by
three preceding daily 5 min exposure to the fumes.180 During
the three days of adaptation, the animals did not show clini-
cal symptoms of respiratory effects, in contrast to the non-
adapted group rats that were severely affected, showing dif-
ﬁculty breathing starting 1 h after exposure. The number of
alveolar macrophages was signiﬁcantly lower in the non-
adapted group.
I. Comparison studies
In order to assess the toxicity of various nanomaterials,
one must compare their toxic effects with those of known
toxic particles. Several studies have pioneered this
initiative.112,224,303,304,315,316. However, the database of stud-
ied materials is limited. The conclusions of these studies in-
dicate that CNTs are extremely toxic, producing more dam-
age to the lungs than carbon black or silica.224 Varieties of
CNT aggregates, and some carbon blacks, were shown to be
as cytotoxic as asbestos see Table IV.112 Silver nanoparticle
aggregates were found to be more toxic than asbestos, while
titanium oxide, alumina, iron oxide, and zirconium oxide
were found to be less toxic.112
VI. APPLICATIONS OF NANOPARTICLES
In this section, we will outline several of the many appli-
cations of nanomaterials, both current and anticipated. To our
knowledge, there is no comprehensive review of nanotech-
nology applications, likely due to the rapid development of
this ﬁeld. We feel that this section is necessary in order to
broaden understanding of the importance that nanomaterials
have and will play in our future, improving the quality of life
through nanomedicine, electronics, and other nano ﬁelds.
Among the established applications of nanomaterials, we
give as examples microelectronics, synthetic rubber, catalytic
compounds, photographic supplies, inks and pigments, coat-
ings and adhesives, ultraﬁne polishing compounds, UV ab-
sorbers for sunscreens, synthetic bone, ferroﬂuids, optical ﬁ-
ber cladding, and cosmetics. Applications currently entering
widespread use include: fabrics and their treatments, ﬁltra-
TABLE IV. Nanomaterials, their morphologies, and their relative cytotoxicity index RCI on murine macroph-









at 5 g /ml
RCI
at 10 g /ml
Ag 1 30 1.5 0.8
Ag 0.4 30 1.8 0.1
Al2O3 0.7 50 0.7 0.4
Fe2O3 0.7 50 0.9 0.1
ZrO2 0.7 20 0.7 0.6
TiO2 rutile 1 Short ﬁbers
5–15 nm diam.
0.3 0.05
TiO2 anatase 2.5 20 0.4 0.1
Si3N4 1 60 0.4 0.06
Asbestos
Chrysotile





Carbon black 0.5 20 0.8 0.6
SWCNT 10 100 nm diam. 1.1 0.9
MWCNT 2 15 nm diam. 0.9 0.8
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tion, dental materials, surface disinfectants, diesel and fuel
additives, hazardous chemical neutralizers, automotive
components, electronics, scientiﬁc instruments, sports equip-
ment, ﬂat-panel displays, drug delivery systems, and
pharmaceutics.
The unique properties of nanomaterials encourage the be-
lief that they can be applied in a wide range of ﬁelds, from
medical applications to environmental sciences. Studies con-
ducted by nanotechnology experts mapping the risks and op-
portunities of nanotechnology have revealed enormous pros-
pects for progress in both life sciences and information
technology.19 Medical applications are expected to increase
our quality of life through early diagnosis and treatment of
diseases, and prosthetics, among others. Ecological applica-
tions include removal of persistent pollutants from soil and
water supplies. Nanotechnology has become a top research
priority in most of the industrialized world, including the
USA, the EU and Japan. In the USA, nanotechnology is now
at the level of a federal program.317 Since 2000, around 60
countries have initiated nanotechnology based initiatives at a
national level.318
A. Electronics
Microelectronics. Many of the current microelectronics
applications are already at a nanoscale.319 During the past
four decades, the smallest feature of a transistor shrunk from
10 m down to 30 nm.319 The ultimate objective of micro-
electronics fabrication is to make electronic circuit elements
that are nanoscopic. For example, by achieving a signiﬁcant
reduction in the size of circuit elements, the microprocessors
or better said, nanoprocessors that contain these compo-
nents could run faster and incorporate more logic gates,
thereby enabling computations at far higher speeds. CNTs
are exciting alternatives to conventional doped semiconduc-
tor crystals due to their varied electronic properties, ranging
from metallic, to semiconducting,320 to superconducting.321
Displays. The resolution of a television or a monitor im-
proves with reduction of pixel size. The use of nanocrystal-
line materials can greatly enhance resolution and may sig-
niﬁcantly reduce cost. Also, ﬂat-panel displays constructed
with nanomaterials may possess much higher brightness and
contrast than conventional displays owing to the enhanced
electrical and optical properties of the new materials. CNTs
are being investigated for low voltage ﬁeld-emission
displays.322 Their combination of mechanical and electrical
properties makes them potentially very attractive for long-
life emitters.
Data storage. Devices, such as computer hard disks that
function based on their ability to magnetize a small area of a
spinning disk to record information, are established nanoap-
plications. Disks and tapes containing engineered nanomate-
rials can store large amounts of information. Future avenues
for magnetic recording that will drastically increase the ca-
pability of data storage include spintronics and nanowires.
High energy density batteries. New nanomaterials show
promising properties as anode and cathode materials in
lithium-ion batteries, having higher capacity and better cycle
life than their larger-particle equivalents.323 Among them are
aerogel intercalation electrode materials, nanocrystalline al-
loys, nanosized composite materials, carbon nanotubes, and
nanosized transition-metal oxides.323
High-sensitivity sensors. Due to their high surface area
and increased reactivity, nanomaterials could be employed as
sensors for detecting various parameters, such as electrical
resistivity, chemical activity, magnetic permeability, thermal
conductivity, and capacitance.
B. Transportation and telecommunication
Car tires. Nanoparticles of carbon black ranging between
10 and 500 nm act as a ﬁller in the polymer matrix of tires,
and are used for mechanical reinforcement.
Car bumpers. Clay particle based composites containing
plastics and nanosized clay are used to make car exteriors
that are lighter and twice as resistant to scratches than usual
materials.324
C. Imaging
Scanning microscope imaging. SWCNTs have been used
as probe tips for atomic force microscopy AFM imaging of
antibodies, DNA, etc.325 Nanotubes are ideal probe tips for
scanning microscopy due to their small diameter which
maximizes resolution, high aspect ratio, and stiffness.
Molecular-recognition AFM tips. SWCNTs with attached
biomolecules are attached to AFM tips, and used for “mo-
lecular recognition” in order to study chemical forces be-
tween molecules.325
D. Biomedical applications
Nanoscaffolds. Nanoﬁber scaffolds can be used to regen-
erate central nervous system cells and possible other organs.
Experiments performed on a hamster with severed optic tract
demonstrated the regeneration of axonal tissue initiated by a
peptide nanoﬁber scaffold.326
Antimicrobial nanopowders and coatings. Certain nan-
opowders possess antimicrobial properties.61,327 When these
powders contact cells of E. coli, or other bacteria species and
viruses, over 90% are killed within a few minutes. Due to
their antimicrobial effect, nanoparticles of silver and titanium
dioxide 100 nm are assessed as coatings for surgical
masks.292
Bioseparation. Nanotube membranes can act as channels
for highly selective transport of molecules and ions between
solutions that are present on both sides of the membrane.328
For example, membranes containing nanotubes with inside
diameters of molecular dimensions less than 1 nm separate
small molecules on the basis of molecular size, while nano-
tubes with larger inside diameters 20–60 nm can be used
to separate proteins.329
Drug delivery. The ability of nanoparticles to target and
penetrate speciﬁc organs and cells contributes to their toxic-
ity; however, this ability may be exploited in nanomedicine.
Nanospheres composed of biodegradable polymers can be
incorporated into drugs, allowing the timed release of the
MR63 Buzea, Pacheco, and Robbie: Nanomaterials and nanoparticles: Sources and toxicity MR63
Biointerphases, Vol. 2, No. 4, December 2007
drug as the polymer degrades.330 When particles are set to
degrade in an acid microenvironment, such as tumor cells or
around inﬂammation sites, this allows site-speciﬁc or tar-
geted drug delivery.
Gene transfection. Surface-functionalized nanoparticles
can be used to permeate cell membranes at a much higher
level than nanoparticles without a functionalized surface.331
This property can be used to deliver genetic material into
living cells, a process called transfection. For example, silica
nanospheres labeled on their outer surfaces with cationic am-
monium groups can bind DNA a polyanion through elec-
trostatic interactions.332 Then nanoparticles deliver the DNA
into cells.
Medical imaging. A variety of techniques currently called
noninvasive have been used for more than a quarter of a
century in medical imaging, for example, superparamagnetic
magnetite particles coated with dextran are used as image-
enhancement agents in magnetic resonance imaging.333 Intra-
cellular imaging is also possible through attachment of quan-
tum dots to selected molecules, which allows intracellular
processes to be observed directly.
Nasal vaccination. Nanosphere carriers for vaccines are in
development. Antigen-coated polystyrene nanospheres, used
as vaccine carriers targeting human dendritic cells, have been
researched for nasal vaccination.334 Nanospheres had a direct
effect on human dendritic cells, inducing transcription of
genes important for, e.g., phagocytosis as well as an immune
response.
Nucleic acid sequence and protein detection. Targeting
and identifying various diseases could be made possible by
detecting nucleic acid sequences unique to speciﬁc bacteria
and viruses, or to speciﬁc diseases, or abnormal concentra-
tion of certain proteins that signal the presence of various
cancers and diseases.335 Nanomaterial-based assays are cur-
rently evaluated as well as more sensitive protein detection
methods. Nucleic acid sequences are currently detected with
polymerase chain reaction PCR coupled with molecular
ﬂuorophore assays. Despite high sensitivity, PCR has signiﬁ-
cant drawbacks, such as complexity, sensitivity to contami-
nation, cost, and lack of portability.335 Current protein detec-
tion methods, such as enzyme-linked immunoabsorbent
assay, allow the detection of protein concentrations at which
the disease is often advanced. More sensitive methods based
on nanomaterials would revolutionize physical treatment of
many cancer types and diseases.335
Smart nanophase extractors. Differentially functionalized
nanotubes are used as smart nanophase extractors, with
molecular-recognition capabilities, to remove speciﬁc mol-
ecules from solutions.329
Treatment for local anesthetic toxicity. Local anesthetic
can be sometimes very toxic, ranging from local neurotoxic-
ity to cardiovascular collapse and coma. In addition to con-
ventional therapies, drug-scavenging nanoparticles have
shown to increase survival rate from no animals in the con-
trol group to all animals in the treated group.336,337
E. Pollution remediation
Although research on environmental applications of nano-
particles is still a new area, it is growing rapidly. The poten-
tial of nanoparticles to react with pollutants in the air, soil,
and water, and transform them into harmless compounds is
currently being researched. Nanotechnology could be applied
at both ends of the environmental spectrum to clean up ex-
isting pollution and to decrease or prevent its generation see
below.
Elimination of pollutants. Due to their enhanced chemical
activity, nanomaterials can be used as catalysts to react with
toxic gases such as carbon monoxide and nitrogen oxide in
automobile catalytic converters and power generation equip-
ment. This could prevent gaseous environmental pollution
arising from burning gasoline and coal. Paints that absorb
noxious gases from vehicle exhaust have already been
developed.338 They contain 30 nm spherical nanoparticles of
titanium oxide and calcium carbonate mixed in a silicon-
based polymer, polysiloxane, and absorb nitrogen oxide
gases from vehicle exhausts, a pollution source that can
cause smog and respiratory problems. The porous polysilox-
ane lets the nitrogen oxide gases diffuse and adhere to the
titanium dioxide particles. UV radiation from sunlight con-
verts nitrogen oxide to nitric acid, which is then neutralized
by the calcium carbonate. The lifetime of the paint is said to
be up to 5 years.338
Water remediation. Iron nanoparticles with a small con-
tent of palladium are tested to transform harmful products in
groundwater into less harmful end products.339 The nanopar-
ticles are able to remove organic chlorine a carcinogen,
from water and soil contaminated with the chlorine-based
organic solvents used in dry cleaners, and convert the sol-
vents to benign hydrocarbons.
F. Cosmetics
Titanium dioxide and zinc oxide become transparent to
visible light when formed at the nanoscale; however, they are
able to absorb and reﬂect UV light, being currently used in
sunscreens and in the cosmetic industry. More cosmetics
products containing nanoparticles are discussed in Sec.
III B 5.
G. Coatings
Nanomaterials have been used for very thin coatings for
decades, if not centuries. Today thin coatings are used in a
vast range of applications, including architectural glass, mi-
croelectronics, anticounterfeit devices, optoelectronic de-
vices, and catalytically active surfaces. Structured coatings
with nanometer-scale features in more than one dimension
promise to be an important foundational technology for the
future.
Self-cleaning windows. Self-cleaning windows have been
demonstrated, which are coated in highly hydrophobic tita-
nium dioxide. The titanium dioxide nanoparticles speed up,
in the presence of water and sunlight, the breakdown of dirt
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and bacteria that can then be washed off the glass more
easily.
Scratch resistant materials. Nanoscale intermediate layers
between the hard outer layer and the substrate material sig-
niﬁcantly improve wear and scratch resistant coatings. The
intermediate layers are designed to give good bonding and
graded matching of mechanical and thermal properties, lead-
ing to improved adhesion.
Textiles. Nanoparticles have already been used in coating
textiles such as nylon to provide antimicrobial
characteristics,340 Also, the control of porosity at the nanos-
cale and surface roughness in a variety of polymers and in-
organic materials led to ultrahydrophobic—waterproof—and
stain resistant fabrics.
H. Materials
Insulation materials. Nanocrystalline materials synthe-
sized by the sol-gel technique exhibit a foamlike structure
called an “aerogel.”341 Aerogels are composed of three-
dimensional, continuous networks of particles and voids.
Aerogels are porous, extremely lightweight, and have low
thermal conductivity.
Nanocomposites. Composites are materials that combine
two or more components and are designed to exhibit overall
the best properties of each component mechanical, biologi-
cal, optical, electric, or magnetic. Nanocomposites contain-
ing CNT and polymers used to control their conductivity are
interesting for a wide range of applications, such as superca-
pacitors, sensors, solar cells, etc.342
Paints. Nanoparticles confer enhanced desired mechanical
properties to composites, such as scratch resistant paints
based on encapsulated nanoparticles.343 The wear resistance
of the coatings is claimed to be ten times greater than that for
conventional acrylic paints.
I. Mechanical engineering
Cutting tools made of nanocrystalline materials such as
tungsten carbide are much harder than their conventional
counterpart due to the fact that the microhardness of nano-
sized composites is increased compared to that of microsized
composites.344
Lubricants. Nanospheres of inorganic materials could be
used as lubricants, acting as nanosized ball bearings.345
VII. CONCLUSIONS AND FUTURE
DIRECTIONS
Human exposure to nanoparticles from natural and an-
thropogenic sources has occurred since ancient times. Fol-
lowing the invention of combustion engines and the devel-
opment of industry, however, signiﬁcant levels of
nanoparticle pollution have arisen in most major cities and
even across large regions of our planet, with climatic and
environmental effects that are generally unknown.
There is heightened concern today that the development
of nanotechnology will negatively impact public health, and
it is indisputable that engineered nanomaterials are a source
of nanoparticle pollution when not safely manufactured,
handled, and disposed of or recycled. A large body of re-
search exists regarding nanoparticle toxicity, comprising epi-
demiological, animal, human, and cell culture studies. Com-
pelling evidence that relates levels of particulate pollution to
respiratory, cardiovascular disease, and mortality has shifted
attention to particles with smaller and smaller sizes nanom-
eter scale. Research on humans and animals indicates that
some nanoparticles are able to enter the body, and rapidly
migrate to the organs via the circulatory and lymphatic sys-
tems. Subjects with preexisting diseases such as asthma and
diabetes, among others may be more prone to the toxic ef-
fects of nanoparticles. Genetic factors may also play an im-
portant role in the response of an organism to nanoparticle
exposure.
As shown in this review, it is clear that workers in nano-
technology related industries may be potentially exposed to
uniquely engineered nanomaterials with new sizes, shapes,
and physicochemical properties. Exposure monitoring and
control strategies are necessary. Indeed, there is a need for a
new discipline—nanotoxicology—that would evaluate the
health threats posed by nanoparticles and would enable safe
development of the emerging nanotechnology industry.19 We
emphasize that this ﬁeld of study should include not only
newly engineered nanomaterials, but also those generated by
nature and pollution.
The ability of nanoparticles to enter cells and affect their
biochemical function makes them important tools at the mo-
lecular level. The toxic properties of nanoparticles can, in
some instances, be harnessed to improve human health
through targeting cancer cells or harmful bacteria and vi-
ruses. These very properties that might be exploited as ben-
eﬁcial may also have secondary negative effects on health
and the environment. For example, nanoparticles used to de-
stroy cancer cells may cause harmful effects elsewhere in the
body, or nanoparticles used for soil remediation may have an
adverse impact upon entering the food chain via microorgan-
isms, such as bacteria and protozoa.
In the following, we highlight important questions and
research directions that should be addressed in the near fu-
ture by the scientiﬁc community involved in the study of
nanoparticle sciences and by government agencies respon-
sible for regulations and funding.
Advanced analysis of the physical and chemical charac-
teristics of nanoparticles will continue to be essential in re-
vealing the relationship between their size, composition,
crystallinity, and morphology and their electromagnetic re-
sponse properties, reactivity, aggregation, and kinetics. It is
important to note that fundamental properties of nanopar-
ticles are still being discovered, such as magnetism in nano-
particles made of materials that are nonmagnetic in bulk
form. A systematic scientiﬁc approach to the study of nano-
particle toxicity requires correlation of the physical and
chemical characteristics of nanoparticles with their toxicity.
Existing research on nanotoxicity has concentrated on em-
pirical evaluation of the toxicity of various nanoparticles,
with less regard given to the relationship between nanopar-
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ticle properties such as exact composition, crystallinity, size,
size dispersion, aggregation, and aging and toxicity. This
approach gives very limited information, and should not be
considered adequate for developing predictions of toxicity of
seemingly similar nanoparticle materials.
Further studies on kinetics and biochemical interactions
of nanoparticles within organisms are imperative. These
studies must include, at least, research on nanoparticle trans-
location pathways, accumulation, short- and long-term toxic-
ity, their interactions with cells, the receptors and signaling
pathways involved, cytotoxicity, and their surface function-
alization for an effective phagocytosis. Existent knowledge
on the effects of nanoparticle exposure on the lymphatic and
immune systems, as well as various organs, is sparse. For
example, it is known that nanoparticle exposure is able to
modulate the response of the immune system to different
diseases, however much research is needed in order to better
understand to what extent this occurs and the full implica-
tions of risk groups age and genotype. In order to clarify
the possible role of nanoparticles in diseases recently associ-
ated with them such as Crohn’s disease, neurodegenerative
diseases, autoimmune diseases, and cancer, nanoscale char-
acterization techniques should be used to a larger extent to
identify nanoparticles at disease sites in affected organs or
tissues, and to establish pertinent interaction mechanisms.
Other important research topics to be pursued include
nanoparticle aging, surface modiﬁcations, and change in ag-
gregation state after interaction with bystander substances in
the environment and with biomolecules and other chemicals
within the organisms. How do these interactions modify the
toxicity of nanoparticles? Do they render toxic nanoparticles
less toxic? Or can they render benign nanoparticles more
toxic? What about the beneﬁcial properties of some nanopar-
ticles? Do they change in the short and long term after un-
dergoing chemical interactions? Research should also be di-
rected toward ﬁnding ways to reduce nanoparticle toxicity
such as antioxidants provided by dietary sources and
supplements, metals chelators, and anti-inﬂammatory
agents.
Understanding and rationally dealing with the potentially
toxic effects of nanoparticles require a multidisciplinary ap-
proach, necessitating a dialogue between those involved in
the disparate aspects of nanoparticle fabrication and their ef-
fects, including but not limited to nanomaterial fabrication
scientists, chemists, toxicologists, epidemiologists, environ-
mental scientists, industry, and policy makers. In order to
achieve an interdisciplinary dialogue, systematic summaries
should be prepared, discussing current knowledge in the
various nano ﬁelds and using a common vocabulary. This
will help bring together scientists in different ﬁelds as well as
policy makers and society at large. These summaries should
include periodic written reviews, conferences, and accessible
databases that contain the collected knowledge of nanopar-
ticle synthesis, characterization, properties, and toxicity in a
format easily comprehensible to a wide audience of scien-
tists. A database initiative has already begun, led by the Na-
tional Institute for Occupational Safety and Health, as the
“Nanoparticles Information Library.”
We also suggest several directions for minimizing human
exposure to nanoparticles, and thereby reducing associated
adverse health effects. National governments and interna-
tional organizations should enact stringent air quality poli-
cies with standardized testing methods and low exposure
limits. With such compelling existing evidence of the corre-
lation between particle pollution levels, mortality, and a wide
range of diseases comprising cardiovascular, respiratory dis-
eases, and malignant tumors, the primary source of atmo-
spheric nanoparticles in urban areas—combustion-based
vehicles—should be mandated to have lower nanoparticle
emission levels. In the light of their potential toxicity, the
commercialization of dietary and cosmetic nanoparticles, as
well as other consumer products incorporating nanoparticles,
must be strictly regulated. In particular, they must be regu-
lated as distinct materials from their bulk constituents. Be-
fore using these nanoparticles, several questions should be
answered: Are they biocompatible? Do they translocate and
accumulate in the body including skin? What are the long-
term effects of uptake and accumulation? In general, con-
sumer products containing nanomaterials should be recycled.
A model initiative began in 2001 in Japan for electrical ap-
pliances, where the retailers, manufacturers, and importers
are now responsible for recycling the goods they produce or
sell.
There is limited existing research regarding ecological
and environmental implications of natural and anthropogenic
nanoparticle pollution, though the role of nanoparticles in
some forms of environmental degradation is well known,
e.g., atmospheric nanoparticles play a central role in ozone
depletion. Nanoparticulate pollution is likely to play an im-
portant role in global climate balance, despite the fact that
current anthropogenic climate changes are attributed solely
to greenhouse gases. This is dangerous as it encourages the
misconception that wood burning does not contribute to pol-
lution and/or climate change. In a simple calculation of car-
bon liberation and ﬁxation, it appears that wood burning, as
a so-called renewable source of energy, is benign to the en-
vironment. A proper accounting of nanoparticle pollution in
addition to CO2 reveals the naivety of this analysis.
Advances in nanotechnology are driven by rapid commer-
cialization of products containing nanostructures and nano-
particles with remarkable properties. This is reﬂected in the
enormous number of publications on nanotechnology. In
comparison, the number of publications on nanoparticle tox-
icity is much smaller, as the funding available for toxicity
studies are mostly government related. One way of increas-
ing funding for nanotoxicity research might be via interna-
tional regulations requiring that a fraction of the revenues of
each company involved in their production and commercial-
ization be dedicated to this ﬁeld of research. Without this
level of commitment, it is likely that a current or future in-
dustrial nanoparticle product, with nonobvious or delayed
toxicity, will cause signiﬁcant human suffering and/or envi-
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ronmental damage. The ﬁeld of nanotechnology has yet to
have a signiﬁcant public health hazard, but it is a real possi-
bility that can and should be prevented.
We conclude that the development of nanotechnology and
the study of nanotoxicology have increased our awareness of
environmental particulate pollution generated from natural
and anthropogenic sources, and hope that this new awareness
will lead to signiﬁcant reductions in human exposure to these
potentially toxic materials. With increased knowledge, and
ongoing study, we are more likely to ﬁnd cures for diseases
associated with nanoparticle exposure, as we will understand
their causes and mechanisms. We foresee a future with
better-informed and, hopefully, more cautious manipulation
of engineered nanomaterials as well as the development of
laws and policies for safely managing all aspects of nanoma-
terial manufacturing, industrial and commercial use, and
recycling.
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